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Abstract 
The 5-HT3 receptor is a ligand-gated ion channel that mediates for example fast 
synaptic neurotransmission in the CNS and PNS. 5-HT3 receptor antagonists are 
established anti-emetics in the clinic, they also offer symptomatic relief for patients 
with irritable bowel syndrome, yet, sometimes serious side-effects limits their use in 
this indication. The 5-HT3 receptor is modulated allosterically by various compounds 
including colchicine, alcohols and volatile anaesthetics but as yet, these modulators 
either lack potency or selectivity, which hinders investigation.  
The present study reports a novel 5-HT3 receptor allosteric modulator that displays 
relatively high potency and selectivity; 5-chloro-indole (Cl-indole). Cl-indole 
potentiated 5-HT3 receptor mediated responses arising from heterologous expression 
of the h5-HT3A receptor (assessed by the affinity shift of agonists to compete for the 
radioligand binding site and by the increase in agonist action upon the h5-HT3A 
receptor-mediated increase in [Ca2+]i; the latter action was evident with a range of 
agonists with very low intrinsic activity to full agonists). Cl-indole was also able to 
modulate allosterically the mouse native 5-HT3 receptor. 
Additional studies provided further support for the role of the C-terminus of the h5-
HT3A subunit to promote stability of the arising 5-HT3 receptor complex and that 
ligand interaction with the 5-HT3A receptor impacted cell surface expression. 
In summary, the study reports the identification of Cl-indole as a positive allosteric 
modulator of the 5-HT3 receptor along with extensions to our knowledge concerning 
a structural component of the 5-HT3A subunit that promotes stability and the 
trafficking of the subunit into the cell membrane. These studies increase our 
understanding of the 5-HT3 receptor, which may contribute to the design of better 
drugs targeting this receptor for therapeutic benefit. 
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Chapter 1: Introduction  
History of 5-HT 
Since 1868 scientists have been mindful of a substance in the blood that could cause 
vasoconstriction. However, it was another 80 years before the active compound was 
positively identified. In 1940, Erspamer isolated a substance that was secreted by the 
enterochromaffin cells in the gastric mucosa, which produced causing smooth muscle 
contraction. He named it enteramine due to the fact that it was found in the gut 
(entero) and it was monoamine (amine). However, it was not until 1948 that Rapport 
was first isolated and purified this substance from the blood by (Rapport 1948) and 
named it serotonin. The term serotonin describes the function of the molecule i.e. sero 
(found in serum) and tonin (causes smooth vascular muscle constriction). (Batis N., 
2006, BMedSc) 
In 1952, Espamer and Asero associated the two substances and discovered that 
serotonin and enteramine is one and the same molecule, 5-hydroxytryptamine (5-HT). 
Nowadays only the term serotonin is used. Within another two years Amin et al. 
(1954) had discovered that 5-HT was also found in the CNS. Nowadays, it is known 
that 5-HT has a very widespread distribution throughout the body and diverse 
functions including vasoconstriction (Fozard et al, 1989), constriction of smooth 
muscle in the gastrointestinal tract GIT (Graig and Clarke 1991), neuromodulatory 
actions in the central and peripheral nervous systems, as well as neurodevelopmental 
influences (Whitaker-Azmitia et al., 1996; Levit et al., 1997). Moreover, it is well 
documented that 5-HT exerts its actions through at least 14 functionally and 
pharmacologically distinct receptors (Barnes and Sharp, 1999, Hoyer et al., 1994).  
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Distribution of 5-HT 
The concept that 5-HT acts as a neurotransmitter within the central nervous system 
(CNS) was first suggested by Twarog and Page in 1953. However, the majority of 
physiological 5-HT, in terms of absolute mass, resides within the gut where it acts as a 
neurotransmitter in the myenteric plexus and a local hormone secreted from  
enterochromaffin cells (Bertrand et al., 2006). 5-HT is also present, at a high 
concentration, in platelets from where it is released as part of the blood coagulation 
process. Indeed, it was this action that lead to its initial discovery (Rapport et al., 
1948).  
 
Localisation of the serotonergic cell bodies and axons within the CNS was originally 
documented by Dahlström and Fuxe in 1964. Nuclei were found to be concentrated 
along the central or midline (raphé) of the brainstem and were originally classified in 
terms of clusters of cells referred to as B1-B9. More extensive anatomical studies 
have sub-divided these into two main groups based on their position within the 
brainstem and their axonal projections. The rostral group, which includes the dorsal 
raphé nucleus (DRN), is comprised of the B7 and B8 cell clusters and represents the 
largest anatomical grouping of serotonergic cell bodies. The median raphé nucleus 
(MRN) is comprised of the B5, B8 and B9 cell clusters. Together these two raphé 
nuclei provide the majority of serotonergic innervation to forebrain areas including 
the cerebral cortex, hippocampus, limbic system and hypothalamus (Jacobs and 
Azmitia, 1992). The caudal group, consisting of cell clusters B1-B4 is located in the 
medulla and caudal pons. This group includes the following nuclei; nucleus raphé 
obscurus (NRO; B2), nucleus raphé pallidus (NRP; B1) and nucleus raphé magnus 
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(NRM; B3). The axons of these cells form the major descending pathways of the 
serotonergic system that innervate the spinal cord, modulating sensory, motor and 
autonomic processing (Törk, 1990) as well as cells that have branching ascending and 
descending axons (Lovick and Robinson, 1983). 
 
The axons of the serotonergic fibres innervating forebrain regions provide a further 
basis for subdivision of the serotonergic system. Morphologically the axons appear as 
either thin, extensively branched fibres that possess small fusiform varicosities (D-
fibres) or axons that appear thick and devoid of varicosities at origin, which branch in 
terminal areas to form thinner fibres with comparatively larger, oval varicosities (M-
fibres). These two sub-populations of serotonergic fibres originate primarily from cell 
bodies of the dorsal raphé nucleus (D-fibres) or the median raphé nucleus (M-fibres). 
Further to morphological and anatomical distinctions, the D-fibres appear more 
vulnerable than M-fibres to neurotoxins such as the amphetamine derivatives, PCA 
and MDMA (Törk, 1990). Finally, it appears that D-fibre varicosities form less 
conventional synapses, which has led to speculations that these projections are 
indicative of a volume or paracrine transmission (local hormone) of the serotonergic 
system (Törk 1990; Hornung 2003; Hensler, 2006). 
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Volume Transmission 
There is indication that volume transmission of 5-HT within dorsal raphé nucleus 
(DRN) (Bunin & Wightman, 1998) potentially be similar to volume transmission of 
neuropeptides in hypothalamus (de Kock et al. 2003), due to its relatively slow action, 
effecting the activity of the cell it is released from via activation of metabotropic 
receptors. Neurones in DRN discharge substantial quantities of 5-HT locally in the 
nucleus from extrasynaptic sites (Bunin & Wightman, 1998), acting both on dendritic 
5-HT1A autoreceptors (Liu et al. 2005), and on 5-HT2 receptors (Liu et al. 2000) 
located on presynaptic GABAergic neurones.  
Diagram 1. Schematic of main serotonergic projections in human brain and spinal cord frpm 
raphe nuclei. Demonstrating extensive efferents of theis et of reticular nuclei. DRM, dorsal 
raphe nuclei; CSD, centralis superior nucleus, pars dorsalis; CSM, centralis superior nucleus, 
pars medianus; RO, nucleus raphe obscruus; NRPa, nucleus raphe pallidus; RM, nucleus 
raphe maglus; VR, nucleus raphe ventricularis (adapted from Azmitia and Gannon 1986) 
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Further, it has been estimated the concentrations of 5-HT in the substantia nigra 
reticulata (SNr) from its initial stored state until it reaches its receptor site, if all 
molecules released per terminal were all in one vesicle could reach concentration of 
90 mM (Bunin and Wightman 1998). When released into a space with the dimensions 
of a SNr synapse the concentration would be 6 mM (Bunin and Wightman 1998). This 
is very high as compared with the affinity of the 5-HT1 receptors. When 5-HT 
diffuses into the extracellular compartment, its measured maximal concentration is 55 
nM, a value much closer to the affinity for receptors and Km for transport. This 
concentration is removed from the extracellular space with a half-life of ∼200 msec 
and allows 5-HT to diffuse >20 μm, a distance sufficient to interact with many 
extrasynaptic elements (Bunin and Wightman 1998). 
5-HT Receptors 
The classification of the 5-HT receptors was reviewed in 1994 by the Receptor 
Nomenclature Committee of the International Union of Pharmacology (IUPHAR) and 
the Serotonin Club, which decided that the structural, physiological and 
pharmacological properties of the receptors would determine their classification and, 
moreover, that newly cloned receptors would be noted in lower case appellation prior 
to confirming the function of the endogenous receptor (Hoyer and Martin, 1997). 
The 5-HT receptors are divided in 7 classes (5-HT1-7) with at least 14 subtypes and 
they belong to the G-protein coupled receptor (GPCR) family (seven transmembrane 
domains), with the exception of the 5-HT3 receptors which are ligand gated ion 
channels of the cys-cys-loop superfamily (similar to nACh, GABAA and glycine 
receptors). (Batis N., 2006, BMedSc) 
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Metabotropic 5-HT Receptors 
5-HT1 receptors 
The 5-HT1 receptor family is a subdivided into 5 receptor subtypes (5-HT1A, 5-HT1B, 
5-HT1D, 5-HT1E, 5-HT1F) all of which are GPCRs negatively coupled to adenylyl 
cyclase and consequently they can reduce cAMP activity. 5-HT1 receptors can be 
found either pre-synaptically (autoreceptors) or post-synaptically (Barnes & Sharp, 
1999). (Batis N., 2006, BMedSc) 
5-HT2 receptors 
The 5-HT2 receptor family consists of the 5-HT2A, 5-HT2B and 5-HT2C (previously 5-
HT1C) receptors (Pritchett et al, 1988; Saltzman et al 1991; Kursar et al 1994). The 
gene of the receptor family has either two introns (5-HT2A, 5-HT2B) or three introns 
(5-HT2C) with no evidence of splice variants contributing to the functional difference 
of the three subtypes. However, it has been reported that the 5-HT2C receptor 
undergoes RNA editing, giving rise to diverse isoforms of the receptor subtype that 
have distribution discrepancy and a minor pharmacological distinction (Burns et al 
1997). The 5-HT2 receptor’s amino acid sequence suggesting it is a member of the 
seven transmembrane receptor superfamily (GPCR). Functionally, all three receptor 
subtypes are positively coupled to phospholipase C and therefore are able to increase 
intracellular calcium levels via the inositosol pathway (Barnes and Sharp, 1999). 
(Batis N., 2006, BMedSc) 
5-HT4 receptors 
The 5-HT4 receptor family includes 8 isoforms of the receptor, which are all coded by 
a very complex gene (700Kb, 38 exons) which generates 7 carboxy-terminal variants 
5-HT4A, (Blondel et al. 1997, Claeysel et al. 1997; 5-HT4B Van den Wyngaert et al. 
1997; 5-HT4C, Blondel et al. 1998); 5-HT4D (Mialet et al. 2000b, Blondel et al. 1998); 
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5-HT4E  (Claysen et al. 1999, Mialet et al. 2000a); 5-HT4F, 5-HT4G (Claysen et al. 
1999)  with their sequences varying after the amino acid 358 (leucine) of the 5-HT4 
receptor sequence (see Diagram 1).  Additionally, a novel splice variant 5-HT4H or 5-
HT4HB has been characterised, which is generated by a 14 amino acid long insertion in 
the 2nd extracellular loop of the 5-HT4B subtype (Bender et al 2000) giving rise to the 
8th isoform of the receptor. All the receptor subtypes are GPCRs and appear to be 
positively coupled to adenylyl cyclase. The splice variants are rare among 5-HT 
receptors, most genes coding for the receptors have no introns. However, the only 
subtype that shows this variation is the 5-HT7 receptor, which is also positively 
coupled to adenylyl cyclase (Heidmann et al., 1997; Barnes & Sharp 1999).  
 
Interestingly the 5-HT4 receptor subtype is the only 5-HT receptor whose 
physiological function (adenynyl cyclase stimulation) was established prior to the 
demonstration of its pharmacological profile (Hungen et al 1997; Barnes & Sharp 
1999) and cloning the gene. (Batis N., 2006, BMedSc) 
5-HT5 receptors 
Two subtypes: the 5-ht5A and 5-ht5B receptor have been identified. The gene for the 5-
ht5A receptor has been cloned in humans, rats, and mice and it has been suggested 
(Francken et al 1998) that it is negatively coupled to adenylyl cyclase and thus causes 
cAMP levels to decrease (Carson et al 1996). Additionally it is also believed that it is 
G-protein coupled to an inward rectifying K+ channel; GIRK1 (Grailhe et al. 2001). In 
contrast, the 5-ht5 receptor is not believed to form functional receptor in humans (only 
Diagram 2. 5-HT4 
receptor splice variants 
after the 358th amino 
acid which corresponds 
to Leucine (L).  
Adapted from Bender et 
al., 2000 
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in rats) as it contains a stop codon within the human receptor sequence. At present, no 
physiological responses mediated by this receptor family have been identified (Batis 
N., 2006, BMedSc) 
5-HT6 receptors 
This receptor class comprises of a single gene product as no subtypes or functional 
splice variants (Kohen et al. 1996) have been identified so far. It has been suggested 
that it is positively coupled to adenylyl cyclase causing increased cAMP activity 
.(Batis N., 2006, BMedSc) 
5-HT7 receptors 
The 5-HT7 receptor family is comprised of 4 isoforms (5-HT7A, 5-HT7B, 5-HT7C, 5-
HT7D) generated by alternate splicing of a single gene (Heidmann et al 1997). The 
receptor has been to shown to increase cAMP levels by the associated G-protein 
interacting with calmodulin-stimulated adenylyl cyclase upon receptor activation 
(Bard et al. 1993; Adham et al. 1998). In addition, the 5-HT7 receptor may also be 
able to activate the mitogen-activated protein kinase Erk, in vitro (Errico et al., 2001). 
(Batis N., 2006, BMedSc) 
Ligand gated ion channels (LGIC) 
5-HT3 receptors 
The 5-HT3 receptor is the only monoamine-gated ion channel (Derkach et al 1989). 
Five subunits have been identified within the 5-HT3 receptor class; 5-HT3A, 5-HT3B, 
5-ht3C, 5-ht3D, 5-HT3E receptors (Mariq et al, 1991; Davies et 1999; Dubin et al 
2002, Hanna et al., 1991; Niesler et al., 2003; Karnovsky et al., 2003).  It is believed 
that they have a pentameric structure (Boess et al, 1995) similar to other members of 
the cys-cys loop LGIC superfamily such as GABAA, nicotinic acetylcholine and 
glycine receptors. All five subunits of the 5-HT3 receptor have been demonstrated to 
have similar structure, with an extracellular N-terminus, possibly containing the 
ligand binding site (Eisele et al., 1993), four putative transmembrane domains (TM1-
4), a large intracellular loop, and a short extracellular C-terminus (Reeves and 
Lummis, 2002). It is believed that the TM2 domain of the subunits forms the central 
channel pore. The homomeric 5-HT3A receptor has been shown to mediate fast 
excitatory responses by depolarising the cell membrane. However, the “non-alpha” 
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subunits (non-5-HT3A subunits) do not appear to form functional homomeric 
receptors. More likely they form heteromeric receptors co-expressing with the 5-
HT3A subunit, influencing the functional rather the pharmacological properties of the 
heteromeric receptor. For example, the 5-HT3AB heteromeric receptor has similar 
pharmacological profile to the homomeric 5-HT3A receptor but the homomeric 
receptors are inwardly rectifying as opposed to the linear relationship of the 
heteromeric receptor (Davies et al., 1999; Brady et al., 2001). However, the 
conductance of the heteromeric receptor is closer to that found in native tissue (Davies 
et al, 1999; Brady et al., 2001). 
 
Diagram 3.  Adapted from Thomson and Lummis 2006; homology model of the extracellular 
and transmembrane domains of the 5-HT3 receptor. The receptor is depicted from the side and 
the cell membrane is highlighted as a grey box. On the right receptor is shown from above, 
looking down towards the membrane and through the central ion-conducting pore.  
 
The 5-HT3 receptor ion channel allows cations to be conducted non-selectively, and 
similar to the nACh receptor, it conducts monovalent ions at similar rates. The TM1-2 
linker sequence contributes towards ion selectivity (Gunthorpe and Lummis, 2001) for 
sodium and potassium ions, as well as Ca2+. However, even though the homomeric 
channel is non-selective for mono and bivalent cations, the heteromeric 5-HT3AB 
9 
 
Chapter 1: Introduction 
 
receptor was less permeable to Ca2+ than Na+ and K+ and impermeable to Mg2+ ions 
(Davies et al., 1999) 
The pharmacological profile of the 5-HT3 receptor is well established (Barnes and 
Sharp, 1999) and a large number of selective ligands are available, such as the 
selective agonists m-chlorophenylbiguanide (Kilpatrick et al., 1990) and SR57222A 
(Bachy et al., 1993), as well as the selective antagonists ondansetron and granisetron. 
These antagonists are the ones that are most widely used for clinical purposes (for 
review Thompson and Lummis, 2007). Similar to other members of the ligand-gated 
ion channel superfamily, 5-HT3 receptors also possesses distinct allosteric binding 
sites via which substances such as alcohol (ethanol), general anaesthetics like 
ketamine and isoflurane, barbiturates and also steroids influence the function of the 
receptor (Parker et al., 1996).  
 
The receptor distribution has been mapped within the central nervous system (CNS) 
and peripheral nervous system (PNS), as well as in the colon, intestine, lung, muscle 
and stomach, kidney and liver. Additionally, recent evidence has shown that the 5-
HT3 receptor is also expressed in a range of lymphocyte populations although its 
importance with respect to lymphocyte function remains to be determined. In fact, the 
mRNA coding for the 5-HT3A receptor is present in a lot of B cell germinal centres 
(GC) and memory B cell populations but is decreased dramatically after the 
maturation of the B cells (the 11th most downregulated gene; Rinaldi et al., 2010); 
implying an important role of the receptor in the transit from GC to mature B cells. 
Indeed, future investigation of the presence and function of a fast excitatory ligand-
gated ion channel in B cells could reveal new insights into the function of the immune 
system and a possible evolutionary link between the maturation of the immune and 
nervous systems.  
Endocytosis of the 5-HT3 receptor 
Interestingly, many members of the LGIC superfamily exhibit cell membrane receptor 
internalisation, via adaptin AP2 mediated endocytosis; these include the ionotropic 
glutamate receptors (Carroll et al., 1999) and GABAA receptors (Kittler et al., 2000; 
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Herring et al., 2003). Further roots of endocytosis could include lipid raft sas 
vehicles as well as caveolae can facilitate clathrin-independent endocytosis(Allen et 
al., 2007); the influence of lipid raft integrity for ligand-gated ion channel function 
has been shown for a variety of receptors (Allen et al., 2007).  
The potential involvement of similar endocytotic mechanisms in the internalisation of 
the 5-HT3 receptor has yet to be identified; however, potential ligand-dependent 5-
HT3 receptor internalisation has been reported (Ilegems et al., 2004). The adaptin AP2 
complex mediates clathrin mediated endocytosis of integral membrane proteins and is 
comprised of four subunits: α-, β-, μ-, and σ-adaptin (Marsh and McMahon, 1999; 
Owen et al., 2004). The adaptin AP2 complex mediates clathrin dependent 
endocytosis by recruiting integral membrane proteins into clathrin coated pits (Marsh 
and McMahon, 1999; Owen et al., 2004). At least two intracellular recognition motifs 
within the recruited protein have been identified: Yxxθ where θ is a large hydrophabic 
amino acid, and dileucine (LL) motifs. 
 
The 5-HT3 receptor subunits have a large intracellular loop between the TM3 and 
TM4. Within this region, the 5-HT3A subunit does not contain any Yxxθ motifs 
(known recognition sites for AP2 complex; Marsh and McMahon, 1999; Owen et al., 
2004). However, it does possess three dileucine (LL) motifs (secondary recognition 
sites for AP2; Marsh and McMahon, 1999; Owen et al., 2004), which may indicate 
interaction with the adaptin AP2 complex. Interestingly, the 5-HT3B subunit possesses 
a Yxxθ [YXEH] and two LL motifs in the large intracellular loop. This could indicate 
and possibly narrow the possible sites for association, if that occurs, between the 
receptor and the AP2-clathrin complex. This could be of particular interest as receptor 
endocytosis influences the cell surface expression of receptors, the regulation of 
which is important in controlling the receptor-mediated function, hence regulating the 
synaptic efficiency of the neurotransmitter. Indeed, initial studies in our laboratory 
using radioligand binding have demonstrated that sucrose, a known inhibitor of 
clathrin mediated endocytosis (Heuser and Andersen, 1989) increases membrane 
associated 5-HT3 receptor expression in 5-HT3A receptor stably expressing HEK-293 
cells (Barnes et al, unpublished).  
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5-HT3 Receptor ligand binding domain 
The 5-HT3 receptor ligand binding site is situated within the extracellular N-terminal 
domain of the receptor. Although initially predicted from homology with other 
LGIC’s, this was first demonstrated convincingly by Eiselé et al. (1993), with a 
chimera of the acetylcholine receptor subunit N-terminal domain and the C-terminal 
5-HT3 receptor four transmembrane domains, which displayed pharmacological 
characteristics of the acetylcholine receptor but 5-HT3 channel-like properties (Eiselé 
et al., 1993). As mentioned previously, a large fraction of the structural data available 
concerning the 5-HT3 ligand binding site is extrapolated from studies on the 
acetylcholine binding protein (AChBP) and nAChR. The AChBP consists of 10 β-
strands and 10 loops, with a predicted binding pocket formed by a series of loops on 
the principle subunit face (binding loops A-C) and a series of β-strands on the 
complementary subunit face (binding loops D-F; Brejc at  al., 2001). Homology 
studies between the AChBP and the 5-HT3A receptor have identified the putative 
corresponding loop A-F regions within the 5-HT3A receptor and the particular 
residues within the binding cleft (Maksay et al., 2003, Reeves et al., 2003, Thompson 
et al., 2005, Joshi et al., 2006).  Mutating these residues to structurally similar or 
dissimilar amino acids has indicated their role in ligand binding and validates much of 
the information arising from structural homology models. Individual residues within 
the loops that effect agonist and/or antagonist binding include Loop A (numbering of 
amino acids residues is in accordance to that of the murine 5-HT3A receptor, on 
which the majority of the studies were preformed); N128, E129, F130 (Boess et al., 
1997, Steward et al., 2000, Thompson et al., 2005, Sullivan et al., 2006, Yan et al., 
2006), Loop B; S182,W183, H185, D189 (Spier and Lummis, 2000, Reeves et al., 
2003, Joshi et al., 2006), Loop C; E225, F226, I228, D229, Y234, E236 (Mochizuki et 
al., 1999, Hope et al., 1999, Schreiter et al., 2003, Beene et al., 2004, Thompson et al., 
2005, Suryanarayanan et al., 2005), Loop D; W90, R92, Y94, (Spier and Lummis, 
2000, Yan and White, 2002, Yan et al., 2006), Loop E; Y141, Y143, Y153, G148 
(Venkataramen et al., 2002, Beene et al., 2004, Price and Lummis, 2004, Joshi et al., 
2006), Loop F; W195, D204 (Spier and Lummis, 2000, Thompson et al., 2006). The 
h5-HT3A subunit amino acid sequence is identical to that of the murine receptor in 
binding loops A, B and D. The differences between the sequences in loops C, E and F 
maybe partially responsible for pharmacological inter-species differences (see below). 
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In addition, a number of residues have been identified within the N-terminal domain, 
which may not have direct involvement in ligand binding but are essential for subunit 
structure/assembly. These include; W95, W102, W121, W214 (Spier and Lummis, 
2000), P56, P104, P123, P170 (Deane and Lummis, 2001), Y50, Y91, Y141, Y234 
(Price and Lummis, 2004).  
There are a somewhat limited number of 5-HT3 receptor agonists available in 
comparison to the extensive list of antagonists, many of which are highly selective. 1-
(m-Chlorophenyl)-biguanide (mCPBG) is a potent high affinity 5-HT3 receptor 
agonist (Kilpatrick et al., 1990), derived from the less potent agonist, phenylbiguanide 
(PBG) (Hoyer and Neijt, 1987). PBG is approximately equipotent to another, but less 
selective, 5-HT3 receptor agonist, 2-methyl-5-HT (Richardson et al., 1985; Hoyer and 
Neijt, 1987; Kilpatrick et al., 1990). However, the above agonists appear to be partial 
agonists in at least some systems (Boess et al., 1992). The endogenous ‘full’ agonist, 
5-HT, is placed in the rank order of agonist affinity above PBG and 2-methyl-5-HT, 
but below mCPBG (Bufton et al., 1993). Agonist binding displays positive co-
operativity with Hill coefficients ranging from 1.5 - 3 (Kilpatrick et al., 1990; Boess et 
al., 1992; Miyake et al., 1995; Steward et al., 2000; Mott et al., 2001). This suggests 
that at least two agonist molecules are required to fully activate the receptor ion-
channel. 
 
Identification of the original selective 5-HT3 receptor antagonists (e.g. tropisetron, 
ondansetron; Richardson et al., 1985; Butler et al., 1988) greatly helped the 
characterisation of 5-HT3 receptors. Modelled on the low potency antagonist cocaine, 
MDL 72222 (Fozard, 1984) was the first 5-HT3 receptor selective antagonist to be 
identified. However, many selective, high affinity compounds soon became available 
including ICS 205-930 (tropisetron, Richardson et al 1985), GR38032F (ondansetron, 
Butler et al., 1988), BRL 43694 (granisetron; Sanger and Nelson, 1989), GR65630, 
and zacopride (for a review on 5-HT3 receptor antagonist structures see, Gozlan and 
Langlois, 1992). A number of non-selective 5-HT3 receptor antagonists are 
recognised including quizapine, which displays nanomolar affinity, the dopamine D2 
receptor antagonist, metoclopramide, and the nicotinic acetylcholine receptor 
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antagonist, d-tubocurarine. The appearance of radiolabelled ligands ([3H]-ICS205-
930; [3H]-GR65630; [3H]quipazine; [3H]zacopride; Hoyer and  Neijt 1987; Kilpatrick 
and Tyers, 1987; Barnes et al., 1988a; Milburn and Peroutka, 1988) allowed the direct 
labelling of 5-HT3 receptors and the performance of competition studies to allow a 
detailed affinity profile of competing ligands (Kilpatrick et al., 1987; Barnes et al., 
1988a; Milburn and Peroutka, 1988; Barnes et al., 1989a; Bufton et al., 1993; Steward 
et al., 1995).  
The affinity of many 5-HT3 receptor selective/non-selective ligands varies between 
species, resulting in characteristic individual pharmacological profiles. For example, 
d-tubocurarine shows approximately 1800-fold lower affinity of for the guinea pig 
and h5-HT3 receptor compared to the murine orthologue (Newberry et al., 1991; 
Bufton et al., 1993; Hope et al., 1999, Yan et al., 2006). In addition, mCPBG is 100 
times less potent at the h5-HT3A receptor than at the rat orthologue and the partial 
agonist, 2-Me-5-HT acts as a full agonist at h5-HT3A receptors (Miyake et al,. 1995). 
More significantly, PBG does not act as either an agonist or an antagonist at the 
guinea-pig 5-HT3A receptor (Butler et al., 1990, Lankiewicz et al., 1998).  
 
Despite speculation that a heteromeric 5-HT3AB receptor would display differing 
pharmacology to that of the 5-HT3A homomer, the heteromeric 5-HT3AB receptor is 
relatively pharmacologically indistinguishable using 5-HT3 selective ligands. Since 
pentameric is the arrangement of receptor subunit, a succession of diverse binding 
sites is possible in the heteromeric receptors. The atomic force microscopy (AFM) 
proposed a subunit arrangement of BBABA in human 5-HT3AB receptors, presenting 
the possibility that ligands bind to A+B–, B+A– and/or B+B– binding sites (Barrera et 
al. 2005). Nevertheless, the understanding is further complicated by the fact that it has 
been indicated by Lummis and colleagues primarily in the murine receptor that at 
least one binding site is at A – A interface for receptor function in the 5-HT3AB 
receptor (Lochner and Lummis 2010); however potentially there may be differences 
in the stoichiometries of mouse and human heteromeric receptors, or potentially data 
from either the atomic force microscopy or mutagenesis study may not represent the 
situation in vivo (Lochner and Lummis 2010; Thomson et al., 2011). Only minor 
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differences are apparent, with a slight reduction in potency of 5-HT and d-
tubocurarine at heteromeric compared to homomeric 5-HT3AB receptors (Davies et 
al., 1999; Hanna et al., 2000; Brady et al., 2001). Selectivity between 5-HT3A and 5-
HT3AB receptors can be achieved, however, with the GABAA receptor channel 
blocker, picrotoxin. The IC50 for picrotoxin is around 30 μM for homomeric 5-HT3A 
receptors compared to 3 mM for heteromeric 5-HT3AB receptors (Das and Dillion, 
2003).  
 
Diagram 3.  5-HT3 receptor binding sites. Model of the 5-HT3 receptor (with two subunits 
removed for clarity) showing granisetron (green) and picrotoxin (red) docked into their 
known binding sites in the ECD and in the pore, respectively. Other possible binding sites 
(pink), whose locations have not yet been confirmed, are an allosteric site in the Extracellular 
domain, an interhelical site in the TMD, and a lipid transmembrane site at the membrane-
receptor boundary. Adapted from Lummis 2012 
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Coupling of agonist binding to channel gating  
The second transmembrane domain (TM2) of each subunit forms the central ion-
channel pore of the cys-cys loop ligand-gated ion-channel family (Akabas et al., 1994; 
Xu and Akabas., 1996; Miyazawa et al., 2003). TM2 is believed to be an α-helical 
structure that bends to form a central “gate” controlling the permeation of ions 
through the cell lipid membrane (Reeves et al., 2001; Panicker et al., 2002; Peters et 
al., 2005). It appears that there is at least one break in the α-helical structure, forming 
a kink in TM2, where the highly conserved 9’ leucine and 13’ valine residues form 
hydrophobic interactions, bringing together adjacent subunit α-helices to form a core 
diameter too small for ion-permeation (Miyazawa et al., 2003; Lummis, 2004).  
 
The gate acts as both a barrier to prevent ion permeation in the closed state and a link 
to transduction mechanisms conveying channel opening (Panicker et al., 2002). It has 
long been documented that the TM2 helices undergo a conformational change upon 
receptor opening (Unwin, 1995). Unwin and colleagues have more recently 
demonstrated that an inner β sheet formation of the nAChR α subunit extracellular 
binding domain is rotated 15º in an activated state (Unwin et al., 2002). Structural 
studies of the nAChR indicated that a region within this inner β sheet, the β1- β2 loop, 
may have an interaction with the protruding TM2 and thereby relay the activation 
twist that breaks the hydrophobic interactions and causes channel opening (Miyazawa, 
2003). In support of this hypothesis, an interaction between the β1-β2 loops and the 
extracellular end of TM2 within the 5-HT3 receptor has been confirmed (Reeves et 
al., 2005). Additional channel gating studies with both the nAChR and GABAA 
receptor indicate the importance of residues within the cys-loop and TM2-TM3 linker 
(Kash et al., 2003; Bouzat et al., 2004; Sala et al., 2005). In the resting state the 
nAChR cys-cys loop and β1-β2 loop straddles the TM2-TM3 linker (Unwin, 2005), 
providing further supporting evidence for these regions being responsible for the 
transduction mechanism that links agonist binding and gating of the pre-
transmembrane domain one region. Specifically, increased potency for both 5-HT and 
2-Me-5-HT resulted after mutation of the amino acid arginine (R222), to an alanine 
residue, with the latter converting from a partial to a full-agonist (Hu et al., 2003). 
More recently, the cis-trans isomerisation of a proline residue, conserved between the 
16 
 
Chapter 1: Introduction 
 
5-HT3 receptor and the nAChR, within the TM2-TM3 linker has been identified as a 
requirement for receptor activation (Lummis et al., 2005). This group has therefore 
suggested that upon agonist binding the cys-cys loop/β1-β2 loop “clamp” is released 
from the TM2-TM3 linker, allowing cis-trans isomerisation of the proline residue, 
resulting in a switch from the closed to open states. The binding of two molecules in 
non-adjacent binding sites, as postulated for the nAChR, may be required to create the 
full torsion twist required for ion-channel opening (Lummis, 2004). 
Ion-channel conduction of the 5-HT3 receptor  
Early studies on 5-HT-induced responses led to the proposal that the 5-HT3 receptor 
incorporated a ligand-gated ion-channel that produced rapid depolarising currents 
mediated by cations (Higashi and Nishi, 1982; Surprenant and Crist, 1988). Further 
direct evidence however, was produced by Derkach et al. (1989). Using an excised 
(outside-out) patch clamp recording technique from on neurons of the guinea-pig 
submucousal plexus, they demonstrated that channel activity similar to that produced 
by the nAChR, could be evoked up to 5 hours after excision of the outside-out patch. 
This finding indicated that neither GTP-binding proteins nor a diffusible intracellular 
second messenger system appeared necessary for 5-HT3 mediated currents. Finally, 5-
HT was shown to act as a fast-synaptic neurotransmitter within the mammalian brain, 
specifically rat amygdala neurons (Suigita et al., 1992). This was the first 
demonstration that an amine, rather than an amino acid, was capable of such activity. 
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Despite having similar electrophysiological properties to the nAChR, single-channel 
conductance of the 5-HT3 receptor is considerably (see further) lower (~ 40 pS for the 
nAChR; Derkach et al., 1989). Moreover, single-channel conductance values varied 
considerably between different studies. Outside-out preparations of native neuronal 
tissue generally yielded single-channel conductances between 8 and 17 pS; In 
comparison, neuronal cell lines expressing the 5-HT3 receptor typically had sub-pS 
single-channel conductances (see table below).  
Anatomical area/ cell line Conductance (pS) Reference 
Guinea pig submucosal plexus 9.2 & 14.8 Derkach et al., 1989 
Rabbit nodose ganglion 16.5 Malone et al., 1991 
Mouse superior cervical ganglion 8.9 Hussy et al., 1994 
Rat superior cervical ganglion 11 Yang et al., 1992 
Mouse and rat hippocampus 8.3 & 10.5 Jones and Surprenant 1994 
N18 0.59 Yang 1990 
N1E-15 0.31/ 0.63/ 5.6 Lambert et al., 1989 
Hussy et al., 1994 
van Hooft et al., 1994 
NG108-15 9 & 13 (undifferentiated) 
4.4 (differentiated) 
Shao et al., 1991 
Cloned receptor 0.63 (m5-HT3A) 
and 
0.24-0.74 (h5-HT3A) 
Hussy et al., 1994 
Brown et al., 1998 
Single channel conductance of 5-HT3 receptor from various species and cell types. 
When taking into consideration that the sub-pS values were determined by fluctuation 
analysis and not directly measured and that the findings of Yang et al. (1992), showed 
significantly lower conductance with fluctuation analysis compared to single-channel 
recording of the rat superior cervical ganglion, the authors suggested that two 
populations of 5-HT3 receptors may exist within these cells. The lower conducting 
population would not be detectable over noise level when directly measuring single-
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channel openings but would influence the fluctuation analysis, resulting in an average 
current of the two receptor forms. 
 
Despite high homology with the nAChR TM2 amino acid sequence and similar 
receptor pore size values being estimated (Yang, 1990; Boess et al., 1992; Peters et 
al., 1992) the TM2 domains for both 5-HT3 and nAChR are surrounded by rings of 
negatively charged amino acids, which appear to control the rate of cationic transport 
through the ion-channel (Imoto et al., 1988; Konno et al., 1991). Investigations into 
the possible mechanisms that lower 5-HT3 receptor cationic conductance highlighted 
the importance of a positively charged lysine residue at position 4’ of the 5-HT3 TM2 
domain. However, mutagenic studies targeted at this residue failed to provide support 
for this hypothesis (Gunthorpe et al., 2000).  
 
Upon cloning of the 5-HT3B subunit it was discovered that the heteromeric 5-HT3AB 
receptor displays a larger single-channel conductance (16 pS) than the homomeric, 
resembling that from studies on native neuronal receptors (Davies et al., 1999). 
Somewhat paradoxically however, the sequence of the 5-HT3B receptor subunit does 
not align with the pattern of negatively charged amino acids shown to promote 
cationic conductance (Imoto et al., 1988; Davies et al., 1999). A series of studies on 
chimeric 5-HT3A and 5-HT3B receptors, led Kelley and colleagues (2003a) to 
identify a region within the TM2-TM3 large cytoplasmic loop which determines 
single-channel conductance, the HA-stretch. More specifically, mutagenesis of three 
arginine residues within this region in the 5-HT3A subunit, to their 5-HT3B subunit 
equivalents, resulted in single-channel conductance levels similar to the heteromeric 
receptor (Kelley et al., 2003a; Peters et al., 2005). The authors proposed that the TM2-
TM3 large cytoplasmic loops of adjacent subunits form a vestibule with portals 
framed by the residues within the HA-stretch, thus directly controlling ion-flux 
(Kelley et al., 2003a; Peters et al., 2004). 
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In addition to affecting the single-channel conductance of the receptor, the presence of 
h5-HT3B subunits within the heteromeric 5-HT3AB receptor also alters the current-
voltage relationship (Davies et al., 1999). Although both homomeric and heteromeric 
receptors have a reversal potential of approximately 0 mV (Brown et al., 1998; Davies 
et al., 1999), the homomeric receptors are inwardly rectifying, opposed to the linear 
current/voltage relationship displayed by the human heteromeric receptor (Brown et 
al., 1998; Davies et al., 1999; Brady et al., 2001). The rodent heteromeric receptors 
are similar to the homomeric receptor and display inward rectification (Hanna et al., 
2000). 
Ion-channel selectivity 
Early electrophysiological studies indicate that the 5-HT3 receptor current consists 
largely of monovalent cations, with relatively low Ca2+ and Mg2+ permeabilities (Peter 
et al., 1988; Lummis 2012). Moreover, divalent cations have an inhibitory effect on 
the 5-HT3 mediated current at higher concentrations (Yang et al., 1990; Lovinger 
1991; Gill et al, 1995). Ca2+ blockade in these studies did not affect the current-
voltage relationship, indicating that these effects are voltage-independent. However, 
in Xenopus ooyctes expressing the cloned rat 5-HT3A receptor, Ca2+ mediated 
blockade did appear voltage-dependent, suggesting some species differences may be 
present (Maricq et al. 1991). Some studies have identified Ca2+ permeability of the 5-
HT3 receptor in both native preparations (Rondé and Nichols, 1998) and in 
heterologous expression systems (Hargreaves et al., 1994) with more recent ion 
permeation studies calculating relative permeabilities of PNa/PCs and PCa/PCs to 0.9 
and 1.00, respectively (Brown et al., 1998).  
 
Upon cloning of the 5-HT3B subunit, some of the aforementioned discrepancies in 5-
HT3 receptor ion-channel permeation were accounted for. Davies et al. (1999) 
reported that the homomeric 5-HT3A receptor is non-selective for both monovalent 
and divalent cations, in agreement with that determined by Brown et al. (1998). The 
heteromeric 5-HT3AB receptor however, was substantially less permeant to Ca2+ ions, 
and impermeable to Mg2+ ions than the homomeric recpetor (Davies et al., 1999). 
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In addition to controlling the conductance of the 5-HT3 receptor, rings of negatively 
charged amino acids within the TM2 domain are important for ion-selectivity (see 
figure 2). Mutation of the negatively charged glutamate residue at position -1’ to an 
uncharged alanine residue, resulted in a relatively non-selective 5-HT3 receptor 
(PNa/PCl = 0.89; Thompson and Lummis, 2003). Further mutation of 13’valine to 
threonine (the corresponding amino acid of the anionic glycine and GABAA 
receptors) and the insertion of a proline residue preceding the Glu -1’Ala residue, 
produced a 5-HT mediated receptor with significant chloride permeability (PCl/PNa = 
12.3; Gunthorpe and Lummis, 2001). Interestingly, the 5-HT3B subunit sequence 
contains an alanine residue rather than a glutamate at position -1’ of the TM2 domain, 
which suggests that only 2 glutamate residues at this position are required for cation 
selection and may contribute to the reduced Ca2+ permeability of the heteromeric 
receptor (Davies et al., 1999). 
  
Figure 2. Representation of TM2 of the 5-HT3A receptor. Coloured according to side chain 
charge of residue; basic (orange); acidic (blue); polar (purple); non-polar (yellow). Adapted 
from Keramidas et al. (2004). 
 
Desensitisation kinetics 
5-HT3 receptor currents rapidly desensitize in the presence of agonist, with a decay 
phase that has been fitted to both monophasic (Neijt et al., 1989; Yang, 1990; Hu and 
Lovinger, 2005) and biphasic (Yakel et al., 1991; Boddeke et al., 1996) exponentials. 
Superfusing concentrations of 5-HT which do not activate the ion-channel also reduce 
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the inward current in response to pressure-applied 5-HT, with receptors fully 
recovering within 2 minute rest periods (Bartrup and Newberry, 1996). The kinetics 
of 5-HT3 receptor desensitization can be modified by a number factors including; 
[Ca2+] (Yakel et al., 1993; Lobitz et al., 2001), voltage (Yakel, 1996), 
tetraethylammonium ions (Kooyman et al., 1993a), phosphatases e.g. calcineurin 
(Boddeke et al., 1996) and alcohols e.g. 5-hydroxyindole (5ΟΗΙ) and trichloroethanol 
(TCE; the active metabolite of the anaesthetic chloral hydrate; Kooyman et al., 1993b; 
Bentley and Barnes, 1998; Zhou et al., 1998). Specific amino acid substitutions at the 
following residues also alter desensitization kinetics; S248 within TM1 (Lobitz et al., 
2001), 4’ lysine and 9’ leucine within TM2 (Yakel et al., 1993; Gunthorpe et al., 
2000), D298 within the TM2-TM3 linker (Hu and Lovinger, 2005) and R427 within 
the large intracellular loop (Hu et al., 2006). Furthermore, Arginine residue A427 
exhibits critical importance for receptor desensitisation  through potential interaction 
with adjoining amino acids (Hu et al., 2006). Finally, 5-HT3 receptor subunit 
composition also appears important. Co-expression of a truncated h5-HT3A subunit 
and the wild-type h5-HT3A subunit, within a heterologous expression system, forms a 
slower desensitizing receptor (Brüss et al., 2000b).  Heteromeric 5-HT3AB receptors 
recover from desensitization considerably faster than the homomeric 5-HT3A receptor 
and kinetic modelling studies indicate that the mechanism of desensitisation is altered 
by the 5-HT3B subunit (Hapfelmeier et al., 2003). 
Allosteric modulation 
An array of different compounds, modulate the 5-HT3 receptor mediated response. 
Assuming a similar action to other ligand-gated ion-channels, the interactions possibly 
occur at sites distinct from the agonist binding domain. Potentiation of the 5-HT3 
mediated current occurs by alcohols such as, ethanol, butanol, isopentanol and 
trichloroethanol (Machu and Harris, 1994; Lovinger and Zhou., 1994; Downie et al., 
1995; Bentley and Barnes, 1998). Furthermore, allosteric modulation of 5-HT3 
receptor function has been shown within neuronal cells of transgenic mice over-
expressing 5-HT3 receptors in frontal cortex neurons, which may indicate a function 
for 5-HT3 receptors in mediating the behavioural effects of alcohol (Sung et al., 
2000). In contrast, some functional studies and experiments with the guinea-pig 5-
HT3A subunit orthologue have shown that ethanol inhibits 5-HT3 receptor mediated 
22 
 
Chapter 1: Introduction 
 
responses (for review see, Parker et al., 1996a). These effects do not seem to occur via 
direct phosphorylation of the putative phosphorylation sites within the 5-HT3 receptor 
(Machu et al., 1999).  Further, via post translational modification by protein kinases 
the kinetics of the receptor can change. The large cytoplasmic loop contains a cluster 
of putative protein phosphorylation sites for PKA which substantially accelerate 
desensitisation (Lankiewicz et al., 2000) 
 
Anaesthetic agents also appear to modulate the 5-HT3 receptor current. Both local and 
general anaesthetics were shown to inhibit the 5-HT-induced influx of [14C]-
guanidinium via a mechanism not correlating with anaesthetic lipophilicity (Barann et 
al., 1993). In addition, the local anaesthetics, bupivacaine, tetracaine, cocaine and 
procaine were shown to inhibit 5-HT3 receptor-mediated currents in rat nodose 
ganglion (Fan and Weight, 1994). Barbiturate anaesthetics, including thiopentone and 
pentobarbital, also inhibit the responses to 5-HT (Jenkins et al,. 1996; Barann et al., 
1997). In contrast, the volatile anaesthetics, which include halothane and isoflurane, 
potentiate the 5-HT3 receptor-mediated current, an effect that is additive to the 
potentiation by ethanol, which therefore indicates that these compounds exert their 
effects at different molecular locations (Parker et al., 1996a; Jenkins et al., 1996).  
Other compounds that have an allosteric effect on the 5-HT3 receptor include; 5-
hydroxyindole analogues that delay agonist dissociation by increasing channel 
opening (van Hooft et al., 1997), gonadol steroids, for example, 17β-estradiol and 
progesterone (Wetzel et al., 1998), imidazolines; ifenprodil and ketamine (Peters et 
al., 1991; Molderings et al., 1996), bisindolymaleimide (Coultrap et al., 1999), L-type 
Ca2+ channel blockers; verapamil, diltiazem, and nimodipine (Hargreaves et al., 1996) 
and divalent cations, for example, Cu2+ and Cd2+, Zn2+ (Lovinger, 1991, Hubbard and 
Lummis, 2000), Mg2+ (Maricq et al., 1991) and Ca2+ (Maricq et al., 1991; Nieymer 
and Lummis, 2001; van Hooft  and Wadman, 2003), which appear to inhibit 5-HT3-
mediated currents at high concentrations (Lovinger, 1991),  
The effect of some of the previously mentioned 5-HT3 receptor allosteric modulators 
is altered by the presence of the 5-HT3B subunit. For example, the heteromeric 5-
HT3AB receptor seems less prone to modulation by ethanol and also the effects of 
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trichloroethanol are much less apparent compared to the homomeric 5-HT3A receptor 
(Hayrepetyan et al., 2005). Similarly, the ability of the volatile anaesthetics to 
potentiate the 5-HT3 receptor mediated responses was reduced, or even inverted to an 
inhibition in the case of isoflurane, by the co-expression of the 5-HT3B subunit with 
the 5-HT3A subunit (Stevens et al., 2005).   
 
5-HT and digestive function 
Serotonin is predominately (~95%) synthesised and stored within the gastrointestinal 
(GI) tract in the enterocromaffin cells (EC) in the enteric mucosa. Smaller stores are 
present in serotonergic neurons of the enteric nervous system (ENS), where 5-HT 
mediates both slow and fast neurotransmission (Gershon, 2004,2005: Gershon and 
Tack, 2007) by acting via multiple receptor subtypes (5-HT1,2,3,4,7, 1P). Animal studies 
indicated that serotonin can activate submucosal intrinsic primary afferent neurons 
(IPANs) via 5-HT1P receptor to initiate a peristaltic reflex (Pan and Gershon, 200; 
Wade et al., 1994). Further, myenteric IPANs by 5-HT3 receptors (Bertrand et al., 
1997) are able to initiate giant migrating contractions (Karaus and Sarna, 1987; 
Nagakura et al., 2002: Sarna, 2007). Additionally, stimulation of the 5-HT4 receptor 
can increase secretion of acetylcholine and calcitonin gene-related peptide (CGRP; 
Grinder, 2003) facilitating neurotransmission in prokinetic pathways (Liu et al., 2005; 
Pan and Callgan, 1994; Ren et al., 2008). 5-HT3 receptors also play a role in the 
regulation of GI motility, visceral sensation and nociception and GI secretion 
processes as well as the modulation of brain-gut axis influencing the GI tract and 
brain crosstalk. (Gershon 2004; 2005). 
 
5-HT3 receptor expression has been shown in the myenteric and submucosal plexus in 
the somata of neuronal cells in human gut. Additionally, they have been identified in 
enterocytes within the mucosal layer and in immune cells within the lamina propria 
(Sakurai-Yamashita et al 2000; Kapeller et al., 2011). Moreover 5-HT3 receptors have 
been shown to be present on cholinergic myenteric neurons modulating the release of 
acetylcholine (Kapeller et al 2011; Gershon 1999; Zhou et al., 1999), as well 
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as submucosal and myenteric ganglia involved in control of secretion and gut motility 
(Galligan 1996; Mawe et al., 1986; Tack et al., 1992; Wade et al 1994). Additionally, 
5-HT3 receptors appear on intrinsic afferents and the vagus nerve and are directly 
linked with crosstalk between GI tract and the brain, known as the brain-gut axis 
(Gershon 2004, 2005). Finally, 5-HT3 receptors are expressed in immune cells and 
activation leads to T cell activation and secretion of cytokines and prostaglandins 
(Khan and Hichami 1999; Fiebich et al., 2004). 
 
5-HT3 receptor and emesis 
Vomiting can be initiated by the release of serotonin from enterochromaffin cells of 
the intestinal mucosa, resulting in the stimulation of peripheral 5-HT3 receptors in the 
adjacent vagal afferent neurons (Minami et al., 2003). This effect is concurrent with 
the local release of serotonin in the area postrema, located on the dorsal medulla 
elongata. The co-action of 5-HT at both locations triggers the vomiting reflex, in 
which co-ordinated contractions of abdominal muscles diaphragm and the muscles 
used in respiratory inspiration causing intense pressure to formed in the stomach 
which released when the upper oesophageal sphincter relaxes leading to rapid 
expulsion of the stomach content through the mouth.   
Whilst vomiting can be considered a protective reflex to rapidly clear potentially 
poisonous substances from the GI tract, it can also be triggered by emotional events 
e.g. fear, disgust and is a common after effect of general anaesthetics. Vomiting is 
also a distressing side effect of cancer chemotherapy and radiotherapy. 
At present the 5-HT3 receptor antagonists tropisetron, ondansetron, granisetron, 
dolasetron and palonosetron are used for controlling chemotherapy and radiotherapy 
induced nausea and vomiting as well as in postoperative nausea and vomiting. 
Furthermore, there is clinical evidence that 5-HT3 receptor antagonists could be 
useful for the alleviation of nausea and vomiting during pregnancy and following 
caesarean section (Fujii et al., 1998; Einarson et al., 2004). The therapeutic effect of 
5-HT3 receptor antagonists derives via the inhibition on the vomiting reflex. It has 
been suggested that the 5-HT3B receptor subunit could play an important contribution 
to the effectiveness of these compounds. Further, Tremblay et al. in 2003 in a study 
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on polymorphisms have demonstrated a positive link between mutation in the 
promoter region of the 5-HT3B gene and the frequency of vomiting  
5-HT3 receptor involvement in eating disorders 
There is evidence that 5-HT receptor antagonists may be helpful in the treatment of 
eating disorders such as anorexia and bulimia, which often co-exist with depressive 
disorder. Increased vagal afferent nerve activity has been demonstrated in association 
with the binge eating and vomiting associated with bulimia. The 5-HT3 receptor 
antagonist ondansetron has been used to suppress the effect (Faris et al.,2000, 2006). 
Additionally, the symptoms of depression were also reduced in those subjects (Faris et 
al., 2006). A number of 5-HT3 receptor antagonists, such as tropisetron, ondansetron 
and bemesetron, are able to improve anorexia (Hammer et al., 1990; Jiang and 
Gietzen, 1994; Washburn et al., 1994). Another 5-HT3 receptor antagonist m-
chlorophenylpiperazine has also been reported to produce a similar improvement in 
patient mood and self-perception of body image, although it has been suggested that 
these affects could be facilitated by actions at other 5-HT receptor subtypes (Frank et 
al., 2001).  
 
5-HT3 receptor in pain and inflammation 
Peripheral and central 5-HT3 receptors are thought to be involved in nociception and 
inflammation (Zeitz et al., 2002; Fiebich et al., 2004; De la Vega et al., 2005; Khan 
and Hichame 1999). In particular, the expression of 5-HT3 receptors has been 
reported on primary afferents (Hamon et at., 1989) that transmit sensory and 
nociceptive signals from periphery to the brain. Clinically, 5-HT3 receptors are 
targeted in treatments for migraine, postoperative pain (Schowrer and Ramadori 1993; 
Schowrer et al., 1995; Kyriakides et al., 1999). Furthermore, following tissue injury a 
complex process of inflammation and nociception is initiated. Painful symptoms have 
been attributed to the serotonin-mediated release of various neuropeptides in 
particular substance P from damaged/ affected tissue. Indeed, 5-HT3 receptor 
antagonists appear to have analgesic effects (Saria et al 1990), particularly, 
tropisetron, in fibromyalgia, rheumatoid arthritis, tendonitis and lower back pain 
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(Faerber et al., 2001; Stratz and Muller 2000; Stratz et al., 2001; Samborski et al 
2004; Stratz and Muller 2004a, 2004b). Interestingly, co-administration of 5-HT3 
receptor antagonists with some NSAIDs have interesting outcomes on their ability in 
alleviating pain. The pain relieving properties of paracetamol when in co-
administration with granisetron or tropisetron are blocked. However, the analgesic 
effect of aspirin when co-administered with ondansetron is unaffected. (Sandrini et 
al., 2002, 2003; Pickering et al., 2006).      
 
5-HT3 receptors and Irritable bowel syndrome (IBS) 
Irritable bowel syndrome (IBS) is a chronic dysfunctional condition of the 
gastrointestinal (GI) tract that affects between 5-20% of the general adult population 
(Agreus et al., 2000; Hillila et al., 2004; Hungin et la., 2003). The incidence among 
women is twice as high as men, and onset after the age of 50 is unusual (Mertz HR 
2003). Symptoms ranging from constipation (IBS-C) to diarrhoea (IBS-D) 
predominate, or a combination/succession of the two (alternating IBS), often 
accompanied with severe abdominal pain and discomfort (Longtreth et al., 2006). The 
direct annual medical costs in the US were estimated to be close to $8 billion, the 
greater proportion of this cost (94%) not attributed to medication but implying unmet 
medical need for IBS therapy. The cost has been estimated as direct medical cost and 
as indirect medical cost approximating productivity loss and sick leave (Hulisz D., 
2004).  The exact pathogenesis of IBS is currently unknown; however, the typical 
symptoms of pain, altered GI motility and secretion disturbance suggest a potential 
dysfunction in neural pathways involved in sensory and motor function. Moreover, 
the interaction and relationship between causal and secondary alterations are unclear. 
Subpopulations of sufferers present changes in gut flora (e.g. post infectious), and 
there is an increased incidence of psychological co-morbidities (depression, anxiety, 
stress) in IBS sufferers. (clinical practice guide-Andresen et al., 2011) 
 
Since the initial description of 5-HT3 receptor presence in the GI tract, various groups 
have speculated on the role of the diversity of 5-HT3 receptor subtypes (Fletcher and 
Barnes 1998; Gaddum and Picarelli 1957). It has been hypothesised that sequence 
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variants of HTR3 genes may contribute to the aetiology of functional GI disorders 
(Humphrey et al., 1999; Jones and Blackburn, 2002). It has been highlighted by the 
Niesler group that variants of HTR3A and HTR3E are associated with IBS-D patients, 
leading to a significant up-regulation of the expression of the receptor subunit in vitro, 
indicating an increased susceptibility in those individuals (Kapeller et al., 2008).  
Given the evidence implicating the involvement of 5-HT3 receptor dysfunction in 
IBS, drugs acting at 5-HT3 receptors have been targeted as potential treatments for the 
condition. Visceral hypersensitivity, as often experienced in IBS, is positively 
influenced by 5-HT3 receptor antagonists (Mayer et al., 2001). Alosetron, ondanseron 
and cilasetron have been shown to display beneficial effects on visceral sensation, gut 
motility and secretion in clinical trials of IBS patients (De Ponti, 2004; Gershon and 
Tack, 2007; Ford et al., 2009). In particular, alosetron appears effective in alleviating 
the symptoms of IBS-D by decreasing gut transit time, increasing fluid absorption and 
reducing pain (De Ponti, 2004; Ford et al., 2009). Unfortunately, the broad utilisation 
of 5-HT3 receptor antagonists (alosetron, ramosetron, palonosetron) has been 
hampered due to incidences, although rare, of severe constipation and ischaemic 
colitis associated with alosetron (Clayton et al 1999; Ford et al 2009) the first of the 
setron class to be introduced. However, ramoretron, was launched in Japan in 2008 
with no reports of the same serious adverse effects indicating that safer modulators of 
5-HT3 receptor can be achieved (Matsueda et al., 2008). 
Future directions; ligands 
Partial activation of ligand gated ion channels is an established drug discovery 
strategy that could potentially improve side effect profiles of classical ligands (Hogg 
and Bertrand 2007) and could potentially be utilised in the treatment of IBS. Based on 
the intrinsic activity that would possess could be used in the treatment either of IBS-C 
or IBS-D. A high affinity 5-HT3 receptor low intrinsic activity partial agonist would 
be predicted to attenuate 5-HT3 receptor function in the presence of excessive 
endogenous serotonin, but still maintain a basal level of receptor function. Such 
compounds could reduce risk of constipation and other unwanted side effects 
associated with classical antagonists currently used in receptor inhibition in IBS-D. 
One such compound is AMR-SER-67 (Usyatinsky et al., 2008) along with other 
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potential compounds by AMRI (Manning et al., 2010).  Furthermore, compounds with 
a high intrinsic activity should alleviate IBS-C symptoms. Indeed, one of the leading 
candidates DDP733 with high intrinsic activity has passed Phase IIb trial for IBS-C 
(Evangelista 2007).  However, in some patients the compound caused emesis, 
predictable outcome for a high intrinsic activity 5-HT3 receptor partial agonist. 
Although 5-HT3 agonists show some promise, the incidence of side effects is a 
hindrance to further development. In addition to the orthosteric 5-HT site the 5-HT3 
receptor complex possesses a topologically distinct allosteric modulatory site, with the 
potential of presenting therapeutic target. The advantage of positive allosteric 
modulators (PAMs) as a target for therapeutic pharmaceutical purposes would be the 
ability to modulate receptor function whilst retaining spatial and temporal control 
(Williams et al., 2011). In particular, a positive allosteric modulator may be able to 
offer relief from reduced gastrointestinal motility disorders such as IBS-C. Of 
particular interest is 5-chloroindole (Cl-indole), a steel corrosion inhibitor (Moretti et 
al., 1996; see Figure 1), which we demonstrated (Newman et al., 2013) to be a 
relatively potent Type II PAM of the 5-HT3A receptor (using nomenclature coined for 
PAMs of the nicotinic Ach receptors (Gronlien et al., 2007; Williams et al., 2011). An 
intriguing possibility is that an endogenous ligand could associate with the Cl-indole 
recognition site expressed in the 5-HT3 receptor analogous to the b-carbolines at the 
benzodiazepine site on the GABAA receptor (Peña et al., 1986; Evans and Lowry, 
2007). This could offer further pharmacological rationale for drug design and more 
avenues to manipulate selectively the function of 5-HT3 receptor for therapeutic 
purposes in the treatment of IBS. As an added advantage, such compound (negative 
allosteric modulators) could prove a useful pharmacological tool in identifying and 
characterise low intrinsic activity partial agonists. This could be of particular 
assistance in the development of partial agonists in targeting the therapy of all forms 
of IBS.   
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Aims 
In an attempt to increase our understanding of the 5-HT3 receptor pharmacology and 
in an effort to aid in the development of drugs that could provide better targeting of 
the receptor with perspective therapeutic applications we aimed to investigate the Cl-
indole and the effect that has on 5-HT3 receptor pharmacology utilising an array of 
experiments and techniques. 
I would test the hypothesis that Cl-indole is a positive allosteric modulator of the 5-
HT3 receptor. I would attempt to characterise and identify the potential response in the 
presence of Cl-indole. Further I would attempt to classify the compound as potent (or 
not) Type I or II PAM of the 5-HT3 receptor, in the human and murine receptor 
subtype. I would then be able to further assess  if there is any species selectivity of the 
drug, which would potential allows to identify mechanistically how it produces its 
effects compared to other PAM (for instance TCE and 5-Hydroxyindole). I would 
then proceed to, using data for the murine receptor subtype from Changeux group 
already published accordingly to the h-5HT3A subunit employing single amino acid 
mutation  in attempted to knock-out the modulatory effect of Cl-indole, thus allowing 
us to map the binding pocket of the allosteric compound. 
 Furthermore, I would try to characterise the pharmacology of Cl-indole using a range 
of full and partial agonists of the 5-HT3 receptor (mCPBG, 2-methyl-5HT, DDP733, 
quipazine, dopamine and 5-HT) in order to understand the potential allosteric site, as 
well as gaining knowledge in distinguishing low intrinsic activity partial agonist from 
antagonists to the 5-HT3 receptor  
In order to fully characterise the response that Cl-indole is able to facilitate, I would 
use Cl-indole to assess if it is able to reactivate desensitised 5-HT3 receptors once an 
agonist has stimulated them.  
Additionally, I would test the hypothesis that the presence of 5-chloroindole and other 
allosteric modulator, like progesterone (an endogenous allosteric modulator),  are able 
to modulate the receptor internalisation, as well as the activity of agonists and/or 
antagonists, which would provide us with further understanding of the mechanism of 
allosteric modulation (positive and negative). Moreover, we would gain further 
understanding of the function of the homomeric 5-HT3A receptor 
30 
 
Chapter 1: Introduction 
 
Moreover the stability of the h5-HT3A receptor and the importance of the c-terminus 
are of interest as the understanding of the receptor pharmacology and allosterism 
maybe be linked to the stability of the receptor and hence I would examine in the 
presence of chaotropic factor the importance of the c-terminus of the subunit. 
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Chapter 2: Materials and Methods 
2.1.1 Quantitation of DNA samples 
The quantity of DNA within a sample was calculated using a spectrophotometer 
(Thermo Spectronic Biomate 3).  At a wavelength of 260 nm (1 cm path length) the 
absorbance, or A260, reflects the quantity of DNA or RNA. An Optical Density (OD) 
reading of one corresponds approximately to, 50 µg/ml for double-stranded DNA, 40 
µg/ml for single-stranded DNA and RNA, and 33 µg/ml for single-stranded 
oligonucleotides. Comparing the ratio of absorption at, OD260:OD280, gives an 
indication of the purity of the sample, where protein absorbance is measured at 280 
nm. Typically an OD260: OD280 > 1.8 is considered relatively pure and the 
concentration of the DNA accurate (Sambrook and Russell, 2001).  
2.1.2 Restriction endonuclease digest 
One unit of restriction enzyme will completely digest 1 µg of DNA in a 50 µl reaction 
in 60 minutes. Restriction endonucleases are supplied with a 10X buffer, which all 
contain magnesium chloride. Some restriction enzymes require bovine serum albumin 
(BSA) at a final concentration of 100 µg/ml, however, the presence of BSA is not 
inhibitory to enzymes that do not require it. Table 3 represents a typical 50 µl single 
digest used in this study; most enzymes require incubation for 1-2 hours at 37ºC. If a 
double digest was required for cleavage at two distinct regions within a DNA 
molecule, this could be completed simultaneously with a buffer compatible to both 
enzymes, or sequentially either after heat inactivation (at 65ºC/80ºC) of the initial 
digesting enzyme or purification via agarose gel electrophoresis (see section 2.3.3). If 
less than 1 µg of DNA was to be digested a smaller scale reaction was used, with a 
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total volume of 20 µl, reducing the volume of constituents, proportionally. Digests 
using specific enzymes were altered to meet the conditions described in the 
manufacturer’s instructions (New England Biolabs (NEB), UK). 
 
Restriction Digest Volume (µl) 
DNA  (1-5µg) x 
100x Bovine Serum Albumin 
(BSA) 0.5 
10x Buffer 5.0 
Restriction Endonuclease (20 
U/µl) 1.5 
ddH2O 
50- sum of 
above 
    Table 3. Constituents within a typical restriction enzyme digest. 
2.1.3 Agarose gel electrophoresis 
Separation of DNA through a solid agarose matrix, can be used to purify products 
from a PCR reaction, fragments from a restriction digest or characterise the restriction 
map of cDNA clones. The net negative charge of DNA allows it to migrate towards 
the anode of an electrophoresis tank, at a rate directly proportional to the size of the 
fragment.   
 
TAE 50x 
TRIS 2 M 
Glacial acetic acid 50 mM 
EDTA pH 8 5% (v/v) 
Table 4. Agarose gel electrophoresis buffer (stored at room Temperature). 
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Agarose 1.5% in 1X TAE buffer (Table 4) was heated in a microwave until fully 
dissolved. After brief cooling, a 10 mg/ml ethidium bromide stock was added giving a 
final concentration of 0.05 µg/ml, the latter binds to the DNA and allows visualisation 
under ultraviolet (UV) illumination. Gels were cast with an appropriate comb and 
allowed to set at room temperature.   
 
6x DNA Loading Buffer 
Bromomphenol Blue 0.25% w/v 
Xylene cyanol FF 0.25% w/v 
Ficoll (Type 400) 15% 
  Table 5. Agarose gel sample buffer (stored at room temperature). 
 
Samples were mixed with a 6X DNA loading buffer (Table 5) and ran alongside DNA 
molecular weight markers (Hyperladder I, Bioline). Typically, the gel was immersed 
in 1X TAE in an electrophoresis tank (Thistle Scientific) and ran for approximately 1 
hour at 100 V. Gels were then viewed under UV illumination using a UV 
transilluminator (Ultraviolet Products (UVP)).  
 
2.1.4  Agarose gel extraction and purification of DNA 
Extraction of DNA from an agarose matrix was achieved using the GenEluteTM Gel 
Extraction Kit (Sigma, NA1111). DNA bands, visualised under ultraviolet 
illumination, were excised from the gel, weighed and incubated with three gel 
volumes (w/v) of gel solubilisation solution at 50-60ºC for 10 minutes. Spin columns 
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were prepared with 500 µl of column preparation solution and centrifuged at 13,000 x 
g for 1 min at room temperature. When the gel had completely dissolved, DNA was 
precipitated with one gel volume of molecular biology grade isopropanol. Gel 
solution was then loaded onto the column, in 700 µl aliquots, centrifuged at 13,000 x 
g for 1 min, discarding the flow-through. The column was then washed with 700 µl of 
Wash solution (Wash Solution Concentrate G supplied, diluted with 95-100% ethanol, 
giving a final concentration of approximately 75% ethanol) centrifuged at 13,000 x g, 
for 1 minute, discarding the flow-through and repeating the spin to remove residual 
ethanol. The column was then transferred to a fresh collection tube and 50 µl of 
ddH20 was added to the column and incubated for 1 min. The column was then 
centrifuged at 13,000 x g for 1 min, and the eluted DNA solution stored at -20ºC. 
 
2.1.5  DNA ligation  
DNA ligases catalyse the formation of phosphodiester bond between the 5’-phosphate 
and 3’-hydroxyl termini of DNA or RNA, of both cohesive ended or blunt ended 
fragments. The majority of enzymes used in molecular cloning are isolated from 
bacteria or bacteriophage. T4 DNA ligase, from bacteriophage T4, was used 
predominantly to ligate cDNA into plasmid vectors (NEB, UK). Reactions to ligate 
cohesive ends were incubated at 4ºC overnight with the buffer supplied containing the 
cofactor and activators, Mg2+, ATP and dithiothreitol (Promega Incorporation, USA). 
Typically, at least two insert vector molar ratios were assembled (1:1 or 3:1) , with 1U 
(Weiss Units) of T4 DNA ligase (Weiss et al., 1968). Table 6 below represents a 
standard 20 µl reaction with a 0.5 kb insert, a 3kb plasmid vector and a molar ratio of 
1:1. Control reactions omitting either the cDNA insert to assess the incidence of self-
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ligating vector or T4 DNA ligase to observe the presence of any undigested vector 
were also prepared. 
 
 
 
 
 
 
Table 6. Components of a typical DNA ligation reaction. 
 
2.1.6 Bacterial Culture 
Growth of bacteria was performed using Luria-Bertani Broth (LB) 25g/l (Sigma). 
Sterility was achieved via autoclaving, and liquid media supplemented with the 
appropriate antibiotic where necessary. Liquid culture was incubated at 37ºC shaking 
at 225-250rpm.  For solid phase growth of bacterial colonies, agar was added to the 
LB at 2% w/v and autoclaved. When required, it was re-melted in a microwave before 
allowing cooling to 55ºc for supplementing with antibiotic. Plates poured and set at 
room temperature were stored at 4ºc for up to 2 weeks.  
 
2.1.6A Generation of chemically ‘super competent’ bacterial cells 
The use of bacteria to propagate plasmid vectors has become wide standard laboratory 
practice. Bacterial cells for example, E.coli, may be electroporated or heat shocked to 
T4 DNA Ligation 
Vector DNA 200 ng 
Insert DNA 34 ng 
10x Ligase Buffer 2 µl 
T4 DNA Ligase 
(Weiss Units) 1U 
ddH20 Final vol. of 20 µl 
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induce the uptake of DNA. Bacteria cells required for DNA propagation were treated 
chemically with cations resulting in a ‘competent state’. The protocol below is based 
on that first described by Cohen et al. (1972). 
5 µl of XL10-Gold® supercompetent cells (Stratagene, USA) frozen at -80ºC, were 
used to inoculate a 5 ml LB culture, supplemented with tetracycline 12.5 µg/ml and 
grown for approximately 12 hours at 37ºC with agitation.  The culture was then used 
to inoculate a 250-500 ml expansion culture containing tetracycline 12.5 µg/ml and 
MgCl2 20 mM. Growth of the bacteria was monitored until the culture had an OD600 
of 0.4-0.8 (exponential growth phase). The cells were centrifuged at 4,000 x g at 4ºC 
and resuspended in 0.4 culture volumes of TB1 (Table 5) and incubated on ice for 5 
minutes. Cells were recovered by centrifugation, the supernatant removed and the 
pellet resuspended in 0.04 volumes of TB2 (Table 5) and incubated on ice for 45-
60mins. Aliquots of 200 µl were frozen in liquid nitrogen before storage at -80ºC. 
Both TB1 and TB2, were filter sterilised prior to use (Fisher Brand, UK). 
 
 
 
 
 
 
Table 7. [A]-TB1 [B]-TB2 Buffer constituents for generation of “supercompetent” 
bacterial cells (stored at room temperature).   
 [A]       TB 1    pH 5.8 (Acetic acid) 
   KC2H3O2 30 mM 
CaCl2 10 mM 
MnCl2 50 mM 
RbCl 100 mM 
Glycerol 15% 
[B]         TB 2  pH 6.6 (KOH) 
MOPS 10 mM 
CaCl2 75 mM 
RbCl 10 mM 
Glycerol 10% 
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2.2 Transformation of competent bacteria 
Approximately 10µl of diluted maxiprep in ddH2O (1:10) was incubated with 200µl 
of super-competent bacterial cells on ice for 20 minutes. A heat shock of 42ºC was 
applied for 1 minute, followed by incubation on ice for 5 minutes. Furthermore, 500µl 
of LB was added and the bacteria were incubated for 2 hours at 37ºc with agitation. 
Then they were plated on to agar LB containing ampicillin10µg/ml and grown 
overnight for approximately 16 hours at 37ºc.  
Single colonies from LB agar plates were chosen and they were grown over 6 hours in 
a 5ml ampicillin supplemented (10µg/ml; Sigma) LB culture. Subsequently, 1ml of 
this culture was added into 250ml of LB containing 10µg/ml ampicillin (Sigma) and 
grown overnight at 37ºc with agitation. The cells were then harvested by 
centrifugation for 5 minutes at 10,000 x g. 
A high purity plasmid purification commercial kit (Marligen Biosciences, Inc) was 
followed as per manufacturer’s instructions. The DNA pellets were resuspended in 
300µl of TE buffer, followed by purity and concentration determination using 
spectrophotometry. 
2.3 DNA extraction and purification from bacterial hosts 
Section 2.3A  Small scale  
Preparation of plasmid DNA from E.Coli was achieved using alkaline lysis with 
sodium dodecyl sulphate (SDS), a method first outlined by Birnboim and Doly in 
1979. The use of an anionic detergent at high pH, disrupts the cell wall, denatures 
proteins and chromosomal DNA. However, the alkali is unable to destroy base pairing 
in a tightly coiled closed circular plasmid (Sambrook and Russell, 2001). Small scale 
purification of plasmids was primarily required for subsequent automated sequencing 
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of cDNA clones. In which case, a commercially available kit (Wizard® Plus SV 
Minipreps DNA Purification System – Promega) using a column to bind, isolate and 
elute DNA was followed as to manufacturer’s instructions.  Where such a pure 
preparation was unnecessary, excess reagent buffers supplied in the kits or produced 
following manufacturer’s instructions were used with an organic solvent i.e. 
chloroform, added to increase purity without the columns. Buffer constituents are 
listed below (Table 8), and the procedure for more crude preparations outlined.  
Single colonies from LB agar plates were picked and grown overnight in a 5 ml LB 
culture supplemented with the appropriate antibiotic, typically ampicillin 100 µg/ml 
(Sigma). 1-5 mls of the culture were harvested by centrifugation, for 5 minutes at 
10,000 x g.  Supernatant was removed and the pellet completely resuspended in 250 
µl of Cell Resuspension Solution. Cells were lysed with 250 µl of Cell Lysis Solution, 
mixing gently by inverting the tube and incubated for 5 minutes at room temperature. 
Upon partial clearing, samples were neutralised with 350 µl of neutralisation solution. 
Precipitated cell debris and chromosomal DNA were pelleted by centrifugation, at 
14,000 x g for 10 minutes at room temperature. An equal volume of chloroform was 
added, mixing with gentle inversion and samples spun at 14,000 x g for 2 minutes. 
The aqueous layer was transferred to a fresh tube and an equal volume of isopropanol 
added to precipitate DNA, followed by centrifugation at 14,000 x g for 30 minutes at 
4ºC. The resulting pellet was washed in approximately 70% ice cold ethanol, spun for 
3 minutes at 14,000 x g, and left to air dry for approximately 10 minutes. Pellets were 
resuspended in 30-50 µl ddH20.  
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            [B]:Stored at room temperature 
[A]: Stored at 4ºC 
 
 
 
         [C]:  Stored at room temperature  
 
Table 8. Buffers supplied by manufactures for small DNA extraction from bacterial 
hosts. [A] Cell resuspenion buffer; [B] Cell lysis solution; [C] Neutralization solution. 
 
2.3B Large scale 
Small scale preparations of plasmid vectors does not yield the quantity of cDNA 
required for experimental procedures such as mammalian cell transfection. Large 
scale extraction was achieved using the same Alkaline – SDS method described in 
section 2.1.7.1. A high purity plasmid purification commercial kit (Marligen 
Biosciences, Inc) was followed to manufacturer’s instructions. DNA pellets were 
resuspended in 300 µl of ddH20, purity and concentration determined by 
spectrophotometry (see section 2.1.1) 
2.4 Polymerase chain reaction 
The polymerase chain reaction (PCR) utilises thermostable DNA polymerases to 
replicate specific regions of DNA, in vitro.  Two synthetic oligonucleotides are 
required to prime DNA synthesis by the polymerase. Additional requirements include 
the four deoxynucleoside triphosphates (dNTPS; Bioline), monovalent and divalent 
Cell  Resuspension Solution 
Tris-HCl pH7.5 0.125 M 
EDTA 10 mM 
RNase A 100 µg/ml 
Cell  Lysis Solution 
NaOH 0.2 M 
SDS 1% 
Neutralization Solution 
Guanidine hydrochloride 4.09 M 
Potassium acetate 0.759 M 
Glacial acetic acid 2.12 M 
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cations, typically Mg2+, a buffer to maintain pH and the template DNA. For faithful 
copying of the cDNA template a proofreading polymerase, Pfu (Stratagene), was 
preferred due to the greater fidelity achieved compared with more common 
polymerase’s such as Taq. The cycles of PCR are divided in to three segments; 1) 
denaturation, 2) annealing and 3) extension. The denaturing temperature is determined 
by the G/C content of the double stranded DNA template and the polymerase stability. 
Higher G/C content, results in a higher denaturing temperature; typical maximum 
temperatures are 94-95ºC. An initial denaturing step may be employed prior to 
cycling to ensure complete separation of the template DNA, especially those that are 
large and/or closed circular. 
 
The annealing temperature is affected largely by the melting temperature (Tm) of the 
oligonucleotides. This can be estimated using a number of equations (see Sambook 
and Russell, 2001) and the annealing temperature is typically set at 3-5ºC lower than 
the oligonuleotide TM, however, optimisation is often required. Extension of the 
annealed primer by the DNA polymerase occurs at the optimum temperature for each 
particular enzyme, for example Pfu’s optimum condition is 72-78ºC. Polymerases 
vary in time required to extend a set number of nucleotides/minute, however, 
extension is often carried out for approximately 1-2 minutes per 1000 base pairs of 
template DNA. A final extension step after cycling has been completed may help to 
fully extend products. Typically, 30 cycles were programmed and carried out in an 
automated thermal cycler (TC-312 Techne®). An example reaction used in this study 
and the appropriate cycling parameters are shown in Table 7 
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         Initial Denature       2 min at  95ºC  
    
                                                     1 min at 95ºC 
                     30 Cycles                1 min at 55ºC 
                                                     2 min at 72ºC 
 
 
                   Final Extension        10 min at 72ºC 
 
Table 9. Components within a typical PCR reaction with example cycling parameters.  
2.5 Mutagenesis 
2.5A Site-directed mutagenesis- QuickChange® 
The QuikChange® site-directed mutagenesis method, (Stratagene) may be used to 
delete, insert or switch nucleotides of a particular cDNA clone within a plasmid 
vector.  
Manufacturer’s instructions for the design of oligonucleotide primers were followed 
meticulously. Forward and reverse complementary oligonucleotides 25-45 base pairs 
in length, contained the desired mutation and had a melting temperature ≥ 78ºC. 
Typically, PCR parameters were as followed; an initial denaturing step of 95ºC for 30 
seconds followed by 12-18 cycles of denaturing for 30 seconds at 95ºC, annealing for 
1 minute at 55ºC and extending for 2 minutes/kb of template at 68ºC. 
 
 
PCR reaction 
DNA polymerase 
buffer x10 5 µl 
 Each dNTP  200 µM 
Template DNA  ~ 10 ng 
Forward Primer 1 µM 
Reverse Primer 1 µM 
DNA polymerase 1- 5U 
ddH20 
Final Vol. of 
50 µl 
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     Table 10. Components of a typical QuikChange® reaction. 
 
2.5B Automated DNA sequencing 
Verification of clone sequence and the success of mutagenesis were achieved by 
automated DNA sequencing. Samples prepared using small scale purification kits 
(section 2.1.7.1) were sent to Lark Technologies LTD (Hope End, Takeley, Essex) 
and sequenced using fluorescent dye terminator sequencing, a method derived from 
the original Sanger di-deoxy chain termination method (Sanger et al., 1977). 
2.6 Cell cultures 
2.6A Maintenance of HEK-293 cells  
Cells were maintained at 37oC in an atmosphere of 95% air, 5% CO2, 100% relative 
humidity (LEEC cell culture incubator).  Grown in T75 (75cm2) tissue culture flask 
containing Dulbecco’s Modified Eagles Medium (DMEM), supplemented with 10% 
(v/v) foetal calf serum and 1% (v/v) penicillin/streptomycin (Sigma).  To maintain 
healthy proliferation the cells were routinely passaged. At 100% confluency, media 
was aspirated off the cell monolayer and washed in 5 ml Dulbecco’s Phosphate-
Buffered Saline (D-PBS; Sigma).  Cells were then dissociated from the flask with 2 
mls of trypsin/EDTA (Sigma) wash followed by incubation with trypsin/EDTA for 
QuikChange®  Reaction 
10X pfu  reaction Buffer 5 µl 
dsDNA template  5-50 ng 
Forward Primer 150 ng 
Reverse Primer 150 ng 
dNTP mix (10mM of each) 1 µl 
ddH20 Final vol. of 50 µl 
Pfu Turbo 1 µl 
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5mins. The reaction was terminated with the addition of 8mls of serum containing 
DMEM that dilutes the trypsin and contains trypsin inhibitor α-1-antitrypsin. The cell 
suspension was then aliquoted 1:5 passage, thus 2mls of cell suspension in a T75 flask 
containing 15mls of complete media.  
All cell culture was completed in a microbiological safety cabinet, preventing 
contamination with bacteria, fungi and viruses. 
 
Section 2.6B  Maintenance of COS-7 cells 
Cell lines isolated from numerous species and tissues have become readily accessible 
commercially. These allow the expression of particular proteins in controlled 
environments, where the effect of mutated proteins can be determined in the absence 
of wild-type protein. COS-7 cells, an ‘established’ cell line from African green 
monkey kidney fibroblast cells, were used in this study, obtained originally by the 
European Collection of Cell cultures (ECACC; 87021302). They have no detectable 
endogenous 5-HT3 receptor protein and are capable of expressing high levels of 
heterogeneously expressed protein. 
 
Cells were maintained at 37oC in an atmosphere of 95% air, 5% CO2, 100% relative 
humidity (LEEC cell culture incubator). For experiments where temperature effects 
on protein expression were investigated, cells were incubated in identical atmospheric 
conditions, at reduced temperatures. Cultures were grown in T75 (75 cm2) tissue 
culture flasks containing Dulbecco’s Modified Eagles Medium (DMEM; Sigma), 
supplemented with 10% (v/v) foetal calf serum and 1% (v/v) penicillin/streptomycin 
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(Sigma).  To maintain healthy proliferation the cells were routinely passaged. At 
approximately 100% confluency, media was aspirated off the cell monolayer and the 
cells washed in 5 mls of Dulbecco’s Phosphate-Buffered Saline (D-PBS; Sigma).  
Cells were then dissociated from the flask with 2 mls of trypsin/EDTA (Sigma) for 2-
5 mins. The reaction was quenched with serum containing DMEM, which in addition 
to diluting the trypsin, contains a trypsin inhibitor, α-1-antitrypsin. Routinely, 8 mls of 
DMEM quenched the reaction forming a 10 ml suspension culture. As an example, for 
a 1:5 passage, 2 mls of this suspension was used to seed a T75 flask containing 15 mls 
of media. Dividing this suspension culture between 10 or 2 flasks manipulated the 
speed of proliferation. All cell culture was completed in a microbiological safety 
cabinet, preventing contamination with bacteria, fungi and viruses. 
 
2.6C Maintenance DG75 Lymphocytes 
Cells were maintained at 37oC in an atmosphere of 95% air, 5% CO2, 100% relative 
humidity (LEEC cell culture incubator).  Grown in T75 (75cm2) tissue culture flask 
containing RPMI 1640 media (P.A.A) supplemented with 10% (v/v) foetal calf serum 
and 1% (v/v) penicillin/streptomycin (Sigma) (complete media). At 100% confluency, 
10mls of cell suspension was added to 20mls complete media. 
 
2.6D Long term storage of cell lines over liquid nitrogen and 
recovery 
Cells were grown to 100% confluency, the adhere cell lines were dissociated from the 
flask with trypsin/EDTA. Media was added to quench the reaction and all cell lines 
were pelleted from the suspension by centrifugation at 1200 RCF for 5 minutes. The 
pellet was resuspended in 1ml of freezing media, 50% foetal calf serum, 40% DMEM 
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or RPMI 1640 as required and 10% Dimethylsulphoxide (DMSO; Sigma). To protect 
cells from ‘snap freezing’ 1ml aliquots in cryovials were frozen overnight at -80oC in 
Mr Frosty™ (Wessington Cryogenics), containing room temperature isopropanol 
which very slowly allowed cells to reach –80oC. Subsequently, the vials were stored 
in liquid nitrogen cell bank. 
When required, cryovials were defrosted at 37oC and added immediately to 7mls of 
supplemented media in a T25 (25cm2) flask. Media was changed the following day 
and when cells reached confluency they were transferred to T75 flasks for culture, as 
described above as required for each cell line. 
2.7 Transient Transfection of Mammalian cell lines by 
electroporation 
The capacitance, voltage, time of pulse and the size of the cuvette were optimized 
previously for both HEK-293, COS-7 cell lines and the following protocol was used 
for both.  
Pulsed electrical fields were used to insert plasmid cDNA into COS-7/HEK 293 cells. 
Although the exact mechanism underlying this highly effective technique is not fully 
understood, it is believed that hydrophilic pores within the cell membrane form with 
greater ease, as the transmembrane voltage increases (Weaver, 1993). During this 
transient pore opening period DNA may enter the cytoplasm. The effectiveness of 
electroporation relates to the pulse field length and strength. The capacitance, voltage, 
time of pulse and the size of the cuvette were optimized previously for the COS-7 cell 
line and the following applied. 
Cells were grown to 100% confluency, dissociated using trypsin-EDTA and quenched 
with 5mls DMEM/MEM. The cells were pelleted by centrifugation at 1200 rcf and 
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resuspended in 1ml of media per flask of cells. The 1ml of cell suspension was added 
to the electroporation cuvette, 4 mm path length, (GeneFlow), containing the 
appropriate cDNA, total amount of 30 µg. The cell suspension containing the cDNA 
was incubated for 15 minutes before electroporating with an Easyject Plus (Equibio) 
at 400 V, 3 msec pulse with capacitance of 150µF. 
 
Cells were immediately transferred to a T75 flask containing 40 mls of media which 
was subsequently divided in two. When transfected cells were required for 
immunocytochemistry techniques, 200 µl of transfection mixture was taken from the 
40mls and added to appropriate wells of a 24 well plate that contained 500 µl of 
media and an autoclaved glass coverslip (13 mm diameter; VWR International). Cells 
were harvested 48-72 hours post transfection. Media was aspirated, and the cellular 
monolayer washed with 5 mls of ice-cold PBS. Cells were dissociated with 5 mls of 
ice-cold PBS using a cell scraper; the flask was subsequently rinsed with an additional 
5 mls of ice-cold PBS to remove all remaining cells. The suspension was centrifuged, 
at 3700 x g for 6 minutes, PBS aspirated, and the pellet ‘snap’ frozen in liquid 
nitrogen and stored at -80 oC until required. 
2.7.1 DG75 Cells Transfection 
In order to transfect the DG75 B lymphocytes two transfection techniques were used, 
electroporation and P.E.I. The following protocol was used after intense optimisation. 
 
2.7.1A Electroporation  
When the cells reached 100% confluency, they were split 1:2 24 hours prior to 
transfection. The cells were, then, pelleted by centrifugation at 1200 rcf for 5mins and 
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resuspended in fresh HEPES buffered RPMI 1640 medium (5µl 1M HEPES 
buffer/ml) at concentration ~107 cells in 1 ml. The cell suspension was cooled on ice 
for 5mins. Additionally, 80µg of plasmid DNA was mixed in with 30µl of TE buffer 
into the electroporation cuvette. Then the 1 ml of cold cell suspension was added to 
the cuvette and it was gently mixed. The cell suspension was then electroporated 
using an Easyject Plus (Equibio) at 310 V, with capacitance of 900µF. Subsequently, 
the cell suspension was mixed well in the cuvette and incubated at room temperature 
for 10mins. The cell suspension was then added to 20mls of warm RPMI 1640 
medium supplemented with 10% FCS and incubated for 24-36 hours at 37oC in an 
atmosphere of 95% air, 5% CO2, 100% relative humidity. 
2.7.1B Polyethelyne (PEI) 
The cells were pelleted by centrifugation at 1200 rcf for 5mins and resuspended in 
fresh RPMI 1640 medium. Moreover, 0.2-10mM PEI was mixed into 10-40μg of 
plasmid DNA in a ratio 1:1 and final volume of 500μl (the plasmid DNA was diluted 
in 5% Glucose in PBS). The mixture was incubated for 5-20mins at room 
temperature. Furthermore, 1ml of the cell suspension was added to the PEI-DNA 
mixture and incubated for 20mins at room temperature. Then the mixture was added 
into 40mls of warm RPMI 1640 media supplemented with 10% FCS and incubated 
for 24-36 hours at 37oC in an atmosphere of 95% air, 5% CO2, 100% relative 
humidity. 
 
2.7.2 Stably expressing the human 5-HT3A subunit 
HEK293 cells stably expressing the human 5-HT3A subunit (HEKh5-HT3A cells; 
Brady et al., 2001) were grown in Dulbecco’s Modified Eagle’s Medium, 
supplemented with 10% (v/v) foetal bovine serum, 1% (v/v) penicillin/streptomycin 
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(10,000 U/ml penicillin and 10 mg/ml streptomycin) and G418 (500 μg/ml) and 
maintained at 37°C, 5% CO2, 95% relative humidity. Approximately 24 hrs prior to 
[Ca2+]i assays, cells were seeded directly into poly-D-lysine coated, black-walled, 
clear bottomed, 96-well plates (Costar) with ~1 x 105 cells per well and similar for 
ELISA.   
 
2.8 Preparation of Dialysis Tubing 
We used dialysis tubing to dialyse FBS for ELISA experiments. Cut the tubing into 
pieces of convenient length (10-20cm). The tubes were then boiled for 10 minutes in 
0.5L of tubing preparation solution 1 ((2% (w/v) sodium bicarbonate 1 mM EDTA 
(pH 8.0)). They were then rinsed twice in distilled water followed by boiling for 
10 minutes in 0.5L of tubing preparation solution 2 (1 mM EDTA (pH 8.0)). Tubes 
were allowed to cool down and stored them in tubing preparation solution II at 4°C. 
Before used tubing was rinsed twice inside and out with distilled water. 
Foetal Bovine serum was dialysed by ultrafiltration  in dialysis tubing with cut off 10- 
14 KDa against 0.15 M NaCl over 48 hrs and the NaCl was renewed 3 times over that 
period.  The dialysis reduces the concentration of "free" low molecular weight 
components such as nucleotides and amino acids.  We were able to determine by 
HPLC that tryptophan and kynurenine reduced over 100 fold. 
 
2.9  Preparation of protein samples 
Whole cell homogenates 
Whole cell lysates were prepared for radioligand binding (section 2.3.4) and Western blotting 
(section 2.3.4). Cell pellets harvested from transfections and frozen in pairs, were resuspended 
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in 5 mls of ice-cold Tris; 50 mM, pH 7.5. The suspension was homogenised, using a Polytron 
(Polytron; Kinematica EmbH Kriens, Switzerland) at maximum speed for 10 seconds 
ensuring the sample was kept on ice. When a high protein concentration was required for 
Western blots, pellets were homogenised by hand in a glass homogeniser; 500 µl of ice-cold 
Tris; 50 mM, pH 7.5 (Fisher Brand, UK).  
Isolation of cell membranes 
To obtain a purer sample of cell membranes, pellets homogenised in 5 mls Tris, as 
described in 2.2.4.1, were centrifuged, for 12 minutes at 20,000 x g, 4 oC. The pellet 
was then resuspended in 20 mls of ice-cold Tris; 50 mM pH 7.5, homogenised for 5 
seconds with a polytron (max setting) and centrifugation repeated. The pellet, 
containing the membrane fraction of the cellular debris, was washed in 20 mls of Tris 
a further 3-8 times. The pellet was finally resuspended in 1-2 mls of Tris; 50 mM pH 
7.5. 
2.10 Characterisation of proteins 
Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) 
 
SDS-PAGE separates proteins according to molecular weight via electrophoresis.  
Gel preparation and electrophoresis 
The gels were cast using glass plates (10.5 x 9.8 cm, with 1mm spacers) from a 
Minigel-Twin tank electrophoresis system (Biometra). 
A 1:29 molar ratio of bisacrylamide:acrylamide (Severn Biotech Ltd), in a 30% stock, 
was used to prepare gel solutions. Table 2 indicates the components of the resolving 
and stacking gels (as well as buffers used for the assay).  
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Resolving gel was poured into plates, 1 cm below the bottom of the required comb 
wells. To ensure a clean levelled line between stacking and resolving gels, butanol 
was added on top of the resolving gel until the resolving gel was set at room 
temperature. Butanol was subsequently removed and the plates were rinsed with water 
to remove any excess unpolymerised resolving gel components. The stacking gel was 
then added and either a 10 well comb was then inserted to cast the wells. The gel was 
then left to set at room temperature. 
The tank was filled with SDS-PAGE running buffer ensuring the wells were fully 
submerged. Samples prepared in equal volume of 2 x SDS-PAGE sample buffer, 
boiled for approximately 10 minutes and centrifuged briefly, they were loaded into 
wells 20µl.  Prestained protein molecular weight markers were also loaded (10µl) to 
Table 2 RESOLVING GEL (10%) STACKING GEL (3.5%) 
30% (w/v) Acrylamide 
stock (ml) 5 0.93 
4x Lower Buffer (ml) 3.75 0 
4x Upper Buffer (ml) 0 2 
Water (ml) 6.12 4.95 
10% (w/v) APS (μl) 100 100 
TEMED (μl) 30 20 
Total volume (ml) 15 8 
Lower buffer: 1.5M Tris, 0.4% (w/v) SDS; pH 8.8 
Upper buffer: 0.5M Tris, 0.4% (w/v) SDS; pH 6.8 
SDS-PAGE reservoir buffer: 25mM Tris, 200mM glycine, 0.1% (w/v) SDS 
2x SDS-PAGE loading buffer: 15% (v/v) glycerol, 125mM Tris, 5mM EDTA, 2% (w/v) SDS, 
0.1%(w/v) bromophenol blue, 1% (v/v) 2-mercaptoethanol; pH 6.8 
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visualise migration and identify molecular weight of protein bands (New England 
Biolabs®, Inc). Electrophoresis was performed at 20mA per gel. 
 
Western Blotting 
Following gel electrophoresis the proteins were transferred via electrophoresis to an 
immunblotting membrane Polyvinylidene difluoride (PVDF; Immobilon P, 
Millipore). Transfer of the protein was achieved using a semi-dry system (Biometra), 
with Whatman 3MM paper saturated in transfer buffer acting as a reservoir. 
Presoaked Whatman papers were stacked ensuring no air bubbles were formed. Four 
papers were layered, before the PVDF membrane, soaked briefly in methanol and 
then in transfer buffer, was placed on the stack, followed by the polyacrylamide gel 
and four additional Whatman papers. Proteins required 0.8mA/cm2 current, in order to 
be transferred onto the PVDF membrane due to their movement towards the anode, 
for approximately 1 hour. 
 
Prior to the incubation with primary antibody, the PVDF was placed in blocking 
buffer (5% milk in TBS-T) for 1 hour at room temperature to block non-specific 
binding. The primary antibody (mouse anti-myc monoclonal antibody; ) was diluted to 
1:1000 concentration in 10mls of blocking buffer and incubated overnight at 4°c with 
gentle rocking  (50 rpm Mini Orbital Shaker SO5; Stuart Scientific). Washing was 
performed for 1hour with multiple changes of TBS-T washing buffer. The secondary 
antibody was then diluted to 1:1000 in 10mls blocking buffer and incubated for 2 
hours at room temperature on orbital shaker; secondary antibody coupled to the 
enzyme horseradish peroxidise (rabbit anti-mouse HRP). PVDF was then washed for 
1 hour with multiple changes of TBS-T washing buffer. The chemiluminescent 
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substrate, SuperSignal® West Pico (Pierce) was mixed as described in manufactures 
instruction and incubated with the PVDF membrane for 5 minutes. Subsequent 
exposure of the blot to Hyperfilm™ ECL™ (Amersham Biosciences) and developing 
using Kodak chemicals, revealed any immunoreactive bands. 
 
Amidoblack Staining 
Amido black powder was dissolved (0.1% w/v) in a 50:10:40 methanol:acetic 
acid:water and used to highlight proteins on the PVDF membrane, before or after 
immunoblotting. Staining appeared after incubation for as little as 10 minutes and any 
background was removed with washing in buffer omitting the dye. 
 
2.11 Radioligand Binding 
5-HT3 binding assay were performed using the labelled antagonist [3H] Granisetron 
(63.5 Ci/mmol, final assay concentration 1nm, PerkinElmer). Transfected cells were 
homogenised by sonication. Calculation of specific binding capacity per mg of 
cellular protein was achieved using 300μl total volume assays. Assays, carried out in 
triplicates, contained 100μl of radioligand, 100μl of whole cell homogenate and 100μl 
of binding buffer (Ice-cold 50mM Tris pH 7.5). To determine the level of non-specific 
binding, additional assays replacing binding buffer with 100μl of “cold” competing 
ligand, typically 10μM Ondansetron, were also measured in triplicate.  Assays were 
incubated for 1 hour at room temperature on a shaker and terminated with rapid 
filtration using a Brandel Cell Harvester (Model M-25RP). Ligand-receptor 
complexes were captured with Whatman GF/B glass fibre filters (Semat Technical 
(UK) Ltd), pre-soaked for 1-3 hours in Tris, Polyethyleneimine 3% (v/v). Filters were 
rinsed 2 times, with 3 mls of ice-cold binding buffer and placed into vials with 
scintillation fluid (Optiphase HiSafe 2; Perkin Elmer) for counting the radioactivity 
content, in a liquid scintillation counter (Tri-carb 1500 TR Liquid Scintillation 
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Analyser; Packard). Mean of triplicates was calculated and the specific binding 
(Total-Nonspecific) of [3H] Granisetron expressed per mg of whole cell homogenate 
protein. 
 
Pharmacological profile 
Studies to determine the range of ligand concentration required to inhibit specific 
binding of [3H]granisetron were performed as described above. Competition curves 
were fitted to a one-site competition model with an iterative curve fitting computer 
programme (KaleidaGraph™, Abelbeck Software). 
   b = (Bmax[L]n/([L]n + (K)n) 
Where b = bound ligand, Bmax = the maximal specific binding, [L] =concentration of 
competing ligand, K = IC50 of the competing ligand (the concentration at which 50% 
of the binding sites are occupied by the competing ligand), n = the Hill coefficient. 
 
2.12 High Progesterone Tratment 
NG108-15 mouse neuroblastomas x rat glioma hybrid cells express functional 5-HT3 
receptor (Yakel and Jackson, 1988; Hoyer and Neijt, 1987) were cultured in T75 
flasks.  DMEM was supplemented with 10% fetal bovine serum, 1% penicillin – 
streptomycin and HAT; 0.1 mM hypoxanthine, 400 nM aminopterin, 0.016 mM 
thymidine. We utilised this cell line gonadal steroid progesterone interacting with 
ligand gated ion channels (Review Rupprecht et al., 2001). To investigate the ability 
of progesterone to effect membrane bound 5-HT3 receptor expression after prolonged 
exposure  NG108-15 cells were culture for 3 days in culture media in the presence of 
either vehicle (chloroform) or 1 μM progesterone (HP) or 1 μM progesterone that was 
withdrawn for the final 6hrs of the incubation (PWD). Cells were then counted and 
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undergone a membrane preparation in 50mM Tris buffer, as described previously. 
Membrane preparations were then used utilising radioligand binding protocol as 
previously were ~1nM [3H]granisetron defined specific binding when competed by 
specific antagonist ondansetron (10 µM) and expressed in fmol bound per million 
cells. 
2.13 Protein Assay Quantification Bradford standard 
Protein concentration of samples was determined using Bio-rad reagent (Bio-rad) 
based on an assay first described by Bradford in 1976. Bio-rad reagent was diluted 1:5 
with ddH20 and filtered with chromatography paper to remove particulate. Bovine 
serum albumin (BSA) was diluted to 0, 0.2, 0.4, 0.6, 0.8 and 1mg/ml with the 
appropriate sample buffer, for use as protein standards. 1ml of filtered Bio-rad reagent 
and 20µl of each sample was added to disposable polystyrene cuvettes (Biorad). 
Cuvettes were inverted, for mixing, and the reaction incubated for 10 minutes. 
Absorbance was measured at 595nm in a spectrophotometer (Thermo Spectronic 
Biomate 3) and BSA standards used to calculate a protein concentration/ absorbance 
curve. Measuring each sample, the spectrophotometer programme gave a protein 
concentration reading for each sample calculated from absorbance at 595nm and the 
BSA standard curve 
2.14 Immunoreactivity 
2.14.1 Immunocytochemistry 
To investigate the expression and cellular localisation of specific proteins appropriate 
antibodies were used. 
Culture media was aspirated from the wells and the coverslips washed 3 times with 
ice-cold PBS. Fixation with 2% (v/v) paraformaldehyde, lower than standard PFA to 
minimise permeabilisation, was achieved at room temperature for 20mins, with 
subsequent washing with PBS for 30mins. We used lower than the standard 4% to 
55 
 
Chapter 2: Materials & Methods 
minimise cell membrane damage and to allow more reliable results of our cell surface 
assay.  
Cells were incubated for 1 hour at room temperature with blocking buffer (PBS, 10% 
foetal bovine serum; FCS). Moreover, primary antibody (monoclonal anti-myc clone 
9B11, Cell Signalling) was diluted 1:1000 with blocking buffer and incubated 
overnight at 4°c. The cells were then washed in PBS prior to incubation for 2 hours at 
room temperature with secondary antibody, horse anti mouse IgG2A AlexaFluor 488 
(Molecular Probes), diluted 1:300 in blocking buffer. After extensive washing the 
cells were then permeabilised with PBS/TX100 0.3% for 1 hour at room temperature 
followed subsequently by hour incubation with blocking buffer TX100 0.3%. A 
second incubation with primary antibody (anti-myc) was preformed overnight at 4°c, 
with antibody diluted 1:1000 in blocking buffer TX100 0.3%. Cells were washed 
repeatedly and incubated for 2 hours at room temperature with secondary antibody, 
1:300 horse anti mouse IgG2A AlexaFluor 568. Cells were then washed extensively 
with PBS. The slides were mounted with VectorShield Hardset mounting medium 
(Vector).  Images were captured using a confocal microscope (Carl Zeiss Laser 
Scanning System LSM 510). ) or using a digital camera with IPLab (Nikon) software.   
 
2.14.2 Surface expression of receptor using ELISA 
Cell surface ELISA was performed under nonpermeant conditions as described 
previously (Kniazeffet al., 2004; Cheng et al., 2005). HEK 293 cells stably expressing 
myc-tagged h5-HT3A receptor or vector control HEK293 cells seeded at 105 cells per 
well in a 96 well tissue culture plate and culture in dialysed or “normal” non- dialysed 
FCS enriched media. 24hrs later, the cells were incubated with 100μg/ml 
cycloheximide or 10μg/ml Brefeldin A and the appropriate drug treatment (vehicle, 5-
HT, ondansetron, DDP733, Cl-Indole) for 5hrs. 
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 The media was then aspired and plates were incubated on ice with 2 ml of ice cold 
PBS; subsequently they incubated PBS containing 5% skimmed milk powder 
(Blocking buffer) for 30 min. Cells were then incubated on ice with the anti-myc 
monoclonal antibody 9E10 / 9B11 in blocking buffer for 2 hrs. The cells were 
aspirated and washed with ice cold PBS, following by incubation with 4% 
paraformaldehyde for 10 minutes and then washing with PBS. Cells were then 
incubated with secondary antibody coupled to the enzyme horseradish peroxidise 
(rabbit anti-mouse HRP) for 1 h. The cells were aspirated and washed three times with 
PBS, three times with PBS, and the reaction product was developed with  3,3',5,5'-
tetramethylbenzidine (TMB) and the reaction was terminated with the addition of 2 M 
H2SO4 after ~15 min. Optical density was measured at 450nm. 
 
2.14.3 Free floating cell Immunocytochemistry  
Typically 107 cells were washed with cold PBS followed by centrifugation. Cells were 
then fixed for 10 min with 4% paraformaldehyde, resuspended in cold PBS and then 
spun at 1200rcf for 5 min. The cells were resuspended in blocking buffer (10% 
FCS/PBS) for 30mins at room temperature (RT) followed by resuspension in anti-
human IgM Alexafluor 488 (1:1000; in PBS), 2hrs at RT. The cells were subsequently 
wash in cold PBS and 0.3% Triton-X100/PBS was added to cells to permeabilise cell 
membranes, incubated for 10 mins at RT then centrifuged for 5 min. Mouse anti-myc 
monoclonal antibody was diluted in 0.3% Triton-X100/PBS buffer (1:1000) was 
incubated with cells for 1 hr at RT. The secondary, goat anti-mouse Alexa Fluor 568 
(1:1000), was added after washing with blocking buffer and incubated for 1hr at RT. 
Cells were then washed with excess PBS to allow membranes to reseal, the final 
pellets were resuspended in  500μl of PBS and an aliquot of cells spotted in duplicate 
onto multiwell slides and left to air-dry. To visualise the nuclei Vectorshield was 
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added to each cell spot, slides were kept in the dark at 4oC. Staining was analysed 
using a Nikon Eclipse E600 epifluorescence microscope. 
2.15 Functional assay  
2.15.1 Calcium influx single Cuvette assay for DG75 cells 
The activity of the expressed h5-HT3A receptors was assayed by measuring 
elevations in the intracellular calcium concentration induced by application of 5-HT 
or other agonists. Two methods were used; either a Fura-2 two-wavelength 
fluorescence ratio measurement or Fluo-4AM. Fura-2 acetoxymethyl ester (Molecular 
Probes) diluted from a 1 mM stock solution in dimethylsulfoxide, was used at a final 
concentration of 2 µM in Hank’s balanced salt solution (HBSS). The cells were 
loaded with Fura-2 or Fluo-4AM for 60 min at 37oC temperature before the solution 
was replaced with fresh HBSS.  
Furthermore, into quartz cuvette 2mls cell suspension was added. Through a hole in 
the holder, chemicals such as receptor agonists could be injected during data 
acquisition to measure acute responses. A magnetic stir crossbar on the bottom of the 
cuvette ensured rapid mixing of the solutions. The experiments were done at 37°C. 
Any changes in intracellular calcium ion concentration were measured by determining 
the ratio of 510 nm light emitted by alternate stimulation with 340 and 380 nm. 
Ionomycin, a known ionophore with preference to Ca2+, (1μM concentration) was 
used to determine the maximum value of response, giving also a positive control for 
the experimental set up, and EGTA/HBSS to chelate Ca2+ from the extracellular 
solution in order to identify minimum response. 
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Fluorescence measurements were performed with a Hitachi F-2000 (Tokyo, Japan) 
fluorescence spectrophotometer. The background autofluorescence of the unloaded 
cells was measured and subtracted from the raw signal before calculation of the ratio. 
 
2.15.2 HEK293 cell Flex Station Quantification of [Ca2+]i 
Cells were washed with 1 x HBSS (Hank’s balanced salt solution; Invitrogen) and 
incubated with Fluo-4 acetoxymethyl (AM) ester (2.5 µM; Molecular Probes) for 60 
min at room temperature.  Cells were then washed in HBSS and incubated for a 
further 30 min (room temperature) prior to assay.  Alteration in [Ca2+]i was measured 
using a FlexStation (Molecular Devices) with fluorescence levels assessed every 3 
seconds. Buffer or Cl-indole was added after 20 seconds, agonist/partial agonist (or 
antagonist tested for agonist activity) was added after 80 seconds and recordings 
continued with the subsequent addition of carbachol (1 mM final concentration; a 
muscarinic receptor agonist used as positive control of calcium influx on HEK293 
cells) at 320 seconds. In antagonism studies, antagonists were preincubated for half an 
hour prior to analysis (Newman et al., 2013).  
For the desensitisation studies the above assay was modified; we were able to instead 
of carbachol to add to the following stimulation by agonist/ partial agonist the cells 
were exposed to vehicle, Cl-indole, trichloroethanol (TCE), 5-HT or quipazine.  
Concentration response data were analysed by computer-assisted iterative curve 
fitting according to the three parameter logistic equation (Barnes et al., 1992a). 
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2.15.3 Single cell electrophysiology 
Macroscopic currents were recorded in the whole-cell recording mode of the patch- 
clamp technique from HEKh5-HT3A cells cultured on coverslips using infrared DIC 
(inverted Olympus FV1000 confocal microscope; Olympus Keymed, Southend on 
Sea, UK). Cells were superfused at ~4 ml min-1 with an extracellular solution (in 
mM; NaCl 140, KCl 2.8, CaCl2 1.0, glucose 10, HEPES 10, pH 7.4 adjusted with 
NaOH). Patch electrodes were pulled from borosilicate glass (O.D. 1.2 mm, I.D. 0.69 
mm; Harvard Apparatus, Edenbridge, UK) using a P-97 puller (Sutter, Novato, CA) 
and filled with intracellular solution consisting of (in mM) 135 CsCl, 2 MgCl2, 10 
HEPES, 1 EGTA, 2 Mg-ATP and 0.3 Na-GTP; pH adjusted to 7.3 with KOH 
(osmolarity ~285 mOsm). Patch electrodes typically had open tip resistances of 4-7 
MΩ. Membrane potentials and currents were recorded using an NPI SEC-10L 
amplifier (Scientifica, Harpenden, UK), low-pass Bessel filtered at 1 kHz (NL-125, 
Digitimer Ltd, Welwyn Garden City, UK) and digitized at 10 kHz by a Power 1401 
(CED Ltd, Cambridge, UK). Experiments were performed at room temperature with 
the cells voltage- clamped at -60 mV. Stimulation and data acquisition were 
controlled using Signal software (version 3; CED) (Newman et al., 2013). 
 
2.15.4 Neuronal contraction of mouse bladder 
Male BALB/c mice, aged 8-12 weeks, were killed with a rising CO2 concentration 
followed by cervical fracture. All experiments were carried out in accordance with the 
UK Animals (Scientific Procedures) Act 1986 and European Communities Council 
Directive 86/09/EEC. The urinary bladder was removed and placed in physiological 
saline (in mM; NaCl 118.4, NaHCO3 25.0, NaH2PO4 1.13, CaCl2 1.8, KCl 4.7, 
MgCl2 1.3, glucose 11.1 pH and [O2] were regulated by continuously bubbling the 
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solution reservoir with 95% O2  and 5% CO2). Other organs were harvested for 
experimental use in other projects. Connective tissue surrounding the bladder was first 
removed before the ventral wall of the bladder was opened longitudinally from the 
bladder neck to the apex of the dome with the urothelium left intact. Tissue strips (6-8 
mm long, 1-2 mm wide) were cut along the craniocaudal axis of the dorsal surface for 
organ bath studies. Each bladder strip was mounted in a 500 µl organ bath and 
connected to an isometric transducer (HLT050/D ADinstrument, Chalgrove, UK) 
under an initial tension of 9.8 mN and allowed to equilibrate (i.e. to accommodate 
under tension) for at least 60 min. Electrical field stimulation was delivered every 
minute by a Grass S48 stimulator (Grass Instruments, Quincy, MA) with a 0.1 ms 
pulse width (PW), at 90 V with a 500 ms train duration (TD) at a train frequency of 10 
Hz. Contraction data were digitized using a Powerlab/4SP data acquisition system 
using Chart v.4.2.3 software (ADInstruments, Chalgrove, UK). (Newman, Batis et al., 
2013) 
2.15.5 Vagus nerve grease gap electrophysiological assay 
Tissue preparation 
Female Wistar rats 150–250 g were killed by cervical dislocation and segments of 
cervical vagus nerve 15–20 mm, without the associated nodose ganglion, were gently 
dissected away from the attached carotid artery and placed in gassed 95% O2/ 5% 
CO2 chilled Krebs buffer mM:  NaCl2 120, KCl 4.75, KH2 PO 1.2, MgSO4 1.2, 
CaCl2 2.5, NaHCO3 25, glucose 11). The connective tissue sheath was removed from 
the nerve and the desheathed nerve e was transferred to an inclined lightly greased 
Vaseline heated Perspex block 27oC. The wick of a silver–silver chloride electrode, 
mounted in a Pasteur pipette, was placed on one end of the isolated nerve. The grease 
barrier was formed by applying grease over the wick of the electrode thereby 
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electrically isolating one end of the nerve. The wick of a second silver–silver chloride 
electrode was placed on to record the potential difference between the two portions of 
the vagus nerve either side of the grease barrier which was monitored After placing of 
the recording electrodes, Krebs buffer 4–5 ml/min; 27oC, constantly gassed with 95% 
O2, 5% CO2 over the portion of vagus nerve in the continuous perfusion chamber. 
The whole procedure was usually completed within 15 min of dissection. 
 
 
 
 
Vagus nerve marked V and trachea marked t as was used for our experemental preparation. 
 
Agonists / Partial agonist assay 
Noncumulative concentration response curves to agonists were obtained by including 
the agonist in the perfusing Krebs buffer for appropriate time followed by a washout 
period between exposures to each agonist concentration.  
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Chapter 3: Results 
3.1 Allosteric modulation 
3.1.1 5-Chloroindole  
3.1.1A  Impact of Cl-indole upon ligand affinity for the h5-HT3A 
receptor 
 
Cl-indole (10 µM; Figure 1) failed to impact radioligand binding saturation data 
arising from [3H]granisetron (0.1-10 nM) binding the h5-HT3A receptor expressed by 
HEKh5-HT3A cells (Bmax = 1130 ± 146 and 1027 ± 66 fmol/mg protein, pKd = 8.85 
± 0.20 and 8.77 ± 0.16 calculated in the absence and presence of Cl-indole, 
respectively [mean ± SEM, n = 3], P > 0.05; non-specific binding defined by 
ondansetron, 10 μM; non-specific binding defined by ondansetron, 10 µM; 
experiments performed previously in the lab, curves not shown). In competition 
studies with 5-HT and the antagonist, tropisetron, Cl-indole (10 µM) increased the 
affinity of 5-HT for the [3H]granisetron specific binding site in HEKh5-HT3A cell 
homogenates but did not modify the affinity of tropisetron (Figure 2; Table 2; 
Newman et al., 2013) Indicating potentially agonist dependency..  
 
 
 
 
 
 
 
 
 
Figure 1 Structure of Cl-indole. 
Figure 2. Impact of Cl-indole (10 μM; filled 
symbols) on the ability of 5-HT (circles) and 
tropisetron (squares) to compete for specific 
[
3
H] granisetron binding to HEK293 cells 
expressing the h5-HT3A receptor. Data 
represent mean from 4 independent 
experiments (Newman et al., 2013). 
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3.1.1B 5-HT3 receptor agonists increase [Ca2+]i in HEKh5-
HT3A cells  
 
In order to further investigate the function of the receptor we have used a calcium 
influx assay using FlexStation platform. The endogenous full agonist, 5-HT (10 nM – 
10 µM) or a range of structurally diverse partial 5-HT3 receptor agonists ((S)-
zacopride, DDP733, RR210, quipazine, dopamine, 2-methyl-5-HT, SR57227A, 
mCPBG) evoked concentration-dependent increases in [Ca2+]i in HEKh5-HT3A cells 
(Figure 3; Figure 5; Figure 6). Maximal responses evoked by the partial agonists 
ranged from inconsistent responses barely above baseline (3% (S)-zacopride) to 89% 
(mCPBG) of the maximal response to 5-HT (Figure 3; Figure 5; Figure 6; Newman et 
al., 2013). It was notable that in the continued presence of 5-HT or partial agonists 
with relatively high intrinsic activity, particularly at the higher concentrations 
investigated, there was an associated tachyphylaxis in the [Ca2+]i response (e.g. 
Figure 3; Newman et al., 2013)indicating potential receptor desensitisation.  
HEK293 cells express muscarinic receptors, which are able via G-protein coupling to 
mobilise calcium. The transient rise in calcium has been attributed to the accompanied 
inositol assembly and is anticipated to be generated by release from intracellular 
stores in endoplasmic reticulum and the sustained calcium increased of the plateau 
  pKi Hill coefficient 
5-HT 6.31 ± 0.03 1.59 ± 0.21 
5-HT + Cl-indole 6.57 ± 0.03* 1.44 ± 0.13 
Tropisetron 8.50 ± 0.10 1.00 ± 0.03 
Tropisetron + Cl-indole 8.39 ± 0.06 0.99 ± 0.04 
Table 2. Impact of Cl-indole (10 μM) upon the affinity (pK
i
) of 5-HT and tropisetron (ICS 205–930; 
(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 1methyl-indole-3-carboxylate) and Hill coefficient 
for the h5-HT
3
A receptor radiolabelled with [
3
H]granisetron (Newman et al., 2013) 
Data represents mean ± SEM from four independent experiments. 
Effect of Cl-indole *P < 0.05 paired two tailed-t-tset. 
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phase has been attributed to extracellular calcium influx (Edelman et al., 1994). 
Therefore, in our experimental set up we use muscarinic acetylcholine receptor 
agonist carbachol, as a positive control in our plates. 
 
Neither 5-HT (10 µM) nor DDP733 (1 µM) increased [Ca2+]i in untransfected 
HEK293 cells, although these cells responded to the muscarinic acetylcholine receptor 
agonist, carbachol (1 mM; data not shown).  
 
 
 
 
20 s 
10000 
RFU 
Vehicle 
5-HT 
Carbachol 
Vehicle 
DDP733 
Carbachol 
(A) 
(B) 
Figure 3. Representative experiment of concentration-dependent ability of 5-HT (A) and 
DDP733 (B) to increase [Ca
2+
]i in HEK293 cells expressing the h5-HT3A receptor and 
blockade of the response by the prior incubation with the selective 5-HT3 receptor antagonist, 
ondansetron (500 nM). The muscarinic receptor agonist, carbachol (1 mM) added where 
indicated. Data representative from at least 5 independent experiments (Newman et al., 
2013; Poster, Batis et al., SFN 2010). 
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3.1.1C Potentiation by Cl-indole of the h5-HT3A receptor-
mediated increase in [Ca2+]i in HEKh5-HT3A cells  
 
Application of Cl-indole (1-100 µM) generally failed to evoke [Ca2+]i response in 
HEKh5-HT3A cells (occasionally a small response was noted with 100 µM Cl-indole) 
yet potentiated in a concentration-dependent manner the impact of a subsequent 
application of 5-HT (Figure 4; Table 3). Whilst Cl-indole induced a relatively small 
percentage increase in the response to a maximally effective concentration of 5-HT (3 
µM), Cl-indole reduced the tachyphylaxis associated with the continued presence of 
relatively high concentrations of 5-HT (Figure 4). The Cl-indole-induced potentiation 
in the maximal 5-HT response was greater at lower sub-maximal concentrations of 5-
HT (Figure 4; Newman et al., 2013).     
  
Figure 4. Concentration-dependent ability of Cl-indole to potentiate responses to 5-HT 
(A; 0.3 µM, B; 3.0 µM) and DDP733 (C; 100 nM) to increase [Ca
2+
]i in HEK293 cells 
expressing the h5-HT3A receptor (data representative from 3-6 experiments. In A-C, 
drugs were added where indicated by the horizontal bar (Newman et al., 2013; Poster, 
Batis et al, SFN 2010) see next page Figure 4D. 
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5-HT3 receptor 
agonist 
Cl-indole 
Emax 
(% increase) 
pEC50 Hill coefficient 
5-HT (3.0 µM) 29±4 5.49±0.05 1.62±0.31 
5-HT (0.3 µM) 318±52 4.95±0.05 1.30±0.06 
DDP733 (100 nM) 730±96 4.87±0.07 1.83±0.32 
Figure 4. D. Concentration-dependent ability of Cl-indole to potentiate responses to 5-HT (0.3 
µM, 3.0 µM) and DDP733 (100 nM) to increase [Ca
2+
]i in HEK293 cells expressing the h5-
HT3A receptor (data representative from 3-6 experiments; Cl-indole concentration-responses 
fitted to a three-parameter logistic equation (see Table 2 for data arising from the analysis). 
(Newman et al., 2013; Poster, Batis et al, SFN 2010). 
Table 3. Efficacy (Emax), potency (pEC50) and Hill coefficient concerning the concentration-
dependent ability of Cl-indole to potentiate the response of 5-HT (0.3 and 3.0 µM) and DDP733 
(100 nM) to increase [Ca
2+
]i in HEK293 cells expressing the h5-HT3A receptor. Data represent 
mean±SEM, n=3-6. (Poster, Batis et al., SFN 2010) 
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Cl-indole also induced a concentration-dependent increase in the maximal responses 
evoked by a range of 5-HT3 receptor partial agonists (Figure 4C; Figure 5; Figure 6A; 
Table 4; (Newman et al., 2013)).  
 
 
 
 
 
 
 
Agonist ± Cl-indole Emax1 pEC50 Hill coefficient 
        
5-HT 100 6.70±0.06 5.20±1.95 
5-HT + Cl-indole 117±5** 6.85±0.03* 2.84±0.26 
        
2-Methyl-5-HT 72±8 5.67±0.06 2.04±0.25 
2-Methyl-5-HT + Cl-indole 121±18* 5.83±0.08 4.74±2.51 
        
mCPBG 89±2 6.41±0.07 2.14±0.35 
mCPBG + Cl-indole 106±10 5.73±0.07** 3.18±0.22* 
        
Quipazine 46±9 7.85±0.17 4.34±1.49 
Quipazine + Cl-indole 115±14** 8.11±0.17 2.70±0.25 
    
DDP733 23±5 8.34±0.10 5.66±2.03 
DDP733 + Cl-indole 71±11** 8.06±0.05* 1.29±0.10 
        
Dopamine 53±5 4.08±0.04 1.19±0.12 
Dopamine + Cl-indole 94±11* 4.29±0.05* 2.44±0.59 
        
SR57227A 82±6 6.43±0.02 2.89±0.76 
SR57227A + Cl-indole 137±18* 7.00±0.00** 1.78±0.10 
        
RR210 30±3 7.10±0.06 0.89±0.03 
RR210 + Cl-indole 92±8*** 7.45±0.05** 2.52±1.16 
        
(S)-Zacopride 3±3 ND ND 
(S)-Zacopride + Cl-indole 25±5** 7.65±0.55 3.50±1.40 
Table 4. Efficacy (Emax), potency (pEC
50
) and Hill coefficient concerning the ability of various 5-
HT
3
 receptor agonists, in the absence and presence of Cl-indole (10 µM), to increase [Ca
2+
]
i
 in 
HEK293 cells expressing the h5-HT
3
A receptor. Data represent mean±SEM, n=4-9. Effect of Cl-
indole *P<0.05, **P<0.01, ***P<0.001 paired two tailed t test (Newman et al., 2013; Poster, Batis 
et al., SFN 2010) 
1
% Maximum response compared to the maximum response of 5-HT in the absence of Cl-indole. 
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It is important to note that an orthosteric ligand dependency (probe-dependence) is 
apparent were depending on the agonist / partial agonist used to evoke a response the 
co-operativity, indicators of efficacy (Emax) and affinity (pEC50) of the orthosteric 
ligand is different in the presence of the Cl-indole, which in turn is different from one 
to the next partial agonist/ agonist. The affinity of the endogenous agonist 5-HT is not 
affected by the PAM but the efficacy (Emax) is increased (Table 4, Figure 5). On the 
other hand partial agonists like SR57227A exhibit a shift of the concentration 
response curve to the left (increase in affinity; fo pEC50 consult table 4) accompanied 
an  upward shift of the Emax plateau (increase in efficacy; Figure 5; for Emax consult 
table 4) characteristics of a positive allosteric modulator. Furthermore in Table 4 
(derived from Figure 5) it is shown that Cl-indole affecting almost all drug (both full 
and partial agonist; with the exception of mCPBG; P>0.05) Emax statistically 
significantly, in varying degrees, by potentiating the calcium influx respond.  
 
Additionally, almost all the drugs tested had an increase in their affinity for the 
receptor, which was statistically significant. Interestingly from our data (Figure 5) we 
are able to conclude that there is an apparent ligand dependency on the modulatory 
effect transduced by Cl-indole establishing an agonist dependency in the efficacy of 
Cl-indole for the receptor.  Thus at maximally effective concentrations of agonists Cl-
indole promoted only small percentage increase in the maximal effect of full agonist, 
like 5-HT, however, responses by agonists with lower intrinsic activity for the 
receptor were potentiated much in a greater manner.  
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 Figure 5 Concentration-dependent ability of various 5-HT3 receptor agonists to induce 
increases in intracellular calcium in HEK293 cells expressing the h5-HT3A receptor in the 
absence and presence of Cl-indole (10 μM). Data represent mean ± SEM, n = 3–6. 
(Newman et al., 2013; Poster, Batis et al., SFN 2010) 
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  A 
B 
Figure 6  Ability of Cl-indole (10, 30 and 100 μM) to potentiate the action of various 5-HT3 receptor 
agonists (A) to increase intracellular calcium in HEK293 cells expressing the h5-HT3A receptor and 
the blockade of the response by the selective 5-HT3 receptor antagonist, ondansetron (500 nM) (B) 5-
HT (3.0 μM), (S)-zacopride (1.0 μM), DDP 733 (1.0 μM), RR210 (1.0 μM), quipazine (30 nM), 
dopamine (300 μM), SR57227A (1.0 μM), mCPBG (1.0 μM) and 2-methyl-5-HT (10 μM). Data 
represent mean % response compared with 5-HT ± SEM (n = 3–15). Effect of Cl-indole *P < 0.05, 
**P < 0.01, ***P < 0.001; antagonism by ondansetron P < 0.01 in all instances except compared with 
(S)-zacopride alone. (Newman et al., 2013; Poster, Batis et al., SFN 2010) 
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[Ca2+]i responses in HEKh5-HT3A cells evoked by 5-HT and the partial agonists in 
the absence and presence of Cl-indole (10-100 µM) were fully antagonised by prior 
application of the selective antagonists, ondansetron (500 nM; Figure 6B data for 
10 μM Cl-indole not shown) and granisetron (500 nM; data not shown). In contrast to 
the 5-HT3 receptor agonists, the selective 5-HT3 receptor antagonists; alosetron, 
BRL46470, ondansetron, ramosetron, and palonosetron (all used at 3 µM) failed to 
evoke [Ca2+]i responses in HEKh5-HT3A cells in either the absence or presence of 
Cl-indole (10-100 µM; Figure 7; (Newman,et al., 2013)). Proving that the receptor 
requires an agonist or partial agonist binding to the orthosteric site for the channel to 
become permeable providing us with a potential tool for distinguishing antagonists 
form very low intrinsic acticity partial agonists like S-Zacopride. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 Failure of Cl-indole (10, 30 and 100 μM) to induce responses from various 5-HT3 receptor 
antagonists assessed by intracellular calcium in HEK293 cells expressing the h5-HT3A receptor. 5-HT, 
full agonist for comparison, and the antagonists; ramosetron, palonosetron, BRL46470, ondansetron, 
alosetron and tropisetron (all 3 μM). Data represent mean % response compared with 5-HT ± SEM (n = 
3–8). (Newman et al., 2013; Poster, Batis et al., SFN 2010) 
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3.1.1D Potentiation by Cl-indole of agonist-evoked currents 
recorded under voltage-clamp from HEKh5-HT3A cells 
In order to further investigate the positive allosteric modulation effects that we were 
able to identify using cell populations to monitor intracellular calcium influx we also 
employed the use of electrophysiological experimental assay in the form of voltage-
clamp, which performed by Drs Gillian Grafton and Andrew Powell and was 
published recently (Newman et al., 2013)   
In detail, at a holding potential of −60 mV, a brief application of 5-HT (10 μM; 
100 ms) to HEKh5-HT3A cells elicited a transient inward current (560 ± 130 pA, n = 
6; Figure 8A). The rising phase was best fitted by a single exponential function with a 
mean time constant of 0.9 ± 0.1 s and the current decayed slowly back to baseline 
(t50 2.1 ± 0.4 s). Repeated applications (5 min interval) of 5-HT significantly reduced 
the amplitude of the inward current, such that by the third application the peak 
amplitude was approximately one-third of the initial response (Figure 8A). In contrast, 
5-HT3 receptor currents evoked by a 10 ms application of 5-HT (10 μM) at the same 
frequency were not reduced by repeated stimulation (Figure 8A) and hence this 
protocol was employed for further investigations (Newman, Batis et al., 2013). 
 
Superfusion of Cl-indole (10 μM) did not alter the holding current of 5-HT3A receptor 
expressing HEK 293 cells, nor did the compound alter the amplitude (control 411 ± 
107 pA, Cl-indole 399 ± 106 pA; n = 6; P = 0.86) or rise time (control 76 ± 16 ms, Cl-
indole 110 ± 40 ms; n = 6;P = 0.31) of 5-HT (10 μM)-induced currents (Figure 8B). 
However, Cl-indole significantly increased the decay time for 5-HT3 receptor-
mediated currents (control t50 = 2.8 ± 0.7 s, Cl-indole t50 = 12.2 ± 2.5 s; n = 6; P = 
0.005); the effect of Cl-indole on decay rate was partially reversible after washout 
(t50 = 6.3 ± 1.0 s; P = 0.04; Figure 8B; (Newman et al., 2013)). 
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The selective 5-HT3 receptor antagonist, ondansetron (100 nM), completely blocked 
the activation of 5-HT3 receptors by 5-HT (10 μM) in both the absence and presence 
of Cl-indole (10 μM). The effect of ondansetron was reversible upon washout with 
subsequent application of 5-HT evoking inward current, which was modulated by Cl-
indole (Figure 9A; (Newman et al., 2013)). 
 
To assess whether Cl-indole affected the ionic permeability of the h5-HT3A receptor, 
the I–V relationship of the macroscopic current response to 5-HT was constructed by 
a voltage ramp (−100 to +60 mV) recorded at the peak of the current response to bath-
applied 5-HT (1.0 μM; 15 s). The reversal potential (E5-HT) in the presence and 
absence of Cl-indole (10 μM) was −2.2 ± 3.1 and −0.5 ± 2.9 mV, respectively n = 
6, P = 0.74) (Figure 9B), suggesting that Cl-indole does not grossly affect the ionic 
permeability of h5-HT3A receptors. The peak 5-HT current recorded at −60 mV was 
significantly increased by Cl-indole (Control 265.8 ± 127.8 pA; Cl-indole 1430.8 ± 
362.9 pA; n = 5, P < 0.05; (Newman et al., 2013)) 
Figure 8. A: ability of repeated application of 5-HT (10 μM) for 100 ms (i) and 10 ms (ii) to evoke 
responses from voltage-clamped HEK293 cells expressing the h5-HT3A receptor. Traces are 
representative of at least three independent experiments, numbers represent the traces corresponding 
to the application number of the 5-HT. Data in histograms represent mean ± SEM, n = 5–6. B: 
ability of 5-HT (10 μM applied for 10 ms) in the absence (control) and presence of Cl-indole (10 
μM, grey trace) to evoke responses from voltage-clamped HEK293 cells expressing the h5-HT3A 
receptor (i) with histograms displaying impact upon decay time (ii), amplitude (iii) and rise time 
(iv); the right hand column in each of these istograms represents results after wash-out of Cl-Indole. 
*P < 0.05, **P < 0.01. Experiments performed by Dr Gillian Grafton and Dr Andrew Powel. For 
details see Newman et al., 2013 
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Application of the 5-HT3 receptor partial agonist, DDP733 (100 nM; 100 ms), evoked 
a relatively small inward current (149 ± 58 pA, n = 6; Figure 9C) which had a slow 
rise time (10.2 ± 3.2 s) and slow decay time (46.5 ± 10.5 s). Superfusion of Cl-indole 
(10 μM), significantly increased the amplitude of DDP733-induced currents (912 ± 
272 pA; P < 0.05; Figure 9C) and slowed the rise time (18.6 ± 3.9 s; P < 0.005). Cl-
indole also prolonged the decay rate of DDP733-induced currents (137 ± 35 s; P < 
0.01; Figure 9C). The effect of Cl-indole upon DDP733-evoked amplitude, rise time 
and decay rate was fully reversed by washout of Cl-indole (33.1 ± 6.5 pA, 11.6 ± 
3.9 s, 52 ± 20 s, respectively). (For details see Newman et al., 2013) 
 
 
 
  
Figure 9. Ability of Cl-indole (10 μM) to potentiate 5-HT3 receptor agonist responses. A: The 
presence of the selective 5-HT3 receptor antagonist, ondansetron (100 nM), completely prevented 
a response to 5-HT (10 μM applied for 10 ms) in the presence of Cl-indole (10 μM). The effect of 
ondansetron was partly reversible by wash-out [subsequent response to 5-HT (10 μM applied for 
10 ms; wash)]. Traces are representative of at least three independent experiments. B: I–V plots 
arising in the presence of 5-HT (1.0 μM) or 5-HT (1.0 μM) plus Cl-indole (10 μM) determined 
around the peak response (indicated #). Drugs were bath applied for 15 s. Traces are 
representative of at least three independent experiments. C: DDP733 (100 nM) in the absence 
and presence of Cl-indole (10 μM); recordings from voltage-clamped HEK293 cells expressing 
the h5-HT
3A receptor (i) with histograms displaying impact upon decay time (ii), amplitude (iii) 
and rise time (iv); the right-hand column in each of these histograms represents results after 
wash-out of Cl-indole. Traces are representative of at least three independent experiments. Data 
in histograms represent mean ± SEM, n = 5–6. *P < 0.05, **P < 0.01. Experiments performed in 
collaboration with Drs Gillian Grafton and Andrew Powell; for details see Newman et al., 2013 
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3.1.1E Native 5-HT3 receptor responses 
Modulation of neuronally mediated contraction of mouse bladder 
 
Furthermore in order to investigate the ability of Cl-indole to modulate native 5-
HT3 receptors, and in a whole tissue assay, the 5-HT3 receptor-mediated increase in 
bladder smooth muscle ‘twitch’ was investigated (Chetty et al., 2007) in collaboration 
with Francesca Caputo and Dr Keith Brain (see details Newman et al., 2013). Under 
control conditions, electrical field stimulation induced a tetrodotoxin (100 nM)-
sensitive contraction of the muscle strips. Using a sub-maximal stimulus protocol (six 
pulses at 10 Hz), consistent contraction amplitudes obtained when the stimuli were 
delivered at 1 min intervals. The selective 5-HT3 receptor agonist, mCPBG (3.0 μM), 
transiently increased the amplitude of contraction, reaching a peak increase of 20 ± 
4% (n = 4 strips; P < 0.05), which subsequently declined in the continued presence of 
mCPBG (30 μM; Figure 10). Cl-indole (30 μM) alone had no effect on the amplitude 
of contraction (6 ± 3%; n = 4; P = 0.46; Figure 10), but subsequent addition of 
mCPBG (3.0 μM) greatly increased the peak amplitude by 54 ± 3%, an effect that was 
maintained in the continued presence of mCPBG (30 μM; Figure 10). (Newman et al., 
2013) 
 
In the presence of the 5-HT3 receptor antagonist ondansetron (500 nM) the 
subsequent application of Cl-indole (30 μM), mCPBG (3.0 μM) did not significantly 
increase the amplitude of contraction (8 ± 7%; n = 6; P = 0.30; Figure 10Cii, open 
bars): in the matching set of bladder strips, Cl-indole (30 μM) + mCPBG (3.0 μM) in 
the absence of ondansetron increased the peak amplitude by 31 ± 10% (n = 5; P < 
0.05; Figure 10Cii - filled bars). The experimental protocols were performed by 
Francesca Caputto and Dr Keith Brain (Newman et al., 2013). 
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   Figure 10. Cl-indole augments the mCPBG-induced potentiation of the neurogenic contractile response in mouse bladder strips. (A) Sample traces from different bladder strips showing that Cl-
indole (30 μM) augments the mCPBG-induced potentiation of contractile response in mouse 
bladder strips. (Ai) mCPBG (3.0 μM) alone only subtly increases the amplitude of contractile 
force generated following field stimulation. (Aii) In the presence of Cl-indole (30 μM), mCPBG 
increases to a greater relative extent the contractile force. For each panel, the black line indicates 
the neurogenic contraction in the absence of mCPBG, and the grey line indicates the subsequent 
response in the presence of mCPBG in the same bladder strip. (Ai) and (Aii) show the response of 
different bladder strips from the same mouse and measured in parallel; the mean amplitudes did 
not vary significantly amongst the two test groups, although different muscle strips (even from the 
same animals) showed a range of typical contractile forces. (Bi) Field stimulation of mouse 
bladder strips (open bars) is subtly augmented by mCPBG (3.0 μM), an effect that shows 
tachyphylaxis (i.e. the plateau contractile amplitude in the continued presence of mCPBG is lower 
than the peak response). This effect is reversible upon removing mCPBG (washout). (Bii, Ci) In 
the presence of Cl-indole (30 μM), the peak response to mCPBG (3.0 μM) was potentiated and the 
tachyphylaxis was prevented (closed bars). The effect of Cl-indole was only partially reversed on 
wash. Cl-indole alone had no significant effect on contraction. (Cii) Responses to mCPBG 
(3.0 μM) in the presence of Cl-indole were blocked by the 5-HT3receptor antagonist ondansetron 
(open bar). *P < 0.05 compared with vehicle, 
#
P < 0.05 compared with mCPBG response in the 
absence of Cl-indole. 
Experiments performed by Dr Keith Brain and Francesca Caputo. (For details of protocol, see 
Newman et al., 2013) 
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Rat Vagus nerve electrophysiology – preliminary data 
 
In a further attempt to establish a model of native 5-HT3 receptor the vagus nerve of 
the rat was used in a grease gap electrophysiological experiment was investigated. 
Under control condition noncumulative concentration response curves to agonists 
were obtained by including the agonist in the perfusing Krebs buffer for appropriate 
time followed by a washout period between exposures to each agonist concentration.  
I was able to demonstrate in preliminary experiments of at least 3 vagus nerves from 3 
individual rats donated port-mortem by Dr Lovick, that the partial DDP733 is able to 
induce a concentration dependent response via depolarisation of the perfused side 
compared to the control side of rat vagus nerve in the grease gap electrophysiological 
experiment comparable to the endogenous ligand 5-HT response.  
A 
 
B 
 
 
Preliminary Figure. Concentration-dependent ability of increasing concentration of 
DDP733 a 5-HT3 receptor partial agonist to increases in depolarisation (mV)of the perfused 
side compared to the control side of rat vagus nerve in a grease gap electrophysiological 
experiment.  A. Typical trace of non-cumulative response to DDP733 (100, 300 nM, 1, 10, 
30μΜ) and 10μM 5-HT. B.  data representative from 3 experiments DDP733 concentration-
responses fitted to a three-parameter logistic equation.  Data represent mean ± SEM, n = 3. 
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This allows the demonstration in native tissue the potential of the vagus nerve as a 
tool for screening and assessing potential compounds with activity in 5-HT3 receptor 
identified in cell lines as well as potential use for testing protocol for preclinical 
screening of drugs for emetogenic and other vagally facilitated effects. We were, due 
to time contains, not able to complete the study intended initially; were we would 
have assessed the ability of Cl-indole to modulate the effect of agonist and partial 
agonist have on native 5-HT3 receptor. 
 
3.1.1F Potentiation by Cl-indole and reversal of the apparent 
desensitisation of the h5-HT3A receptor-mediated increase in 
[Ca2+]i in HEKh5-HT3A cells  
 
Similar to our initial hypothesis full agonists, like 5-HT, caused near complete 
desensitisation of the response; the response did not fully recover; with only a small 
percentage of the initial response, when Cl-indole (100μM) was added subsequently 
(Figure 11A). However, after response to a partial agonist (DDP733; Figure 11B), the 
addition of Cl-indole increased [Ca2+]i to levels similar to those observed by full 
agonist (Figure 11B and 11C). These findings suggest that while the apparent full 
desensitisation induced by full agonists is almost irreversible in our population model, 
the partial desensitisation, or the partial population of cells, induced by partial 
agonists can be reversed, by Cl-indole. The addition of vehicle control post 
stimulation by either full agonist or partial agonist had no effect on the [Ca2+]i (Figure 
11A, 11B and Table 5) in HEK293 cells stably expressing h5-HT3A receptor. Similar 
effect with the use of Cl-indole was observed with the known positive allosteric 
modulator TCE used at the higher concentration (5mM) on [Ca2+]i following HEKh5-
HT3A cells exposure to either the maximal and submaximal concentrations of 5-HT, 
but not when the lower concentrations of TCE were introduced (1 – 3 mM; Table 5). 
When TCE was used following partial agonist (DDP733 and quipazine) effect on 
[Ca2+]i  the response levels increased to comparable levels to those observed from full 
agonist alone was used to initiate responses above the base line and at least partially to 
those observed following 5-HT addition (Table 5).  
Furthermore the subsequent introduction of maximal 5-HT (100 μM) was unable to 
overcome the apparent desensitisation caused by 5-HT either at submaximal or 
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maximal concentration. However, following initial responses to partial agonist 
DDP733 both at maximal and submaximal concentration 5-HT appeared to be able to 
overcome the apparent receptor desensitisation, at least partially (Table 5).   
 
Notably the addition of maximal quipazine (10μM) following a calcium response 
initialised by either full agonist 5-HT (3 or 100 μM) or partial agonists DDP733 (0.1 
or 1 μM) and quipazine (10 μM) appeared to cause a decrease in the observed [Ca2+]i 
compared to the proceeding base line of response. 
 
 
 
 
Figure 11.   Ability of subsequent application of Cl-indole 
(100 μM) to potentiate agonist-induced increases, in HEK293 
cells expressing the h5-HT3A receptor, induced [Ca
2+]i by A. 
5-HT (3 μM); B. DDP733 (1 μM). Data representative from 3-
6 experiments (Poster, Batis et., SFN 2010) 
C.  Prolonged bath application of 5-HT (10 μM) induced an 
inward current through 5-HT3A receptors which rapidly and 
completely desensitised. Subsequent picospritzer application 
of 10 μM Cl-Indole (1s, 20 psi; denoted by arrow) revealed a 
smaller inward current. Experimental protocol for figure 11C, 
only, was contacted by Drs Gillian Grifton and Andrew Powel 
(Newman et al., 2013) 
C 
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To further characterise the effect of Cl-indole, we also employed an 
electrophysiological protocol in collaboration with Drs Gillian Grifton and Andrew 
Powel. In more detail, we examined, once more, whether the compound could re-
activate desensitized 5-HT3 receptors. Prolonged bath application of 5-HT (10 μM) 
produced a large transient current (2.52 ± 0.75 nA; n = 4) that decayed rapidly to 8.9 ± 
4.0% of the peak response. In the continued presence of 5-HT, pressure ejection of Cl-
indole (10 μM) elicited an inward current (0.97 ± 0.54 pA; Figure 11C; Newman et 
al., 2013) 
 
 
 
 
 
 
 
 
 
 
  
Table 5 representing post stimulation additions of drugs and the effect they have on intracellular [Ca2+] 
in HEK293 cells stably expressing h5-HT3A receptor. Increase (+) compared to control in calcium or 
decrease (-) or no effect (0); (the greater the number of individual symbols the greater the deviation from 
the control) 
82 
 
Chapter 3: Results 
 
3.1.2 Potentiation by other allosteric modulators of the h5-HT3A 
receptor-mediated increase in [Ca2+]i in HEKh5-HT3A cells 
3.1.2A TCE allosteric modulators of the h5-HT3A receptor-
mediated increase in [Ca2+]i in HEKh5-HT3A cells 
 
 
 
 
 
Further to investigate if other potential PAMs were able to induce changed to the 
receptor pharmacology we introduced in our assay the application of 2,2,2-
trichloroethanol (TCE) (0.25 - 10 mM), a known 5-HT3  receptor modulator (Bemtley 
and Barnes, 1998; Lovinger et al., 2000), that generally failed to evoke [Ca2+]i 
response in HEKh5-HT3A cells  yet potentiated in a concentration-dependent manner 
the impact of a subsequent application of 5-HT (Figure 10). Whilst TCE induced 
relatively no change in the response to a maximally effective concentration of 5-HT (3 
µM); there was an apparent decrease in the percentage response obtained at the higher 
concentrations of TCE (3 and 10 mM). The TCE-induced potentiation in the maximal 
response was greater at lower sub-maximal concentrations of 5-HT (0.3 μM; ~10%; 
Figure 12); however, once more there was an apparent decrease in the percentage 
response obtained at the higher concentrations of TCE (3 and 10 mM).    
 
Figure 12 Concentration-dependent ability of increasing concentration of trichloroethanol 
(TCE) when administered prior to 5-HT either 0.3 μM or 3 μM to induce increases in 
intracellular calcium in HEK293 cells expressing the human 5-HT3A receptor; representing 
the percentage of response compared to the response identified when in the presence of 
vehicle 3μM of 5-HT was used. Data represent mean ± SEM, n > 3. 
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[Ca2+]i responses in HEKh5-HT3A cells evoked by 5-HT in the absence and presence 
of TCE were fully antagonised by prior application of the selective antagonists, 
ondansetron (500 nM; not shown). 
  
3.1.2B 5OHI allosteric modulators of the h5-HT3A receptor-
mediated increase in [Ca2+]i in HEKh5-HT3A cells 
 
The well-characterized positive allosteric modulator (PAM), 5-hydroxyindole (5OHI), 
has diverse effects on 5-HT3 receptors. It has been noted that a mix of allosteric and 
orthosteric effects (Kooyman et al., 1994; Hu and Lovinger, 2008) is demonstrated by 
5OHI. Indeed, one study failed to show any effect, suggesting that 5-hydroxyindole is 
a PAM at rodent receptors, with no activity at their human counterpart 
(Grønlien et al., 2010). 
Application of 5-hydroxyindole (5OHI) (0.01 - 3 mM) generally failed to evoke 
[Ca2+]i response in HEKh5-HT3A cells; yet potentiated in a concentration-dependent 
manner the impact of a subsequent application of quipazine (Figure 13). Whilst 5OHI 
induced a relatively negligible percentage change in the response to a low 
concentration of quipazine (10 nM); there was an apparent decrease in the percentage 
response obtained at the higher concentrations of 5OHI used (3 mM). The 5OHI-
induced potentiation in the maximal 5-HT response was greater at higher 
concentrations of quipazine (30 nM; Figure 13) however once more there was an 
apparent decrease in the percentage response obtained at the higher concentrations of 
5OHI (3 mM); resembling more of a “bell” shape response curve.    
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[Ca2+]i responses in HEKh5-HT3A cells evoked by quipazine in the absence and 
presence of 5OHI  were fully antagonised by prior application of the selective 
antagonists, ondansetron (500 nM; data not shown). 
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Figure 13. Concentration-dependent ability of increasing concentration of 5-
hydroxyidole (5OHI) when administered prior to either 10nM or 30nM of quipazine, 
a 5-HT3 receptor partial agonist, to induce increases in intracellular calcium in 
HEK293 cells expressing the human 5-HT3A receptor; representing the percentage of 
response compared to the response identified when in the presence of vehicle 
appropriate quipazine concentration was used. Data represent mean ± SEM, n >3. 
85 
 
Chapter 3: Results 
 
3.1.2C  Potentiation by 5OHI of the h5-HT3A compared to the 
mouse receptor-mediated increase in [Ca2+]i in HEK293 cells transiently 
expressing either the murine or the human myc tagged 5-HT3A subunit 
 
 
 
 
 
In a further attempt to characterise the allosteric modulation Cl-indole is able to 
produce we were interested in potentially comparing if the murine and the human 
subtype of the receptor would behave differently in the presence of Cl-indole allowing 
us to use preciously identified amino acids important for the activity of other PAMs 
identified in the murine receptor. Application of 5-hydroxyindole (5OHI; PAM) (0.03 
- 1 mM) appear to potentiate the impact of a subsequent application of quipazine 
(30nM; Figure 14) to [Ca2+]i response in HEK293 cells expressing either the human 
or the mouse 5-HT3A subunit, in a concentration-dependent manner,. Whilst 5OHI 
induced a significant percentage change (to 118% from the 100% of the control) in 
the response to quipazine (30 nM) in the mouse receptor subunit; there was an 
apparent plateau in the percentage response obtained at the higher concentrations of 
5OHI used (0.3 - 1 mM). The 5OHI-induced potentiation in the maximal quipazine 
response was greater (138% relative to control) at the HEK293 cells expressing the 
human 5-HT3A subunit (Figure 14); however, there was an apparent decrease in the 
10 
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M  
Figure 14. Concentration-dependent ability of increasing concentration of 5-
hydroxyindole (5OHI) when administered prior to quipazine (30nM) a 5-HT3 receptor 
partial agonist to induce increases in intracellular calcium in HEK293 cells expressing 
either the human or the mouse 5-HT3A receptor. Data represent mean ± SEM, n = 3–4. 
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percentage response obtained at the higher concentrations of 5OHI (0.5 - 1 mM); 
introducing an apparent in increased affinity of 5OHI for the human receptor 
compared to the mouse 5-HT3A subunit (Figure 14; apparent EC50 of 44 μM for the 
murine compare to 24.1 μM for the human 5-HT3A receptor). Indicating the human 
subtype to be more sensitive to Cl-indole, which would not limit us from using. 
  
3.1.3  L288S subunit Myc-tagged h-5HT3A single amino acid 
mutation by quickchange attempted to knock-out the modulatory 
effect of 5OHI 
Hu et al (2006) have previously identified in the murine 5-HT3 receptor mutation to 
serine of Leucine 293 (L288 in human) mutation to alter gating and alcohol 
modulatory actions. We subsequently wanted to test if this was true in our model.  
Application of 5-hydroxyindole (5OHI) (0.1 μM - 1 mM) appear to potentiate the 
impact of a subsequent application of quipazine (30nM; Figure 15) to [Ca2+]i response 
in HEK293 cells expressing either the myc tagged (h)5-HT3A or L288S  mutated 5-
HT3A receptor, in a concentration-dependent manner, with response reaching a 
plateau at 10μM 5OHI (Figure 15). No significant difference was observed in the 
pharmacodynamics of 5OHI in the presence of the Leu288Ser mutation compared to 
the wild – type receptor (response range between 100 and ~ 112 %; Figure 15). 
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 Figure 15 Concentration-dependent ability of increasing concentration of 5-
hydroxyindole (5OHI) when administered prior to quipazine (30nM) a 5-
HT3 receptor partial agonist to induce increases in intracellular calcium in HEK293 
cells expressing either the myc tagged h5-HT3A receptor or the mutated L288S 
receptor. Data represent mean ± SEM, n = 3–6. 
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Application of quipazine (0.3nM - 1 µM) was introduced to evoke [Ca2+]i response in 
HEK293 cells expressing either the myc tagged (h)5-HT3A receptor or the mutated 
L288S receptor in a concentration-dependent which was subsequently compared to 
responses arising from 5-HT (Figure 16). Furthermore, the prior presence or absence 
of 10 μΜ 5OHI was used to assess if changes in the binding site of 5OHI, as 
described in the murine 5-HT3A receptor which is located at Leu293 of the M2 
domain in the mouse and rat (Hu and Lovinger) which is equivalent to the L288 in the 
human subunit changed to Serine, was able alleviate the induced increase in the 
response to quipazine. No apparent difference was established when [Ca2+]i 
flexstation assay was utilised (Figure 16) and the pharmacological profile of quipazine 
in the presence or absence of 5OHI appeared almost identical within the particular set 
of cells expressing either L288S or “wild-type” 5-HT3A subunit.   
However, when we compare the two receptors between them we see a different 
apparent affinity of quipazine (EC50 2.39e-8 and 1.96 e-8 M for vehicle and 5OHI 
L288S compared to EC50 1.30e-8 and 1.29e-8 M for vehicle and 5OHI wild type 5-
HT3A subunit).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16  Concentration-dependent ability of increasing concentration of 
quipazine (Molar) a 5-HT3 receptor partial agonist to induce in the absence or 
presence of 10μM 5OHI increases in intracellular calcium in HEK293 cells 
expressing either the myc tagged h5-HT3A receptor or the L288S mutated 
receptor. Data represent mean ± SEM, n = 3–6. 
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Cl-indole also induced a concentration-dependent increase in the maximal responses 
evoked by a range of 5-HT3 receptor partial agonists (Figure 4C; Figure 5; Figure 6A; 
Table 4).  
3.1.3  L288S mutant compared to h-5HT3A to potentially knock-out 
the modulatory effect of Cl-indole in HEK293 cells 
 
We further wanted to characterise the potential effect the mutant would have on the 
Cl-indole modulation. Application of Cl-indole (30 μM) appear to potentiate the 
impact of a subsequent application of endogenous full agonist 5-HT (3 μM; Figure 
17) to [Ca2+]i response in HEK293 cells expressing either the myc tagged (h)5-HT3A 
or L288S  mutated h5-HT3A receptor, as well as partial agonist DDP733 (0.3μM; 
Figure 17). The effect of Cl-indole potentiation of the response appear to be blocked 
by the substitution of leusine 288 to a serine for when challenged with 5-HT however 
the statistics were blunted when a t-test was done for the paired observation (P= 
0.0504).  
 
  
Figure 17 Ability of Cl-indole (30 μM) to potentiate the ability of  5-HT3 receptor full 
agonist  5-HT (3 μM) and partial agonist DDP733 (0.3 μM) to increase intracellular 
calcium in HEK293 cells expressing either the h5-HT3A receptor or the single amino acid 
L288S mutant of the h5-HT3A Data represent mean ± SEM, n = 4 - 8. 
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3.2 Utilising Recombinant receptors 
 
3.2.1 The stability of the h5-HT3A receptor and the importance of 
the c-terminus  
 
In order to explain potential role different regions have in the receptor stability and 
potential play a role to receptor function and pharmacology we have been also 
interested in previously reported regions of the receptor. Following previously 
published observation that the C-terminus of the human (h) 5-HT3A subunit is 
important for the expression of the homomeric 5-HT3A receptor within the cell 
membrane, suggesting a role for the C-terminus in the promotion of receptor stability 
(Butler et al., 2008). We further assessed the stability of the h5-HT3A receptor in 
comparison with that arising when the C-terminal alanine is truncated (ΔAla455 [N-
4TM-QY]; see Butler et al., 2008 for construct terminology; see Template 1). 
 
 
 
Expression of the h5-HT3A subunit and mutants/truncations by COS-7 cells and 
radioligand binding assays were performed as described previously (Butler et al., 
2008). Briefly, COS-7 cells were transiently transfected with the appropriate cDNA 
via electroporation and harvested 48 h post-transfection to generate binding 
homogenates to assess the impact of urea upon specific ~ 1 nM [3H]granisetron 
binding. [3H]Granisetron specific binding (defined by ondansetron, 10 µM) arising 
from expression of the truncation mutant of the h5-HT3A subunit, N-4TM-QY 
(ΔAla455), was more susceptible to disruption by increasing concentrations of urea 
relative to the specific binding arising from expression of the wild-type h5-HT3A 
subunit (Figure 18; P<0.05, Mann Whitney U test). In contrast, there was no 
significant difference in the urea sensitivity of [3H]granisetron specific binding arising 
from expression of the and N-4TM-AAA relative to the wild-type h5-HT3A subunit 
(Gln453Ala and Tyr454Ala; data not shown).  
Template 1. Graphical 
representation of the 
wild-type h5-HT3A 
subunit and truncation 
mutant of the h5-HT3A 
subunit N-4TM-QY 
(ΔAla455) (Poster, Batis 
et al., BPS 2008) 
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Additionally, the pharmacology of the wild-type h5-HT3A receptor and the N-4TM-
QY were assessed when challenged with cold 5-HT, ondansetron and quipazine 
assessed [3H]granisetron (~1nM; Figure 19)  and no difference in the pharmacology 
was identified (table 6) with pKi values and Hill slope numbers being almost identical 
for endogenous agonist 5-HT, specific competitive antagonist ondansetron and partial 
agonist quipazine. 
 
 
 
 
  
2 3 4 5 6 7 8 9 
Figure 18 Specific [
3
H]granisetron (~1 nM) binding levels arising from expression of the wild-type 
h5-HT3A subunit () and the truncation mutant N-4TM-QY () by COS-7 cells. Data represent 
mean ± SEM, n= 4. Comparison between the urea-induced inhibition of specific binding between the 
two constructs; *P<0.05, Mann Whitney U test (Poster, Batis et al., BPS 2008). 
pKi
 Ligand 5-HT Ondansetron Quipazine
Subunit       
wild-type h5-HT3A 6.59 ±0.18 8.46 ±0.19 8.89 ±0.12
N-4TM-QY 6.74 ±0.29 8.46 ±0.22 8.94 ±0.12
Hill number
 Ligand 5-HT Ondansetron Quipazine
Subunit       
wild-type h5-HT3A 1.41 ±0.13 0.85 ±0.08 1.11 ±0.04
N-4TM-QY 1.48 ±0.44 0.82 ±0.09 1.40 ±0.30
Table 6. pKi values and Hillslope number of various 5-HT3 receptor ligands, to compete with 
[
3
H]granisetron (~1 nM) at either wild-type h5-HT3A subunit and the truncation mutant N-4TM-QY. 
Data represents mean ± SEM, (n≥3) (Poster, Batis et al., BPS 2008). 
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3.3 Receptor internalisation / up-regulation 
The potential ability of agonist, partial agonist, PAM and antagonist to affect the 
receptor internalisation and recycling would be investigated further by employing an 
ELISA assay. 
3.3.1 Cycloheximide utilised in whole cell ELISA assay to 
determine Surface expression of myc - tagged h5-HT3A receptor 
expressed in HEK293 cells 
 
To assess if the interaction of h5-HT3A receptor with ligands has an effect on the cell 
surface we utilised an ELISA assay. HEK293 cells expressing myc – tagged h5-HT3A 
receptor were cultured on 96 well plates.  In order to identify the receptor 
internalisation we introduced to the cells cycloheximide (100 μg / ml) a known 
inhibitor of protein biosynthesis regularly used in assays to determine protein half –
life (Zhou P. 2004) and trafficking (Ilegems et al.,2004). In order to establish the 
appropriate incubation length of the cells with cycloheximide, without disrupting the 
cell surface expression of the 5-HT3A receptor, we used 100 μg/ml (~355.42 μM) 
cycloheximide to incubate HEK293 cells expressing myc- tagged h5-HT3A receptor. 
24 hours following the transfer onto 96 well plates, for 19, 9, 6, 3 and 0 hours prior to 
fixing them. Cells were then fixed using 2% paraformaldehyde and cell surface 
detection was performed in the absence of detergent, and total expression levels were 
determined following Triton X-100 treatment. Receptor expression was determined 
using an HRP-conjugated secondary antibody and assayed using 3,3′,5,5′-
tetramethylbenzidine (TMB; Sigma) as the substrate, with detection at 450 nm after 
30 min following the addition of 0.5 M H2SO4.  
 Figure 20. ELISA in HEK293 cells stably expressing myc-tagged h5-HT3A subunit. 
Incubated with 100μg/ml cycloheximide inhibitor of protein biosynthesis at various time 
points (0, 19, 9, 6 3 hrs) at the final period prior to fixing the cells 
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We were able to determine that following 6 or more hours of incubation with 
cycloheximide were sufficient to start observing increases greater than ~10% in 
receptor down regulation (Figure 20) and therefore we decided that as previously 
described assay (Ilegems et al., 2004) we would use 5 hours incubation with 
cycloheximine (Wettstein, et la., 1964).   
 
3.3.2 Ability of various ligands to influence surface receptor 
expression of myc - tagged h5-HT3A receptor expressed in HEK293 
cells 
 
We investigated whether using HEK293 cells expressing myc-tagged h5-HT3A 
receptor and following incubation with different types of ligands we can influence the 
cell surface expression of the myc – tagged h5-HT3A receptor. Moreover since foetal 
bovine serum contains 5-HT (~0.3 μM; Mothersill et al., 2010) we were interested to 
further investigate the potential difference the normal serum compared to the dialysed 
serum could potentially have on cell surface receptor expression.  
HEK293 cells expressing the myc –tagged h5-HT3A receptor were plated onto 96 
well plates (in hexaplets wells) and following 24hrs of growth cells were incubated 
with either normal serum media or dialysed serum media for an additonal 24 hours of 
which the final 5 hours cycloheximide (100 μg/ml) was also added. Moreover, in 
addition to the cycloheximide that all cells were treated a proportion had 5-HT (10 
μM) introduced or ondansetron (30 μM) or 30 μM ondansetron with 10 μΜ 5-ΗΤ or 
Cl-indole (30μM) or 30μM Cl-indole with 10μM 5-HT (Figure 21). Following whole 
cell ELISA assay we identified surface receptor immunoreactivity and expressed it as 
a percentage relative to control. The results when analysed statistically and they were 
grouped to be compared to the type of ligand used into categories agonist, antagonist 
and allosteric modulator if two drugs were combined the antagonist or allosteric 
modulator was introduced in the incubation 1 minute prior to the agonist.  
 
The cells that exposed to non-dialysed serum for the period of our investigation when 
incubated with the various treatments (5 hrs) exhibited no significant changes in the 
receptor levels expressed in the cell surface relative to the control (5 hrs 
cycloheximide). 
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However, the cells growing in dialysed serum exhibited differences compare to 
control in surface receptor expression.  Specifically we were able to identify apparent 
up – regulation of surface myc – tagged h5-HT3A receptor (~21.7 %; figure 19) 
induced by the specific antagonist ondansetron (30 μM; Figure 21); further when the 
antagonist ondansetron was co-incubated with 5-HT induced an apparent receptor up-
regulation (~ 31.7 %; figure 21). However, neither of the changes were statistically 
significant. 
 
Interestingly when the positive allosteric modulator 5-chloroinole (30 μM) was used 
on its own in HEK293 cells expressing myc – tagged h5-HT3A receptor grown in 
dialysed serum, we identified no significant change to the surface receptor expression 
however when co-incubated with 5-HT (10 μM) we identified an apparent up-
regulation in surface myc – tagged 5-HT3A receptor expression.  Total level of signal 
did not change, used to standardise the experiments through the plates to establish 
consistent receptor expression.  
 
 
 
Figure 21. HEK293 cells stably expressing myc-tagged h5-HT3A receptor subunit were 
utilised in a live cell ELISA to test the ability of agonist like 5-HT and antagonist 
ondansetron to induce internalisation of the receptor (in the presence of cycloheximide), 
as well as the allosteric modulator 5-Chloroindole when incubated either with dialysed 
or non-dialysed FCS in the culture media.  95 
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Further, there is an apparent inhibition of ondansetron response between dialysed and 
non-dialysed serum used indicating potential 5-HT (0.3 μM estimated in FBS) left 
non-broken down or a pool of compounds that can anchor the receptor in non-dialysed 
serum. 
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3.3.3 The ability of Progesterone treatment to influence 5-HT3 
receptor trafficking in NG108-15 cells 
 
NG108-15 mouse neuroblastoma x rat glioma hybrid cells express functional 5-HT3 
receptor (Yakel and Jackson, 1988; Hoyer and Neijt, 1987). We utilised this cell line 
in order to investigate the potential effect the gonadal steroid progesterone which 
appear to interact allosterically with ligand gated ion channels (Review Rupprecht et 
al., 2001) and potentially have an effect on behavioural changes and various disorders. 
To investigate the ability of progesterone, a non-competitive inhibitor of 5-HT3 
receptor, to effect membrane bound 5-HT3 receptor expression after prolonged 
exposure NG108-15 cells were culture for 3 days in culture media in the presence of 
either vehicle (chloroform) or 1 μM progesterone (HP) or 1 μM progesterone that was 
withdrawn for the final 6 hrs of the incubation (PWD). Cells were then counted and 
undergone a membrane preparation in 50 mM Tris buffer. Membrane preparations 
were then used utilising radioligand binding protocol were ~1nM 3H]granisetron 
defined specific binding when competed by specific antagonist ondansetron (10 µM) 
and expressed in fmol bound per million cells (Figure 22). Statistically significant 
increase in membrane bound 5-HT3 receptor was identified for both high 
progesterone and progesterone withdrawn incubation compared to the vehicle treated 
cells (Figure 22) 
 
 
 
Figure 22. High progesterone treatment to identify 5-HT3 receptor radioligand binding in 
NG108-15 cells. They were incubated in the presence of vehicle (VEH), high progesterone (1 
μM; HP) and also high progesterone (1 μM) that was subsequently was withdrawn the final 
6hrs of incubation (PWD). Then competition binding was performed on the membrane 
preparations. n>3 
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3.4 Native response investigation in cell system 
3.4.1 Identification of expression of mRNA of various 5-HT3 
subunits in DG75 cells. 
As model of a Burkitt’s lymphoma disease and a tool of testing a peripheral 5-HT3 
subunits, we utilised the DG75 cell line which could potentially also is a good vehicle 
for transfection. We wanted initially to establish if the cells were expressing native 
receptor. DG75 cells, a lymphoblastoid cell line, were used for mRNA extraction and 
the construction of cDNA in order for RT-PCR screening assay to determine the 
detectable levels of the five individual human HT3A-E subunit coding. We were able 
to identify expression of mRNA coding for the 5-HT3A, 5-HT3B and 5-HT3E subunit 
but lacked detectable levels of 5-HT3C and 5-HT3D subunit mRNA in separate 
experiments with n= 3 -6 (table 7) and representative results were always compared 
with HEK293 cells overexpressing the different subunits as positive control (Figure 
23).     
 
 
  
Receptor subunit DG75 cells expression  
HT3A + + + + 
HT3B + + + + + 
HT3C - - - - - - 
HT3D - - - 
HT3E + + + 
 
 
Table 7; Screening for the identification in DG75 cells the presence of the different subunits of 
h5-HT3 receptor. Demonstration of separate experiments were cDNA was used to identify 
presence positively (+) or not (-) of mRNA expression in DG75 cells.  
(Symbols represent individual experiments)  
Figure 23. Typical example of h5-HT3A (HT3A), h5-HT3B (HT3B), h5-HT3E 
(HT3E) subunit trace in DG75 cells compared to positive control and negative 
control 
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3.4.2 Ability of 5-HT to evoke responses investigated in DG75 cell 
by calcium influx assay 
 
Using calcium influx assay using a single using a cuvette fluorometer to measure 
sequential chances in absorbance representing calcium influx bound to Fluo-4 AM we 
have further assayed the 5-HT (0 – 1mM) interference with fluorescence, prior to 
testing any compounds, in lysed DG75 cells that were previously loaded with Fluo-4 
AM (Figure 24). We have found that as 5-HT additive concentration increases the 
percentage absorbance relative to 0 mM 5-HT is decreasing to almost complete 
abolition indicating that the autofluorescent properties of the 5-HT are interfering with 
the absorbance recorded due to  calcium influx into the cells.  
 
 
Utilising DG75 cells, concentration response curve were obtained to 5-HT (0.1 – 3 
μM; Figure 25), however, the specificity of the response to 5-HT had not been 
possible to be attributed to a specific 5-HT sensitive receptors. We attempted to 
identify which 5-HT sensitive receptor was responsible for the observed response by 
utilising the following antagonists; 0.5 and 1 μM ondansetron, 0.5 and 1 μM 
ritanserin, 0.5 and 1 μM spiperone, 1 and 10 μM paroxetine1 and 10 μM clozapine, as 
well as all possible combinations of the previous drugs, and 1 μM GR113808, 1 μM 
methiothepin and 10 μM renzapride (individual traces not shown; Table 8 for Ki for 
receptors). 
  
 
Figure 24. Concentration dependent ability of additive concentrations of 5-HT (0, 1, 
10, 100, 300 μM; 1mM)  to interfere with absorbance relative to vehicle when added 
to lysed DG75 cells previously loaded with 2 μM Fluo-4 AM  
[5-HT] additive 
150s  0μM 
220s  1μM 
300s  10μM 
400s  100μM 
500s  300μM 
600s  1mM 
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Figure 25. Concentration-dependent ability of 5-HT to increase [Ca
2+
]i DG75 cells and 
the muscarinic receptor agonist, thapsigargin (non-competitive inhibitor of  sarco / 
endoplasmic reticulum Ca
2+ 
ATPase) added where indicated. (A) is representative of 
typical trace from data of at least 5 independent experiments. (B) 5-HT concentration-
responses fitted to a three-parameter logistic equation. Data represent mean ± SEM, n 
> 4.  
A 
B 
100 
 
Chapter 3: Results 
 
 D
ru
g
5-
HT
1A
5-
HT
1B
5-
HT
1D
5-
HT
1E
5-
HT
1F
5-
HT
2
5-
HT
2A
5-
HT
2B
5-
HT
2C
5-
HT
3
5-
HT
4
5-
HT
5
5-
HT
6
5-
HT
7
SE
RT
m
et
hy
se
rg
id
e
16
.9
8
2.
5
69
23
7
34
6.
66
3.
25
4.
3
1.
27
> 1
0,
00
0
63
.0
9
11
6
83
.0
9
> 1
0,
00
0
rit
av
se
rin
29
19
28
9
72
0.
45
3.
28
6.
60
69
3
> 1
0,
00
0
16
44
.8
3
sp
ip
er
on
e
19
4.
6
10
00
0
23
96
.7
6
50
51
> 1
0,
00
0
1.
17
11
14
.1
8
60
2.
56
> 1
0,
00
0
25
11
.9
10
9.
82
clo
za
pi
ne
12
3.
7
51
9
21
32
69
8
13
0
15
.8
1
8.
37
13
.4
89
6
24
1
> 1
0,
00
0
38
57
13
.4
9
48
16
24
pa
ro
xe
tin
e
0.
58
on
da
ns
et
ro
n
7.
33
m
et
hi
ot
hi
pi
n
41
.3
4
12
.0
5
5.
78
17
9.
53
64
8.
83
3.
16
23
1.
81
4.
46
68
4
38
.9
87
.1
7
0.
39
3.
71
GR
11
38
08
87
0.
96
10
00
0.
25
Re
ce
pt
or
 [K
i(n
M
)]
Dr
ug
ad
re
ne
rg
ic 
Al
ph
a1
A 
 a
dr
en
er
gic
 A
lp
ha
2A
  a
dr
en
er
gic
 A
lp
ha
2C
  d
op
am
in
e D
1
do
pa
m
in
e D
2
do
pa
m
in
e D
3
Do
pa
m
in
e D
4
hi
sta
m
in
e H
1
m
us
ca
rin
ic 
 M
1
m
us
ca
rin
ic 
 M
2
m
us
ca
rin
ic 
 M
3
m
us
ca
rin
ic 
 M
4
NE
RT
m
et
hy
se
rg
id
e
> 1
0,0
00
10
6
88
.3
rit
av
se
rin
93
3
84
24
30
sp
ip
er
on
e
74
.47
39
8.5
0.1
25
0.2
95
27
2
clo
za
pi
ne
1.6
7
14
2
26
6.2
5
53
.5
1.6
3
16
.2
20
4
58
16
.5
pa
ro
xe
tin
e
72
34
0
56
.67
on
da
ns
et
ro
n
m
et
hi
ot
hi
pi
n
GR
11
38
08
Re
ce
pt
or
 [K
i(n
M
)]
Ta
bl
e 
8.
  K
i f
or
 v
ar
io
us
 re
ce
pt
or
s o
f d
ru
gs
 u
se
d 
to
 id
en
tif
y 
5-
H
T 
se
ns
iti
ve
 re
sp
on
se
  
101 
 
Chapter 3: Results 
 
3.5 Transiently transfected DG75 cells with myc –tagged h5-
HT3A cDNA 
3.5.1 Investigation of immunoreactivity of myc –tagged h5-HT3A 
receptor expression in DG75 cells 
 
Protein expression was verified by SDS-PAGE followed by Western blotting. 20 μg 
of protein from whole cell homogenates were loaded per well on 10% polyacrylamide 
gels. Western blotting was achieved using mouse anti-myc monoclonal (9E10) 
primary antibody, with an anti-mouse secondary antibody conjugated to horseradish 
peroxidase (HRP).  
 
 
 
  Figure  26 (A) Myc-tagged-5-HT3A subunit immunoreactivity expressed in DG75 
lymphocytes transiently transfected with myc-h5-HT3A subunit cDNA and harvested at 48 
hours (D2), 3 days (D3) and 6 days (D6). Untransfected DG75 cells were used as control. 
Immunoreactivity was identified with monoclonal mouse anti-myc primary antibody 9E10 
(2:100); primary antibody was detected using a HRP-conjugated goat anti-mouse (1:1000).   
(B) Radioligand Binding performed on the same cells were competition binding of 
[
3
H]granisetron (~1 nM) with  and 5-HT3 receptor antagonist ondansetron to identify 
specific binding. 
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Figure 26, confirms the expression and is representative from at least 3 experimental 
replicates. Prestained protein markers were run alongside all samples to determine the 
approximate molecular weight of immunoreactive protein bands. Protein appears 
faithfully expressed in DG75 cells transfected with the cDNA. Receptor produced 
multiple immunoreactive bands between the molecular weights of 43 kDa and 63 
kDa. This is consistent with previous studies on the 5-HT3A receptor subunit (Hovius 
et al., 1998, Monk et al., 2004). Predicted molecular weight of the back bone peptide 
(53 kDa, Belelli et al., 1995) appear to be  an underestimate, with the differences in 
values reported from molecular size determined by SDS-PAGE attributed to the 
addition of oligosaccharides (N-glycosylation). Further, cells were harvested at 
different time points post transfection (2, 3, 6, and 14 days) to identify the optimum 
time point for using the cells with the strongest signal identified as being between 48 
and 72 hours post transfection (Figure 26A). 
 
3.5.2 Radioligand binding assay to identify formation of myc –
tagged h5-HT3A receptor complex expression in DG75 cells 
 
To establish whether the DG75 cells were able to form receptors exhibiting expected 
radioligand binding levels, competition binding studies were performed for the two 
strongest time points identified in the Western Blot assay (48 and 72 hours post 
transfection; Figure 26A) and alongside whole cell homogenates of HEK293 cells 
stably expressing h5-HT3A receptor was used. Whole cell homogenates were assayed 
with ~1 nM [3H] granisetron and competing ligand, the selective 5-HT3 receptor 
antagonist ondansetron (Figure 26B). Similar pattern of receptor expression with the 
one observed with the Western Blot assay was also observed with the radioligand 
birding competition assay. Both of the observations gave us the confidence that DG75 
cells were a good enough expression system for the receptor for us to pursue at 
approximately 48 hours post transfection.  
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3.6 The ability of endogenous agonist 5-HT to evoke 
increase in calcium influx in DG75 cells  
 
Transiently transfected DG75 cells expressing the myc – tagged h5-HT3A receptor 
were used to determine receptor function. Furthermore, using a cuvette fluorometer to 
measure sequential chances in absorbance representing calcium influx bound to Fluo-
4 AM (Figure 27) when cells were challenged with endogenous agonist 5-HT. 
Experiments were repeated at least on three separate occasions following separate 
transfections of DG75 cells with the receptor cDNA. Additionally, prior incubation of 
the cells with specific competitive antagonist ondansetron (100nM) inhibited the prior 
observed 5-HT response. The response was re-established when using the same pool 
of DG75 cells expressing myc – tagged h5-HT3A receptor the addition of 5-HT 
produced comparable response to the one initially observed.  We therefore can 
conclude that we were able to have a functional h5-HT3A receptor response in a 
model of a B lymphocyte that we could use further in an investigation and 
exploitation of 5-HT3 receptor in a potential treatment targeting immune cells. 
 
 
 
 
myc tagged h5-HT3A subunit
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Figure 27. Representative trace of the ability of 5-HT added at 30sec to increase [Ca
2+
]i in 
DG75 cells expressing the myc tagged h5-HT3A receptor and blockade of the response by 
the prior incubation with the selective 5-HT3 receptor antagonist, ondansetron (100 nM). 
Data representative from at least 3 independent experiments were a 5-HT response was 
reestablished following a wash out period of the ondansetron. 
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Chapter 4: Discussion 
POSITIVE ALLOSTERIC MODULATOR FOR 5-HT3 RECEPTOR 
In the present study we have demonstrate that Cl-indole is a relatively potent positive 
allosteric modulator of the h5-HT3A receptor and also the native and recombinant 
receptor expressed in other species; like the mouse native 5-HT3 receptor. In order to 
demonstrate this, primarily we utilised the rapid 5-HT3 receptor mediated increase in 
[Ca2+]i, assessed using a Ca2+-sensitive chromophore and quantified using a 
FlexStation; as has been previously established (Price and Lummis, 2005). Thus, we 
demonstrated that HEKh5-HT3A cells formed a functional h5-HT3A receptor, based 
on confirming receptor pharmacology by utilising a range of selective and non-
selective 5-HT3 receptor ligands. Additionally, the pharmacological profile we 
assembled comprised differential maximal responses by a diversity of partial agonists, 
with the majority of which with recognised sub-maximal intrinsic activities.  
 
Further evidence supporting a selective modulation of [Ca2+]i via the 5-HT3A 
receptor in our protocol arise from studies performed in parallel where 5-HT3 receptor 
agonists failed to evoke responses in native HEK293 cells, indicating that our 
recombinant receptor had to be involved in the response. Furthermore, when we used 
5-HT3 receptor selective concentrations of the specific competitive antagonist 
ondansetron prior to the regular protocol the response was completely abolished.  
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Cl-indole when applied alone failed to evoke increase in [Ca2+]i; with the exception of 
an occasional minor increase, only detected when used at the highest concentration of 
Cl-indole tested (100 µM).  
 
Notably, Cl-indole potentiated the response to a range of agonists of the 5-HT3 
receptor. It is noticeable that the efficacy of Cl-indole was agonist-dependent. 
Therefore, at maximally effective concentrations of the agonists, Cl-indole promoted 
only a comparatively small percentage increase in the maximal effect of the full 
agonist 5-HT, yet responses by agonists with lower intrinsic activity (efficacy) for the 
5-HT3 receptor, were potentiated to a rather greater degree. Consequently, in the 
presence of Cl-indole, all of the partial 5-HT3 receptor agonists tested in the present 
study ((S)-zacopride, DDP733, dopamine, mCPBG, 2-methyl-5-HT, quipazine, RR 
210, SR57727A; Richardson et al., 1985; Neijt et al., 1986; Kilpatrick et al., 1990; 
Bachy et al., 1993; Downie et al., 1995; Yamazaki et a., 1996; Evangelista, 2007), 
which displayed intrinsic activities ranging from 3-89%, evoked responses 
comparable to the responses elicited by maximal (saturating) concentrations of the 
endogenous full agonist, 5-HT. This observation was also accompanied the apparent 
shift in an agonist dependent manner of the efficacy and/or affinity of the orthosteric 
ligand used to evoke the calcium response. This agonist dependence has major 
implications for drug discovery, and even possible therapeutic use, because the 
identification and consequent classification of an allosteric ligand will depend on the 
orthosteric ligand that is used to identify the response. 
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In addition to Cl-indole potentiating the maximal 5-HT3 receptor response to agonists, 
the tachyphylaxis associated with the response, which was particularly evident with 
saturating concentrations of the higher efficacy agonists, was less apparent in the 
presence of Cl-indole. Thus, the additional ability of Cl-indole to slow the apparent 
desensitisation of the receptor indicates that Cl-indole is a Type II PAM of the h5-
HT3A receptor (using the nomenclature recently devised for PAMs of the nicotinic 
acetylcholine receptors; Grønlien et al., 2007 and was further used Johnstone et al., 
2011). 
 
It has been suggested that all ligand-gated ion channels are both activated and 
desensitised by agonists in a concentration-dependent manner, and can become 
desensitised at lower agonist concentrations than those required to substantially 
activate the receptor (Keramidas and Lynch, 2013; Quick and Lester, 2002; Yakel et 
al., 1991). Thus, under conditions of continuous exposure, such as those that may be 
approached with chronic drug treatment, agonists may have a discreetly narrow 
effective concentration range restricted to the section of overlap in which the 
receptors are activated but not fully desensitised (Hogg and Bertrand, 2004). We were 
further interested to investigate the hypothesis that Cl-indole could convert h5-HT3A 
receptors that were already desensitized by an agonist back to a conducting state. 
Notably, it appears that Cl-indole can also induce a potential reversal of the apparent 
desensitisation, assessed by [Ca2+]i via the flexstation, induced by low and high 
intrinsic activity agonists of the h5-HT3A receptor. When the cells were challenged 
with endogenous full agonist 5-HT at submaximal concentration (3 μM) and at 
saturating concentration (100 μM) full response was established followed by an 
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apparent desensitisation which was partially rescued by the addition, subsequently, of 
Cl-indole and by the maximal concentration of TCE; inducing a sustained response 
that developed slowly. These results suggest that Cl-indole potentially activated 
receptors that were presumably agonist-bound but desensitised. Furthermore, when 
the partial agonist DDP733 at submaximal and at saturating concentration was used 
evoked a response and produced a sustained calcium influx; when Cl-indole was 
subsequently added a potential full reversal, similar to the response one observes 
when using a full agonist, of the probable desensitisation was determined. This is in 
line with the reported activity of α7 nACh receptor PAM PNU-120596 resulted in a 
large and sustained inward current when was applied to cultured rat hippocampal 
neurons that were desensitised by saturating concentration nicotine (Hurst et al., 
2005). Notably, a smaller rescue response was observed when TCE was used; 
potentially indicating that TCE can reach in a lesser extent the allosteric site of the 
receptor in order to overcome the apparent desensitisation. 
  
Further, when saturating concentration of 5-HT was used instead of Cl-indole, as a 
subsequent addition drug, only a small response was recovered less than 10% of that 
of 5-HT would induce on its own, indicating probably that the DDP733 with its high 
affinity low intrinsic activity out competes the full agonist 5-HT and potentially 
induces ligand-bound desensitisation.    
 
Moreover, it is now appreciated that 5-HT3 receptor antagonists can have contrasting 
characteristics. For example, palonosetron binds with positive co-operativity (Rojas at 
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el., 2008), as do 5-HT3 receptor agonists including most with low intrinsic activity 
(e.g. Barnes et al., 1992). In addition, palonosetron evokes receptor internalisation 
(Rojas et al., 2010). Interestingly, it has been demonstrated by the Connolly lab 
(Hothersall et al., 2013) actual surface receptor inhibition rather than internalisation 
could be responsible for prolonged inhibition in their assays. Another atypical 5-HT3 
receptor antagonist, BRL46470, has an enhanced binding capacity to recombinant 5-
HT3A receptors (Steward et al., 1995). However, in the present study, both 
palonosetron and BRL46470 behaved as other ‘classical’ 5-HT3 receptor antagonists 
(alosetron, ondansetron, ramosetron) in that they failed to evoke 5-HT3 receptor 
mediated responses even in the presence of a maximal concentration of Cl-indole. 
This directly contrasts the ability of Cl-indole to elicit robust 5-HT3 receptor mediated 
responses from the low intrinsic activity partial agonists investigated in the present 
study. Such findings suggest that the atypical characteristics of the 5-HT3 receptor 
ligands, palonosetron and BRL46470, are not explained by a low level of intrinsic 
activity associated with these molecules.  
 
An additional ‘atypical’ 5-HT3 receptor ligand (S)-zacopride; previously designated 
as an antagonist (Smith et al., 1988). When radiolabelled, (S)-zacopride is one of the 
most suitable radioligands to effectively label the 5-HT3 receptor (e.g. Barnes et al., 
1992a), yet 5-HT3 receptor agonists and partial agonists fail to compete with positive 
co-operativity, unlike their competition for other 5-HT3 receptor radioligands (e.g. 
Barnes et al., 1992a). In addition, (S)-zacopride does not display the same ability, as a 
range of 5-HT3 receptor antagonists, to modulate animal behaviour in various tests 
suggestive of therapeutic potential (Barnes et al., 1990; Young and Johnson, 1991; 
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Barnes et al., 1992b; 1992c; File and Andrews, 1993 but see Bill et al., 1995). 
Furthermore, unlike other 5-HT3 receptor antagonists, (S)-zacopride can induce 
emesis (King, 1990; although see Smith et al., 1989 and Costall et al., 1990) and 
evoke the Bezold-Jarisch reflex in the ferret (Middlefell and Price, 1991); both 
responses involve the vagus nerve (Brown, 1966; King, 1990), which expresses high 
levels of functional 5-HT3 receptors (e.g. Ireland and Tyers, 1987; Kilpatrick et al., 
1989). To interpret these findings it was subsequently hypothesised that (S)-zacopride 
may display agonist actions at the 5-HT3 receptor, besides the identified 5-HT4 
receptor agonism of (S)-zacopride (e.g. Eglen et al., 1990; Baxter et al., 1991) - this 
receptor also activates the vagus nerve (Bley et al., 1994; Coleman and Rhodes, 1995) 
- complicates interpretation of animal data from in vivo models. The failure of (S)-
zacopride to activate native 5-HT3 receptors in in vitro assays, including the isolated 
vagus nerve (rabbit and rat vagus nerve; Barnes et al., 1990; Bentley and Barnes, 
1998) clearly does not correlate with the agonist hypothesis. However, the 5-HT3 
receptor desensitises rapidly in the continued presence of agonist, which can make 
identification of relatively small responses difficult. Hence in the present study we 
utilised the ability of Cl-indole to manifest robust 5-HT3 receptor mediated responses 
from 5-HT3 receptor ligands with low intrinsic activity to make a direct in vitro 
assessment of the nature of (S)-zacopride’s interaction with the h5-HT3A receptor. 
Consistent with (S)-zacopride’s atypical characteristics when compared to ‘silent’ 5-
HT3 receptor antagonists, (S)-zacopride displayed an inconsistent at best very low 
level intrinsic activity for the h5-HT3A receptor (3% compared to 5-HT) that was 
converted into robust responses by the presence of Cl-indole. Hence the present 
finding offers direct evidence that (S)-zacopride is a very low intrinsic activity partial 
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agonist at least for the h5-HT3A receptor, which distinguishes this ligand from a 
range of classical 5-HT3 receptor antagonists. 
 
We have further utilised the rat vagus nerve in a series of grease gap 
electrophysiological experiments in order to investigate the impact the low intrinsic 
activity partial agonist DDP733 would have. We were able to demonstrate the 
concentration-dependent ability of DDP733 to increase the depolarisation of the rat 
vagus nerve. 
We were unable however to perform conclusive experiments on the vagus in the 
presence of Cl-indole due to limited tissue availability, costs and time constrains of 
this study. 
 Additionally with collaboration with Prof. Kumar we have conducted preliminary 
experiments utilising the rat carotid body, which is expressing 5-HT3 receptors 
(Yoshioka et al., 1991; Wang et al., 2002). We have identified that potentially 
DDP733 shows no activity in the rat, but used in the presence of Cl-indole induces 
activity of the carotid body, response which was returned to normal upon wash out of 
the compounds. These preliminary results together with the in vitro data that we have 
presented in this study can potentially further support our hypothesis that Cl-indole is 
a PAM to the 5-HT3 receptor and can play an important role in deciphering native 
integrative 5-HT3 mediated responses. 
 
In terms of the molecular mechanism of Cl-indole, the greater tendency to impact the 
maximal response to partial agonists associate a modulation of early transitions within 
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the conformational wave elicited by agonists, that would result in receptor function 
(Lape et al., 2008). The early transitions arise in the region of the orthosteric binding 
loops in the N-terminus, particularly the degree of capping of the agonist ligand 
(potentially by loops B and C; Miller and Smart, 2009). If the degree of capping of the 
agonist correlates with the degree of intrinsic activity of a partial agonist and by 
association, the stability of the pre-activated receptor ‘flip-state’ (Lape et al., 2008) 
then this molecular region of the subunit may be the target of Cl-indole within the 5-
HT3 receptor complex.  
 
Uncompleted work by other members of the lab is investigating this hypothesis, 
which may also elucidate whether the Cl-indole recognition site that alters the 
maximum response to agonist is also responsible for the reduced apparent 
desensitisation rate in the presence of Cl-indole. The identification and mapping of the 
allosteric binding pocket and its proximity to the orthosteric binding site could 
potentially allow for an investigation of the some potentially bitopic (binding at both 
ortho- and allo- steric site) ligands which could potentially endogenously exist (maybe 
a break down product of monoamines or indoles). We could also speculate that such 
potential ligand can also give rise to an understanding of biological complexity 
(receptor reserves could be interpreted both ways if such theory existed); potentially 
providing us with pharmacological tools to discriminate between the different 
homomeric and heteromeric 5-HT3 receptor and also the opportunity to develop novel 
drug discovery methodologies.  
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Patch clamp recordings using HEKh5-HT3A cells demonstrated that Cl-indole 
potentiated h5-HT3A receptor mediated responses, particularly the maximal responses 
evoked by the partial agonist DDP733 in comparison to 5-HT. This effect of Cl-indole 
was not associated with change in the driving force for the 5-HT3 receptor mediated 
current as the reversal potential was unchanged in the presence of Cl-indole (see 
further Newman et al., 2013). 
 
5-Substituted indoles, such as 5-hydroxyindole (5OHI), have been recognized as 
PAMs of 5-HT3 receptors. However, reports indicate that 5OHI has both orthosteric 
and allosteric binding activities (Kooyman et al., 1994; Hu and Lovinger, 2008), 
signifying at least two binding sites, one of which could potentially overlap the 
orthosteric site. Furthermore, 5OHI has allosteric effects on the nicotinic α7 receptor 
(Bertrand and Gopalakrishnan, 2007) and one report suggests that 5OHI is a PAM at 
rodent but not human receptors (Grønlien et al., 2010). These studies, consistent also 
with our results, cast considerable doubt on 5-hydroxyindole's selectivity and its 
mixed mode of action renders its use as a pharmacological tool debatable. 
 
Further, It has been identified in the murine 5-HT3A subunit that the substitution of 
the TM2 leucine 298 (human equivalent is Leu288) with serine is detrimental to the 
positive allosteric effects of 5OHI and TCE, on the murine receptor (Hu and Lovinger 
2008). Additionally, this site (L288) has been highlighted as having a significant 
effect on the activity of the negative allosteric modulator (NAM) PU-02, the most 
potent and selective NAM for the 5-HT3 receptor characterised, appears to be acting 
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through a transmembrane intersubunit site comprised of the upper three helical turns 
of TM2 and TM3 in one subunit and TM1 and TM2 in the adjacent subunit (Trattnig 
et al., 2012). In the present study, we attempted to demonstrate if the equivalent 
mutation would have the same effect in human 5-HT3A receptor when exposed to 
5OHI and TCE and potentially abolish the positive allosteric effect established by Cl-
indole utilising the Flexstation calcium influx assay.  
 
Initially we attempted to demonstrate that the L288S receptor would have a 
detrimental influence in the positive modulation of 5OHI and TCE utilising the 
calcium influx assay when the cells were challenged with the partial agonist 
quipazine. We were unable to identify any difference in the pharmacology of 
quipazine (Hill number and EC50, EMax) in the dose response curve obtained in the 
presence or absence of 5OHI with the dose response curves being almost identical. 
We were not able to statistically show a reduction in the potentiation effect that Cl-
indole has when co-administered with 5-HT (P=0.0504 t test; the P value is verging to 
significance; however, as the variation in the different experiments was minute 
providing an over confidence in the changes; “Statistics Notes: Interaction 2: compare 
effect sizes not P values” http://www.bmj.com/content/313/7060/808) and there was 
no effect in the potentiation of calcium influx when the cells in the presence of Cl-
indole were challenged with the partial agonist DDP733. 
 
Excitingly, however, we were able to identify a small difference in quipazine 
pharmacology in the L288S (pEC50 = 7.62 ± 0.062) compare to normal myc-tagged 
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h5-HT3A receptor (pEC50 = 7.885 ± 0.045) but statistically significant (P=0.026; 
student t-test).  We therefore were not able to identify the L298 to have the same 
effect in the human subunit compared to the reported influence that has in the murine; 
even though that 5OHI appears to have a greater effect in the human subunit compare 
to the mouse 5-HT3A receptor in our model as our data suggest when were stimulated 
with quipazine (figure 14), contraindicating reports from Grønlien 
(Grønlien et al., 2010).  
Additionally, we demonstrated in our lab, that unlike 5-hydroxyindole, 5-chloroindole 
is not an allosteric modulator of nicotinic α7 receptors highlighting the selectivity of 
Cl-indole over 5-hydroxyindole. Although closely related structures, Cl-indole 
exhibits a higher potency and selectivity than 5-hydroxyindole, making it a more 
attractive pharmacological tool for the exploration of the allosteric modulation of the 
5-HT3 receptor (see further Newman et al., 2013). 
 
It is of interest that Cl-indole concentration-response studies identified Hill 
coefficients greater than unity. This suggests that multiple Cl-indole molecules bind to 
a given h5-HT3A receptor in a cooperative manner. Given the pentameric molecular 
symmetry of the homomeric h5-HT3A receptors investigated in the present study, five 
identical Cl-indole recognition sites within the single receptor complex are 
conceivable. Studies investigating the concentration-response pharmacology of Cl-
indole at heteromeric and mutant 5-HT3 receptors may provide insights into the 
molecular target and mechanism of Cl-indole’s interaction. 
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In order to identify whether the action of Cl-indole can potentially be translated from 
recombinant to native 5-HT3 receptors, we investigated the effect of the compound 
upon the previously described 5-HT3 receptor mediated increase in the neurogenic 
contraction of the mouse urinary bladder (Chetty et al., 2007). It has been identified 
that expression of 5-HT receptors additional to 5-HT3 receptor subtype exists in this 
preparation (Chetty et al.,2007; Newman et al., 2013); thus, a just-maximal 
concentration of the selective 5-HT3 receptor agonist, mCPBG, which behaves as a 
full agonist in this preparation, was employed (Chetty et al., 2007). While mCPBG 
alone caused a small increase in the amplitude of nerve-stimulation evoked 
contraction, this effect showed marked tachyphylaxis consistent with 5-HT3 receptor 
desensitisation. This is consistent with results obtained with recombinant 5-
HT3 receptors; Cl-indole potentiated mCPBG increases in the neurogenic contraction 
of the mouse urinary bladder and prevented the tachyphylaxis. Responses to mCPBG 
in the absence or presence of Cl-indole were prevented by the inclusion of 
ondansetron (500 nM). Together with the data from HEKh5-HT3A cells, these 
observations indicating that Cl-indole acts similarly on native and heterologously 
expressed 5-HT3 receptors. Thus, Cl-indole evoked equivalent responses in both 
species. 
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CONCLUSION 
Whilst the ability of various alcohols and general anaesthetic agents to modulate 
multiple LGIC family members supports the common ancestry of these proteins, this 
lack of receptor selectivity may hinder therapeutic utility of pharmacologically 
targeting these sites. Hence, an important progression of the present work would be to 
investigate the selectivity of action of Cl-indole across other members of the LGIC 
superfamily members (e.g. preliminary data indicates Cl-indole is also Type II PAM 
of the 5-HT3AB receptor isoform - potentiates agonist-evoked responses and reduces 
rate of desensitisation; Newman et al., unpublished observation). An allosteric 
recognition site selective to the 5-HT3 receptor would offer intriguing therapeutic 
potential. For instance PAMs may offer relief from reduced gastrointestinal and 
bladder motility disorders (e.g. constipation-dominant irritable bowel syndrome and 
atonic bladder that commonly associated with the autonomic failure of diabetes 
mellitus). It also remains an intriguing possibility that an endogenous ligand impacts 
the Cl-indole recognition site expressed by the 5-HT3 receptor in a way that rational 
drug design to prevent this interaction, or the identification of inverse allosteric 
receptor ligands, analogous to the action of ß-carbolines at the benzodiazepine 
receptor site on the GABAA receptor (e.g. Peña et al., 1986; for review see Evans and 
Lowry, 2007), may offer further pharmacological avenues to manipulate selectively 
the function of the 5-HT3 receptor for therapeutic benefit.  
In summary, the present study has identified Cl-indole to be a potent Type II PAM of 
the 5-HT3 receptor. 
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5-HT3 RECEPTOR STABILITY 
It has previously shown that the C-terminus of the human 5-HT3A subunit is 
important for the expression of the homomeric 5-HT3A receptor within the cell 
membrane, and suggested a role for the C-terminus in the promotion of receptor 
stability (Butler et al., 2008). In the present study, we further assessed the stability of 
the h5-HT3A receptor in comparison with that arising when the C-terminal alanine is 
truncated (ΔAla455 [N-4TM-QY]; see Butler et al., 2008). 
 
Expression of the h5-HT3A subunit and mutants/truncations by COS-7 cells and 
radioligand binding assays were performed as described previously (Butler et al., 
2008) 
There was no significant difference in the pharmacological profile of the wild-type 
h5-HT3A subunit and truncation mutant of the h5-HT3A subunit N-4TM-QY. 
Specific binding arising from expression of the truncation mutant of the h5-HT3A 
subunit, N-4TM-QY (ΔAla455), was more susceptible to disruption by increasing 
concentrations of urea relative to the specific binding arising from expression of the 
wild-type h5-HT3A subunit (P<0.05, Mann Whitney U test). In contrast, there was no 
significant difference in the urea sensitivity of [3H]granisetron specific binding arising 
from expression of the wild-type h5-HT3A subunit and N-4TM-AAA (Gln453Ala and 
Tyr454Ala). 
There was no significant difference in the pharmacological profile of the wild-type 
h5-HT3A subunit and truncation mutant of the h5-HT3A subunit N-4TM-QY. 
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The current study further supports the role of the C-terminus of the h5-HT3A subunit 
to promote stability of the arising 5-HT3 receptor complex. 
The present study in combination with the work published by Butler et al., (2008) 
demonstrates an important role for the C-terminus in the formation of the functional 
h5-HT3A receptor. Butler et al. were able to demonstrate the partial restoration of 5-
HT3 receptor binding and cell membrane expression when cells expressing C-terminal 
mutant 5-HT3A subunits were grown at a lower temperature (27 oC) suggests that the 
C-terminus stabilises the 5-HT3 receptor allowing subunit folding and subsequent 
maturation but were not able to exclude the ‘docking’ (a recognition site of this region 
of the subunit) role for the C-terminus as well as the stability to receptor complex; as 
we were able to, using a chaotropic agent, to see the difference a single amino acid 
can have in a mature receptor complex.  
With our present study we further support the hypothesis that the C-terminus is 
important in the stability of the receptor complex. 
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5-HT3A RECEPTOR SURFACE EXPRESSION 
Receptor immunolabelling allowed monitoring of the plasma membrane targeting as 
well as the ligand-induced endocytosis/ up-regulation of the h5-HT3A receptor in 
living cells. Reports that the receptor appears on the plasma membrane approximately 
5hrs after transfection (Ilegems et al., 2004) and that maximum receptor formation 
occurs 36-50 hrs post-transfection was reconfirmed in this study when we were 
establishing our protocol. 
 
In the current study, we have attempted to demonstrate that the cell surface expression 
of recombinant 5-HT3A receptors is effected by the prolonged presence of agonist 
and antagonist. We were unable to detect any changes in immunoreactivity to 5-HT3A 
receptor in HEK293 cell surface when all treatment protocols were contacted in 
medium supplemented with non-dialysed foetal bovine serum (which potentially 
contains 5-HT ~0.3μM; Mothersill et al., 2010). In contrast, changes in expression 
were indicated when dialysed serum was used.  Furthermore, it has been indicated by 
our data that competitive antagonists (ondansetron) potentially induces an apparent 
up-regulation of 5-HT3A receptor in the surface.  
 
Potentially these findings indicate that up-regulation of 5-HT3A receptor is 
independent of receptor activation as indicated by the inability of a competitive 
antagonist (ondansetron; to which Cl-indole failed to induce any response resulting in 
calcium influx) to block the 5-HT induced apparent up-regulation, and the finding that 
even antagonist treatment alone could potentially induce an apparent up-regulation.  
121 
 
Chapter 4: Discussion 
 
Antagonist-induced up-regulation has also been shown for GABAA receptors with a 
competitive antagonist (Eshaq et al., 2010). Mutations of the agonist-binding site of 
GABAA receptors completely blocked the agonist-induced up-regulation (Eshaq et 
al., 2010). Competitive antagonists for nACh receptors (α4β2 subtype) are unable to 
induce up-regulation, however, non-competitive antagonists significantly up-regulate 
nACh receptors (Peng et al., 1994, Kuryatov et al., 2005). This could potentially allow 
the hypothesis that the non-competitive antagonists for nACh receptors are more 
effective at promoting subunit assembly in the endoplasmic reticulum.  
Further we have also demonstrated that non-competitive allosteric antagonist 
(progesterone; highest reported concentration of progesterone in rat plasma is about 
20 μM in late pregnancy; Ichikawa et al., 1974) was able to induce significant up-
regulation in cell surface 5-HT3A receptor in neuroblastoma cell line and that 
withdrawal of the progesterone reduced the surface 5-HT3A receptor; however, the 
effect of previous prolonged exposure was still sufficient to present receptor up-
regulation compare to control in both treatment protocols with progesterone. An 
intriguing possibility is that such funding could have a key role in potentially 
understanding why specific conditions are gender predominant (like IBS) as well as 
being correlated to the changes arising from the menstrual cycle. It could potentially 
explain also changes in mood, anxiety and depression that are potentially following a 
pattern depending on the gonadal steroid concentration circulating.  
 
However, we were unable to detect any change in the surface expression of 5-HT3A 
receptor when exposed to agonist (5-HT) or to PAM (Cl-indole). This is despite the 
fact that previous studies have demonstrated that prolonged exposure to agonists have 
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been shown to increase the surface expression of other members of the Cys-loop 
LGIC family. Nicotine, an agonist for nACh receptors, has been well documented to 
increase the surface expression of nACh receptors in cultured cells (Bencherif et al., 
1995), rodents (Schwartz and Kellar, 1985, Wonnacott, 1990), and human smokers 
(Benwell et al., 1988, Perry et al., 1999, Govind et al., 2009). Additionally, Eshaq and 
colleagues (Eshaq et al., 2010) showed that the GABAA receptors expressed in 
HEK293 cells are also up-regulated in the presence of GABA.  Reports also indicated 
that exposure to 5-HT (for 24 hours) leads to approximately a threefold increase in 
total binding to cells stably expressing 5-HT3 receptors (Sanghvi et al., 2009). 
Furthermore, it has  been demonstrated (Eshaq et al., 2010) that 5-HT increases 
surface levels of 5-HT3A and GABA was unable to up-regulate 5-HT3 receptors, as 
well as, the observation that 5-HT was unable to up-regulate GABAA receptors, 
suggesting that this phenomenon requires a ligand that works at the appropriate 
orthosteric site. Interestingly though, there have been reports indicating that agonist 
induced 5-HT3 receptor endocytosis initialised after just 5 mins of incubation, with 
specific agonist, with the plasma membrane associated receptor numbers to decrease 
by a factor of three (Ilegems et al., 2004), bearing in mind that potentially on their 
study they have only established that the observation is true in the presence of ligand 
and not necessarily induced by ligand as further controls would have been required. 
Furthermore, regarding the internalisation of 5-HT3A receptors in recombinant 
systems (Ilegems et al., 2004; Morton et al., 2011) as well as the expression of brain-
derived neurotrophic factor reduces the 5-HT3 receptor (Huang and Morozov, 2011), 
the mechanisms however remains elusive. Nottingly it has been reported that 
regarding trafficking to the surface of 5-HT3A receptor the assembly and trafficking 
signals (Boyd et al., 2002; 2003) and post-translational modification (Sun et al., 2003; 
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Monk et al., 2004; Massoura et al., 2011) control recruitment to the membrane. We 
could speculate that ligand induced regulation of 5-HT3 receptors may promote 
changes in receptor function that are isolated from acute pharmacology.  5-HT3 
receptor internalisation has been reported in the gastrointestinal system following 
excess 5-HT (Freeman et al., 2006) and in recombinant systems, following exposure 
to palonosetron (Rojas et al., 2010). Associating clinical efficacy of drugs for the 
receptor and for pathological explanations of high concentrations of 5-HT. 
This is also true for other receptor of the cys-loop super family such as GABAA 
(Hearing et al., 2003; Barnes, 2000) and nicotinic acetylcholine (St John and Gordon, 
2001) receptors, as well as other ligand-gated channel such as P2X1 receptor (Dutton 
et al., 2000).  
All of which are indicating that ligand induced changes in cell surface expression of 
ligand gated ion channel receptors could be either pro- endocytosis (down regulation) 
or pro- up-regulation, exhibiting possibly temporal dependency in preference of one 
state to the other, as well as possibly the type of ligand that is occupying the binding 
site either the orthosteric or even the allosteric in terms of its efficacy. 
   
However, it has been indicated by our data that the presence of Cl-indole with a full 
agonist potentially has an up-regulatory effect on the 5-HT3A receptor when co-
administered with 5-HT.  
The up-regulation of nACh and GABAA receptors require saturating concentrations of 
agonist (Peng et al., 1994, Wang et al., 1998, Kuryatov et al., 2005, Vallejo et al., 
2005, Eshaq et al., 2010). Up-regulation of nACh receptors by nicotine requires the 
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presence of nicotine for at least six to eight hours (Wang et al., 1998, Kuryatov et al., 
2005, Vallejo et al., 2005), similar to the time course we utilised for 5-HT3A 
receptors. It remains unclear if the up-regulation of GABAA receptors is dependent 
upon agonist concentration. However, GABAA receptors were up-regulated with one 
hour of GABA exposure followed by 5 hours in the absence of agonist (Eshaq et al., 
2010). This appears different for the nACh and potentially 5-HT3A receptors, which 
require the presence of agonist for several hours of exposure. This discrepancy could 
be due to the proposed transport or synthesis of GABA intracellularly. Observation 
which could lead to the potential speculation that such ligands are providing 
potentially some kind of chaperone assistance to the maturation and assembly of the 
receptor complex and to the transportation and clustering of the receptor to the 
surface. 
 
It has been well established that agonist-induced up-regulation of both nACh 
receptors and GABAA receptors is independent of receptor translation (Peng et al., 
1994, Wang et al., 1998, Kuryatov et al., 2005, Lester et al., 2009, Eshaq et al., 2010). 
Multiple hypothesis for the mechanism of the translation-independent up-regulation of 
nACh receptors have been proposed, including alterations in surface turnover (Peng et 
al., 1994), and the enhancement of subunit assembly by nicotine (chaperone effect) in 
the endoplasmic reticulum (Kuryatov et al., 2005, Lester et al., 2009). Furthermore, 
GABAA receptors are also up-regulated by a chaperone effect (Eshaq et al., 2010). 
This hypothesis could potentially be exploited further in the investigation of 5-HT3 
receptor providing us with a comparable account of the possible existence of this 
phenomenon in the 5-HT3 receptor. 
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Further; it has been hypothesised that clathrin mediated receptor endocytosis (Heuser 
and Andersen, 1989), indicated as a possible mechanism of the endocytosis of the 5-
HT3A receptor the AP2 adaptin-clathin mediated endocytosis. This is a rational 
possibility as other members of the ligand-gated ion channel super family potentially 
undergo endocytosis via this mechanism, such as the ionotropic glutamate receptors 
(Carroll et al., 1999) and GABAA receptors (Kittler et al., 2000; Herring et al., 2003); 
however, the potential involvement of similar endocytotic mechanisms in the 
internalisation of the 5-HT3 receptor has yet to be reported. 
 
Moreover, structural studies with the acetylcholine binding protein have shown that 
there are slight structural differences arising to the receptor complex around between 
agonist bound and competitive antagonist bound proteins (Shahsavar et al., 2012). 
Furthermore, there are distinct conformational changes on the extracellular domain of 
glycine receptors between activation and desensitisation (Wang and Lynch, 2011). It 
is possible that conformational changes in the 5-HT3A receptors could lead to 
changes in the rate of internalisation and thus change the receptor expressed on the 
cell surface. It remains unclear how many of these extracellular changes would affect 
the intracellular domains of the receptor leading to changes in internalisation. Further 
studies are required to appreciate the structural similarities between the antagonist 
blocked and the desensitised receptors and if such structural changes could modify 
receptor internalisation. 
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Conclusion 
Our study allowed the direct observation of ligand induced changes in surface 
expression of the 5-HT3A receptor in response to exposure to various agonist, 
antagonist and allosteric modulators. Ligand up-regulation/ down regulation could 
have implications for patients using serotonin selective re-uptake inhibitors for 
depression, 5-HT3 receptor antagonists like ondansetron for post-operative or 
chemotherapy induced nausea and emesis, or palonosetron for IBS. Potentially 
prolonged exposure to drugs that are directly or indirectly interacting with 5-HT3 
receptors in different areas of the body where there is receptor clustering such as the 
GI tract or chemoreceptor trigger zone or lymphocytes could affect treatment 
outcomes as well as potentially induce treatment resistance or adaptive response to the 
treatment. Additionally some treatments maybe could be predisposing to IBS or 
depression or even be silently protective against certain conditions or leukaemia’s. 
However, further studies are needed to confirm the potential up-regulation or down 
regulation in tissue and whole organisms and the role they have in normal and disease 
function.    
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B lymphocytes 
“Wild type” DG75 lymphocytes appear to have the capacity, determined by their 
expression of mRNA, to express 5-HT3A, 5-HT3B and 5-HT3E subunits of the 
receptor but not 5-HT3C and 5-HT3D. When investigated further, DG75 lymphocytes 
display relatively small amounts (~16 fmol/mg) of 5-HT3 receptor specific 
radioligand binding, as determined by specific antagonist ondansetron, and did not 
demonstrated any detectable immunoreactivity on SDS-PAGE/Western Blotting and 
immunocytochemistry. However, when we investigated if a functional receptor exists 
in B lymphocytes (DG75 as a model) by using a calcium influx assay we determined 
that there is a 5-HT concentration dependent response relatively low, reflecting 
possibly low receptor density also identified by the low radioligand binding. In further 
determining which 5-HT sensitive receptor was responsible for the calcium influx, we 
used a number of specific antagonists (ondansetron, ritanserin, spiperone, paroxetine, 
clozapine, as well as all possible combinations of the previous drugs, and GR113808, 
methiothepin and renzapride; for receptor affinities see Table 8), but we were 
unsuccessful in blocking the 5-HT response; and therefore we were unable to allocate 
the response to a specific 5-HT sensitive receptor that could mediate a calcium influx, 
resulting in the arrest of further development of the investigation.  
 
However, upon transient transfection of DG75 cells with myc-tagged h5-HT3A 
subunit, specific radioligand binding was identified (170 - 580 fmol/mg 24 – 48 hrs 
post-transfection). Additionally, when the same preparations were used for SDS/Page 
Western blotting protocol the expression of the myc-tagged h5-HT3A subunit was 
verified and the appropriate immunoreactivity band was identified at molecular 
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weight ~55 kDa which is in accordance with previous reports (Monk et al., 2004); 
representing, possibly, N-glycosylated form of the 5-HT3A receptor.  
 
When we used the same protocol as previously to determine the functionality of the 
receptor we transfected, we were able to obtain 5-HT response, induced calcium 
influx, that have shown to be 5-HT3 receptor specific; as determined by the blockage 
of the response by specific antagonist ondansetron.  
Agonist/antagonist up-regulation or down-regulation or direct stimulation or 
inhibition of 5-HT3 receptors as a side effect of a main treatment could have 
implications for patients using serotonin selective re-uptake inhibitors for depression, 
ondansetron for post-operative nausea and emesis, or chronic pain patients using 
morphine or palonosetron for IBS management. If as the recent literature suggests and 
our study potentially highlights the selective expression of 5-HT3 receptors in 
immune cells changing possibly their metabolic fate or the maturation pathway or 
even being to be proven important target for blood cancer therapies there is great 
interest in defining their involvement in health and disease.   
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General Conclusion 
In summary, the present study has identified Cl-Indole as a relatively potent and 
selective type II PAM of the h5-HT3A receptor and also the native and recombinant 
receptor expressed in other species. Further, we have demonstrated the ability of Cl-
indole to slow desensitisation kinetics, which was particularly evident with saturating 
concentrations of the higher efficacy agonists, and was less apparent in the presence 
of Cl-indole; and could even reverse apparent tachyphylaxis. Compared to the 
previously characterised 5-hydroxy-indole, Cl-indole has a greater affinity and 
efficacy at the 5-HT3 receptor and appears to be selective to this receptor over the 
human nicotinic alpha-7 receptor, the 5-HT3 receptors closest family member. 
Availability of compounds such as Cl-indole will aid investigation of the molecular 
basis for allosteric modulation of the 5-HT3 receptor, which may help in the discovery 
of novel therapeutic drugs targeting this receptor (Newman et al., 2013). 
 
Our study also allowed the observation of 5-HT3A receptor ligand-induced changes in 
surface expression of the 5-HT3A receptor in response to exposure to various agonist, 
antagonist and allosteric modulators. These findings could have implications for 
patients receiving medications that impact the 5-HT3 receptor. 
 
In the present study, we have further reinforced the understanding that 5-HT3 receptor 
stability is affected by the three amino acid C-terminus of the 5-HT3A receptor 
subunit.   
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BACKGROUND AND PURPOSE
The 5-HT3 receptor is a ligand-gated ion channel that is modulated allosterically by various compounds including colchicine,
alcohols and volatile anaesthetics. However the positive allosteric modulators (PAMs) identified to date have low affinity, which
hinders investigation because of non-selective effects at pharmacologically active concentrations. The present study identifies
5-chloroindole (Cl-indole) as a potent PAM of the 5-HT3 receptor.
EXPERIMENTAL APPROACH
5-HT3 receptor function was assessed by the increase in intracellular calcium and single-cell electrophysiological recordings
in HEK293 cells stably expressing the h5-HT3A receptor and also the mouse native 5-HT3 receptor that increases neuronal
contraction of bladder smooth muscle.
KEY RESULTS
Cl-indole (1–100 μM) potentiated agonist (5-HT) and particularly partial agonist [(S)-zacopride, DDP733, RR210, quipazine,
dopamine, 2-methyl-5-HT, SR57227A, meta chlorophenyl biguanide] induced h5-HT3A receptor-mediated responses. This
effect of Cl-indole was also apparent at the mouse native 5-HT3 receptor. Radioligand-binding studies identified that Cl-indole
induced a small (∼twofold) increase in the apparent affinity of 5-HT for the h5-HT3A receptor, whereas there was no effect
upon the affinity of the antagonist, tropisetron. Cl-indole was able to reactivate desensitized 5-HT3 receptors. In contrast to its
effect on the 5-HT3 receptor, Cl-indole did not alter human nicotinic α7 receptor responses.
CONCLUSIONS AND IMPLICATIONS
The present study identifies Cl-indole as a relatively potent and selective PAM of the 5-HT3 receptor; such compounds will aid
investigation of the molecular basis for allosteric modulation of the 5-HT3 receptor and may assist the discovery of novel
therapeutic drugs targeting this receptor.
LINKED ARTICLES
Recent reviews on allosteric modulation can be found at:
Kenakin, T (2013). New concepts in pharmacological efficacy at 7TM receptors: IUPHAR Review 2. British Journal of
Pharmacology 168: 554–575. doi: 10.1111/j.1476-5381.2012.02223.x
Roche D, Gil D and Giraldo J (2013). Mechanistic analysis of the function of agonists and allosteric modulators: reconciling
two-state and operational models. British Journal of Pharmacology 169: 1189–1202. doi: 10.1111/bph.12231
Abbreviations
AM, acetoxymethyl; Cl-indole, 5-chloroindole; E5-HT, reversal potential for 5-HT-evoked current; HEKh5-HT3A, HEK293
cells stably expressing the human 5-HT3A subunit; LGIC, ligand-gated ion channel; mCPBG, meta chlorophenyl
biguanide; PAMs, positive allosteric modulators
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